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1. INTRODUCTION 
1.1 General principles of the signal transduction 
Signal transduction is a process that the living organisms use to coordinate all biochemical 
reactions in their cells in order to respond to extracellular signals. The cell reactions may 
result in short- or long-term changes not only in the metabolism and/or in the cell function 
but also in processes such as proliferation, differentiation, apoptosis and immune defense. 
In order for a cell to express a response, first the external signal must be recognized by a 
cell-specific membrane receptor protein and transferred to a cell-understandable syntax. 
Second, the signal is passed over suitable effector proteins through intracellular signal 
molecules. Finally, a specific biochemical process is triggerd (Lodish et al., 2004; Pollard 
and Earnshaw, 2002). 
Fundamental components of the intracellular signal transduction comprise of effector 
proteins and small molecule messengers. An incoming signal is passed on from its 
specific membrane receptor to downstream proteins, which in turn have other effector 
proteins. By this way, more proteins are involved in the signal chain (Krauss, 2003). The 
small molecule messengers play a role as connectors among effector proteins.  
One of the predominant principle of the intracellular signal transduction is the change in 
concentration of diffusible messenger substances, so-called second messengers, which 
bind to and activate effector proteins (Krauss, 2003). Calcium (Ca2+) and the cyclic 
nucleotide cAMP (cyclic Adenosin-3', 5 ' - mono phosphate) are well-known 
representatives of these signal molecules; they diffuse among cell compartments and 
work by binding to a certain “switch” proteins and/or - enzymes and lead to the activation 
of the enzymes e.g. the Ca2+-binding protein calmodulin or cAMP-dependent protein 
kinase PKA (Pollard and Earnshaw, 2002).  
A second universal principle relies on the cascade of sequential enzymes; here the signal 
is passed on and amplified from membrane receptors to sequentially-activated enzymes. 
In eucaryotic cells the so-called MAPK (mitogen-activated protein kinase) cascade is best 
examined. The MAPK cascade is often activated by mitogenic signals, which promote cell 
division activities. The MAPK pathway is composed of modules containing at least three 
types of protein kinases, which transmit the signal by sequential phosphorylation in a 
hierachical way. The MAPKKKs (MAP Kinase Kinase Kinase) standing top in the 
hierarchy are Serine/Threonine-specific protein kinases. They phosphorylate the 
subordinate MAPKKs (MAP Kinase Kinase) downstream of the module at two serine 
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residues, which are separated by 3 other amino acids. The MAPKKs are dual-specificity 
protein kinases, which phosphorylate the down-stream MAPKs at Tyrosine and Threonine 
residues in the T-X-Y (Tyrosine-X-Threonine) motif. The MAPKs are divided into different 
subgroups depending on their sequence homology, input signals, and the preceeding 
MAPKKs. MAPKs designate their own downstream substrate proteins. As serine/threonine 
kinases they phosphorylate a number of cytosolic and nuclear proteins. Of the at least six 
different MAPK pathways that have been identified to date in mammalian cells, the best 
investigated are ERK, JNK/SAPK and p38 (Widmann et al., 1999; Garrington and 
Johnson, 1999; Pearson et al., 2001; Kyriakus and Avruch, 2001; Krauss, 2003). 
Effector molecules transfer new demands to the cell e.g. protein production through the 
functional proteins, enzymes. The function and morphology of a cell are determined by 
expression of specific genes. Furthermore, the cellular processes e.g. development, 
differentiation, metabolism are characterized by a variable pattern of gene expression 
(Krauss G. 2003). By this view, transcription factors like the CREB (cAMP response 
element binding protein) are especially important due to their influence on the gene 
expression. Most importantly, an effector is not assigned to only one signal pathway. The 
transcription factor CREB is, for this reason, a good example. Originally, CREB was 
identified as a substrate of the cAMP signal pathway. Today it is known that numbers of 
extracellular factors affect the CREB-mediated gene transcription by at least three 
separate signal pathway (Shaywitz and Greenberg, 1999; Lodish et al., 2004; Pollard and 
Earnshaw, 2002). 
1.2 The transcription factor CREB 
The ubiquitously expressed transcription factor CREB, cAMP-response element binding 
protein, is involved in numerous cell signalling pathways (Shaywitz and Greenberg, 1999; 
Tardito et al., 2006). CREB binds to its recognition sequence, CRE, with the consensus 
motif 5’-TGACGTCA-3’ and mediates the activation of cAMP-responsive genes (Shaywitz 
and Greenberg, 1999). CREB target genes include, for instance, metabolic enzymes 
(Lactate dehydrogenase, Phosphoenolpyruvate carboxylkinase (PEPCK), Pyruvate 
carboxylase etc.), transcription factors (c-Fos, STAT3, c-Maf etc.), cell cycle or survival 
(Proliferating cellular nuclear antigen PCNA, Cyclin A, Cyclin D1, Bcl-2 etc.), growth 
factors (insulin, TNFα, etc.), immune regulators (T-cell receptor-α, Interleukine-6, etc.), 
signalling proteins (Mitogen-activated protein kinase kinase phosphatase MKP-1, 
Glucose-regulated protein 78, etc.) and many others (Mayr and Montminy, 2001).  
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1.2.a. Structure of CREB 
In mammals, the CREB family is composed of CREB, CREM and ATF-1, which have the 
basic-leucine zipper (bZip) in the structure (Mayr and Montminy, 2001). The CREB gene 
comprises 11 exons, which form 2 main spliced products designated CREB-α (341) and 
CREB- (327). CREB-α comprise 14 amino acids more than the -form (Fig. 1). These 
two forms function equally.  
The primary structure of CREB includes a kinase inducible domain (KID) which is centrally 
located and composed of 60 amino acids. The domains Q1 and Q2 (constitutive 
activators) are glutamine-rich, which flank the KID. The leucine zipper domain is located in 
the C-terminus of CREB, which mediates CREB dimerization. The basic domain which is 
responsible for DNA binding is positioned between Q2 and leucine zipper domains (Mayr 
and Montminy, 2001).  
 
 
 
 
 
 
1.2.b. Characteristics and functions of CREB 
The bZip domain of CREB binds as a dimer to the CRE site on the promoter of target 
genes (Montminy et al., 1986). CREB activates gene transcription when the serine 133 in 
the KID is phosphorylated and CREB interacts with other co-factors (Mayr and Montminy, 
2001).  Besides the Mitogen-Activated Protein Kinase (MAPK) ERK1/2 and p38, an 
increase of the intracellular concentration of cAMP which activated protein kinase A (PKA) 
and membrane depolarization with elevation of intracellular calcium concentration and 
stimulation of calcium-calmodulin dependent protein kinases (CaMK I, II, and IV) lead to 
the phosphorylation of CREB at Ser-133 (in CREB-341) (Tan et al., 1996; Gonzalez et al., 
1989; Sun et al., 1994; Mayr and Montminy, 2001). This phosphorylation is essential for 
the recruitment of the CREB co-activator, CREB binding protein, CBP which has histone 
11 3 1 2 6 4 5 10 7 9    8 
           
Q1 Q2 KID bZIP 
          
CREB gene 
CREB-α  (341) 
CREB- (327) 
α 
Figure 1: CREB structure (Mayr and Montminy, 2001). 
The CREB gene includes 11 exons. Post-transcription splicing forms 2 main proteins 
designated CREB-α (341) and CREB- (327). Both have the same function because 
important domains - such as KID, Q1 and 2, and bZIP - are conserved. The difference is 
only that CREB-α includes 14 amino acids more than the -form.  
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acetylase activity and associates with RNA-polymerase II complexes (Mayr and 
Montminy, 2001; Shaywitz and Greenberg, 1999; Nakajima et al., 1997). Besides CBP, 
the CREB-directed gene transcription depends also on its interaction with other proteins. 
Among these, the interaction of the CREB-Q2 domain with TAFII130 of the TFIID complex 
which belongs to the general transcriptional machinery (Nakajima et al., 1997) plays an 
important role in the process since TFIID complex integrates with TBP- TATA-box binding 
protein- to stabilize the whole transcriptional machinery on the promoter of target genes. 
Additionally, some findings showed that the phosphorylation of CREB at Ser119 
(corresponding to Ser-133 in CREB- α) which recruits CBP to involve in transcription is not 
sufficient for transcriptional activity. The stimulated CREB-directed gene transcription is 
inhibited by the immunosuppressive drugs cyclosporin A and FK506 independent of the 
phosphorylation of Ser119 (Oetjen et al., 2005; Schwaninger et al., 1995; Schwaninger et 
al., 1993a). Recently, a new co-activator of CREB named transducer of regulated CREB 
(TORC) was identified (Iourgenko et al., 2003). TORC promotes CREB-directed gene 
transcription through phosphorylation-independent interaction with the bZip DNA 
binding/dimerization domain of CREB (Conkright et al., 2003a, b). 
 
 
 
 
 
 
 
 
 
 
CREB has diverse functions in different tissues. For instance, it regulates the growth-
factor-dependent cell survival (Mayr and Montminy, 2001). CREB-/- mice have a lower 
TBP 
CRE 
RHA 
 
CREB 
 
CREB 
T 
O 
R 
C 
      TFIIB 
CBP CBP 
Pol 
II 
TAFI
I 
130 
TFII 
D 
P P 
TATA 
Gene  transcription 
Figure 2: CREB-directed gene transcription (described following Conkright et al. 2003, Screaton 
et al. 2004, Ravnskjaer et al. 2007)  
Homodimerised CREB binds to the cAMP-responsive element and is phosphorylated at Ser 119 by some 
stimuli. CBP is recruited to KID domain of CREB after this phosphorylation. The complex TAFII 130/TFII D 
interacts with the Q2 domain of CREB, which integrates with TFIIB and TATA-box binding protein (TBP) 
and enhance the CREB binding to the promoter of target gene. Besides, TORC binding to the bZip domain 
of CREB as tetramer also enhance the interaction between CREB and TAFII 130 component of TFIID. The 
glutamine-rich region of C-terminal TORC also binds to TAFII 130 component. RNA-Polymerase II 
associates with CBP through RNA-Helicase A (RHA), which activates the CREB target gene transcription. 
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number of developing T cells than the control littermates (Rudolph et al., 1998). The 
transgenic mice expressing a non-phosphorylatable CREB in pituitary or a dominant-
negative A-CREB in chondrocytes had dwarfish phenotype, which was shown to be partly 
due to blockage of proliferation (Struthers et al., 1991; Long et al., 2001; Inoescu et al., 
2001). Some genes involved in this process include cyclinD1 and cyclin A, which are 
probably regulated by CREB (Desdouets et al., 1995; Lee et al., 1999; D’Amico et al., 
2000). Overexpression of the anti-apoptotic Bcl2 gene reduced the cell death caused by 
dominant-negative CREB expression (Riccio et al., 1999, Bonni et al., 1999). 
Especially, a quarter of CREB-dependent genes are involved in metabolic regulation 
(Mayr and Montminy, 2001). Glucose homeostasis is also regulated by hepatic enzymes 
which are CREB-dependent (Herzig et al., 2001, 2003; Mayr and Montminy, 2001). CREB 
modulates glucagon production in the pancreas (Schwaninger et al., 1993), which in turn, 
glucagon enhances glucose output from the liver during fasting by stimulating the 
transcription of gluconeogenic genes via the cyclic AMP-inducible factor CREB (Koo et al., 
2005). 
CREB appears to have a special meaning for the function and the mass of the β-cells: It 
binds to the promotor of rat insulin I gene and the promotor of human insulin gene and 
activates their transcription (Oetjen et al., 1994; Eggers et al., 1998; Oetjen et al. 2003a, 
b). Transgenic mice, which overexpress a dominant-negative mutant of CREB in the β-
cells, become diabetic because of apoptotic β-cell death (Jhala et al., 2003). These 
evidences emphasize the crucial role of CREB in metabolism and cell survival. 
1.3 Transducer of regulated CREB (TORC), a CREB coactivator 
The transducer of regulated CREB 1 (TORC1) was first identified in 2003 as coactivator of 
the transcription factor CREB, which potently induces known CREB1 target genes 
(Iourgenko et al., 2003). A number of TORC1-related proteins were discovered, such as 
two human genes hTORC2 and hTORC3 which are 32% identical to TORC1, or a single 
drosophila gene dTORC1 with 20% idendical to TORC1 (Iourgenko et al., 2003). In mice, 
the orthologs of TORC1, TORC2, and TORC3 were found. The fugu and drosophila have 
only TORC1 orthologs (Iourgenko et al., 2003). The protein sequences include a highly 
conserved N-terminal coil-coil domain (residues 8-54 of hTORC1) (Iourgenko et al., 2003). 
TORC isoforms are expressed differently in distinct tissues. TORC1 is present abundantly 
in the prefrontal cortex and the cerebellum of the brain, and TORCs 2 and 3 are highly 
expressed in B- and T-lymphocytes (Conkright et al., 2003a). TORC1 was shown to be 
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involved in hippocampal long-term synaptic plasticity (Kovacs et al., 2007; Zhou et al., 
2006), whereas TORC2 is involved predominantly in the regulation of glucose 
homeostasis (Dentin et al., 2008; Dentin et al., 2007; Koo et al., 2005; Liu et al., 2008; 
Screaton et al., 2004). 
1.3.a. Structure of TORC 
TORC proteins have a highly conserved N-terminal predicted coiled-coil domain, a so-
called CREB binding domain (CBD), (Fig. 3) which interacts with the bZip domain of 
CREB. The coiled-coil structure of TORC1 is located at aa 1-42 (Conkright et al., 2003a). 
Additionally, a protein kinase A (PKA) phosphorylation consensus sequence is also 
present in all TORC isoforms (Iourgenko et al., 2003). 
TORC 2 has a nuclear localizing sequence (NLS) at aa 56-144 and two nuclear export 
sequence (NES1 and 2) within aa 145-320. Both NLS and NES motifs are conserved in all 
three isoforms of the TORC family (Screaton et al., 2004). 
By fusing the C-terminus of TORC isoforms with DNA-binding domain of GAL4 and 
applying reporter gene assays with minimal promoter linked to GAL4-binding sites, 
Iourgenko et al. discovered that all TORC isoforms have a transactivation domain at the 
C-terminus (Fig. 3) (Iourgenko et al., 2003).  
A study on the phosphorylation of TORC2 showed that it has twelve independent 
phosphorylated serine residues in which seven residues are in the central region (aa 300-
500), and the Ser-171 is dephosphorylated by elevation of Ca2+ influx and cAMP levels 
(Screaton et al., 2004). TORC2 has two motifs which mediate the binding of 
calcium/calmodulin-dependent phosphatase calcineurin and two multiple phosphorylated 
regions which interact with the 14-3-3 protein (Screaton et al., 2004). 
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Figure 3: Structure of TORC (modified from Screaton et al., 2004) 
The CREB binding domain (CBD) is a highly conserved predicted coiled-coil structure, located 
at the N-terminus of TORC. TORC has a nuclear localisation signal (NLS) and two nuclear 
export sequences (NES). The transactivation domain (TAD) is located C-terminal.  
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1.3.b. Regulations and functions of TORC 
The nuclear translocation of TORC is pivotal to their role in CREB-directed gene 
transcription. In the basal condition, TORC2 and 3 are phoshorylated on Ser-171 and Ser-
163, respectively, by the salt-inducible kinase-1(SIK1), a member of the family of AMP-
activated protein kinases (AMPK). However, phosphorylation of TORC1 on Ser-167 may 
be due to SIK1 and as yet unidentified kinases (Screaton et al., 2004; Katoh et al., 2006). 
SIK1 is found to repress CREB activity in both nucleus and cytoplasm, and enhance 
Phospho-TORCs relocation from the nucleus to the cytoplasm where they are 
sequestered via phosphorylation-dependent association with 14-3-3 proteins (Screaton et 
al., 2004; Katoh et al., 2004). SIKs are activated by the tumour suppressor kinase LBK1 
through phosphorylation at a threonine in the A-loop of SIKs (Katoh et al., 2006).  
Besides SIKs, AMPKs (5’-AMP activated protein kinases) were also identified as kinases 
of TORC proteins. Activated AMPK kinases phosphorylate TORC2 at Ser-171 which 
results in inhibition of O-glycosylation, interaction with 14-3-3 proteins, sequestration in the 
cytoplasm, and prevention of transcriptional activation (Koo et al., 2005; Takemori et al., 
2007a; Dentin et al., 2008). LKB1 can also phosphorylate and activate AMPK (Shaw et al., 
2005). 
Recently, Ser-275 on TORC2 (equivalent to Ser-261 on TORC1) was indentified as 
another regulatory phosphorylation site (Jansson et al., 2008). In beta cells, the 
phosphorylation of TORC2 on Ser-171 responds primarily to cAMP signals (Koo et al., 
2005; Screaton et al., 2004), whereas Ser-275 phosphorylation of TORC2 is induced by 
low level glucose and is blocked by glucose influx-induced calcineurin (Jansson et al., 
2008). MARK2 (MAP/microtubule affinity-regulating kinase) specifically phosphorylates 
TORC2 at both Ser-171 and Ser-275, leading to TORC2 interaction with 14-3-3 proteins 
and attenuation of CREB-dependent gene transcription (Jansson et al., 2008). Despite 
Ser-369 of TORC2 is the interaction site with 14-3-3 proteins, it does not control the 
nuclear localization of TORC2 (Jansson et al., 2008). 
In contrast with the other studies whereby phosphorylation of TORCs leading to their 
cytosolic accumulation and transcriptional reduction, MEKK1 (a MAPKKK) induces the 
transcriptional activity of TORC1 by direct phosphorylation on as yet unidentified sites of 
its C-terminal 220 aa which results in its nuclear localization. 
Another mechanism that downregulates TORC activity was found due to proteosome-
dependent degradation. Dentin et al. (2007) showed that on Ser-171 phosphorylated 
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TORC2 sequestered in the cytoplasm undergoes polyubiquitination at K628 leading to its 
degradation. 
TORC nuclear localization increases under elevation of intracellular cAMP or Ca2+, signals 
enhancing CREB-directed gene transcription, (Bittinger et al., 2004; Screaton et al., 2004). 
Indeed, cAMP and Ca influx work in different ways and converge on the 
dephosphorylation of TORCs at regulatory sites and shuttle between nuclear and 
cytoplasm. 
An increase in calcium influx activates the calcium/camodulin-dependent phosphatase 
calcineurin which binds directly to and dephosphorylates TORCs at regulatory 
phosphorylation sites leading to TORC nuclear localization (Bittinger et al., 2004; Screaton 
et al., 2004), 
Distinctly, elevation of intracellular cAMP by treatment with forskolin, a bicyclic diterpene 
activating the enzyme adenylyl cyclase, inhibits TORC phosphorylation activity of SIK by 
activating PKA which was shown to phosphorylate SIK1 at Ser-577 (Katoh et al., 2004; 
Takemori and Okamoto, 2008). 
In the nucleus, TORC binds to the leucine zipper of CREB and activates the CREB-
dependent gene transcription (Screaton et al., 2004). p300/CBP recruitment of TORC to 
CREB is not dependent on phosphorylation of CREB at Ser-133, as p300/CBP does. 
However, TORCs enhance the association of TAFII130 with CREB independent of Ser-133 
phosphorylation (Conkright et al., 2003). In the nucleus, TORC is shown to interact directly 
with CBP and they together mediate CREB target gene transcription (Ravnskjaer et al., 
2007; Xu et al., 2007). 
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TORC coactivators have been shown to be involved in many physiological and 
pathological processes. Regarding cell metabolism, TORC 2 modulates the signals of 
insulin and gluconeogeneis (Canettieri et al., 2005; Koo et al., 2005; Dentin et al., 2007, 
2008). TORCs regulate mitochondrial biogenesis and energy metabolism through 
activation of peroxisome proliferators-activated receptor  coactivator 1 (PPAR1) gene 
transcription (Wu et al., 2006). TORCs are also transcriptional activators of steroidogenic 
acute regulatory protein (StAR), a mitochondrial protein involved in cholesterol metabolism 
(Takemori et al., 2007b). 
Figure 4: The nucleo-cytoplasmic shuttling of TORC (Screaton et al., 2004, Gonzalez et al., 
1989, Takemori and Okamoto, 2008, Katoh et al., 2004 and 2006; Sun, P. et al, 1994). 
In basal conditions TORC proteins are phosphorylated (at Ser171 of TORC2 or Ser163 of 
TORC3) by salt inducible kinase (SIK). The phospho-TORCs translocate from the nucleus to the 
cytoplasm where they are sequestered through interaction with 14-3-3 proteins. 
Under stimulated condition, such as with Forskolin, the elevation of intracellular cAMP activates 
protein kinase A (PKA) and release the C subunit from tetramers of PKA. Diffusion of the C 
subunit into the nucleus leads to phosphorylation of CREB at Ser133, which activates CREB-
directed transcription. In addition, PKA phosphorylates SIK1 and 2 at Ser577 and Ser587, 
respectively, which inhibit the phosphorylation of TORCs by SIKs. The PKA-induced 
phosphorylation of SIK also enhances SIK cytoplasmic redistribution.  
In the calcium-dependent pathway, the increase of intracellular Ca2+ level activates the 
calcium/calmodulin-dependent phosphatase leading to dephosphorylation of TORCs and to 
accumulation of TORCs in nucleus where they enhance the phospho CREB-independent gene 
transcription. High Ca2+ levels also activate calcineurin (CN), calcium/calmodulin-dependent 
kinase (CaMK), which phosphorylates CREB at S133 and activates CREB-directed 
transcription.  
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In addition, TORCs have also some roles in cell development and death. TORC2 
regulates the development of B-cells (Kuraishy et al., 2007) or induces the expression of 
antiapoptotic BCL2 gene (Kim et al., 2008). In the hippocampus TORC1 is necessary for 
late-phase long-term synaptic potentiation (Zhou et al., 2006; Kovács et al., 2007). 
Other findings demonstrated the role of TORCs in tumorigenesis (Siu and Jin, 2007). 
TORC1 fused with MAML2, an oncoprotein found in malignant salivary gland tumor, 
promotes oncogenesis through activating CREB and its target genes (Coxon et al., 2005; 
Wu et al., 2005). TORCs are also essential coactivators of the Tax oncoprotein of human 
T-cell leukemia virus type 1 (HTLV-1) in the activation of viral long-terminal repeats (Koga 
et al., 2004; Siu et al., 2006). This coactivation is inhibited by BCL3 (Hishiki et al., 2007).  
1.4 Dual leucine zipper bearing kinase 
The Dual leucine zipper bearing kinase (DLK) was first characterized from embryonic 
mouse kidney by Holzman et al. (1994) using degenerate oligonucleotide-based 
polymerase chain reaction cloning. DLK homologs identified in human and rat cell lines 
were termed ZPK (human zipper protein kinase) and MUK (MAPK upstream kinase), 
respectively. (Reddy and Pleasure 1994; Blouin et al. 1996; Hirai et al. 1996) 
A DLK transcript is expressed in a tissue-specific and developmentally regulated pattern: it 
was identified in aldult ovary and most abundant in adult brain and all developmental 
stages of embryonic brain, kidney, lung, and heart (Holzman et al., 1994); by studies on 
embryonic mice, DLK transcripts have been found in other organs such as skin, intestine, 
pancreas (Nadeau et al. 1997); DLK transcripts were detected in some organs of the adult 
mouse, most abundant in the central nervous system, as well as in the epithelial 
compartment of the stomach, intestine, liver and pancreas (Blouin et al. 1996).  
At the protein level, DLK protein is predominantly present in synaptic termini of neurons, 
where it is bound to both the plasma membrane and cytosolic compartments (Mata et al. 
1996); DLK protein and mRNA were also observed in mouse brain, human skin, (Germain 
et al. 2000; Hirai et al. 2005; Robitaille et al. 2005), mouse pancreatic islets of Langerhans 
(Oetjen et al. 2006) and in mesenteric white adipose and brown adipose tissue of mature 
mice (Couture et al. 2009). 
In the nuclei of neurons, DLK was also detected in a small quantity (Merritt et al. 1999). 
DLK was shown to associate with the Golgi apparatus in fibroblasts (Douziech et al. 
1999). 
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1.4.a Structure of DLK 
The ZPK gene, a homolog of DLK, is located on human chromosome 12, which encodes a 
protein of 859 amino acids (Reddy et al. 1995). In the mouse, DLK gene is located on 
mouse chromosome 15 (Watanabe et al. 1997).  
The mouse DLK protein is composed of 888 amino acids, which is recognized as a protein 
with an apparent molecular mass of 130 kDa through immunoblot by the anti-DLK immune 
serum. It has a kinase catalytic domain, a leucine zipper domain which includes two 
leucine/isoleucine motifs with a short spacer region in between, and the glycine- and 
proline- rich domains at both N-terminal and C-terminal ends (Fig. 5) (Holzman.L.B et 
al.1994). 
 
 
 
 
 
Sequence alignment showed that DLK is closely similar to the members of the Mixed 
Lineage Kinase family, a subfamily of Mitogen-activated protein kinase kinase kinase 
MAPKKK (Gallo and Johnson 2002). They share two common structural features: their 
catalytic domain has amino acid sequence similar to those of serine/threonine-specific and 
tyrosine-specific protein kinases; and they contain two Leucine/Isoleucine zipper motifs, 
which are separated by a short spacer region, located C-terminally near the catalytic 
domain (Dorow et al., 1993, Holzman et al., 1994). However, the catalytic domains of MLK 
members are more identical to each other than that of DLK. The zippers of DLK have 24% 
sequence identity and 46% sequence similarity to the zippers of MLK3, whereas MLK3 
zippers are 61% identical and 76% similar to MLK1 and 2 (Holzman, L.B et al., 1994).  
DLK and LZK (leucine zipper bearing kinase, characterized by Sakuma et al., 1997), 
which share 90% identity in catalytic and leucine zipper domains, are suggested as a 
distinct subgroup of MLK subfamily. They lack both CRIB (Cdc42/Rac interactive binding)-
motifs and a N-terminal SH3 (Src homology 3)-domains which are contained within the 
MLK1/2/3 proteins. Additionally, both have C-terminal sequences which are different from 
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Figure 5: The structure of DLK protein (Holzman.L.B et al., 1994). 
DLK composes of two glycine-proline rich domains at both C- and N-termini. The kinase 
catalytic domain located from residue 156 to 405 includes 11 subdomains typical of 
serine/threonine and tyrosine protein kinase families. Two heptad repeats of nonaromatic 
hydrophobic amino acids of leucine zipper motifs located from residue 421 to 501 are separated 
by a spacer of 25 amino acids. 
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each other and from those of MLK1/2/3 (Holzman et al., 1994, Sakuma et al., 1997, 
Nihalani et al., 2000). 
Wallenda and DLK-1, two orthologs of DLK identified in Drosophila melanogaster and 
Caenorhabditis elegans, respectively,  share sequence identity of 23% and 31% to mouse 
DLK, respectively. 
1.4.b Characteristics and function of DLK 
MLK members are characterized by an autocatalytic activity and leucine zipper-based 
homodimerization (Dorow et al. 1993, Gallo et al. 1994, Tanaka and Hanafusa, 1998). 
Given such features, Mata et al. (1996) experimented on COS7 cell line and showed that 
DLK autophosphorylates in vivo and migrate at 260 kDa on nonreducing SDS-PAGE, and 
the Flag-tagged DLK immunoprecipitated with the Myc-tagged DLK. This led to conclusion 
that DLK is able to autophosphorylate and homodimerize (Mata et al. 1996).  
MLK members are composed of hybrid structures of catalytic domains and exhibit mostly 
serine/threonine-specific autocatalytic activity in vitro (Gallo et al., 1994). Likewise, DLK 
was shown to autophosphorylate on serine and threonine, but not tyrosine (Holzman et 
al., 1994). Additionally, DLK phosphorylates -casein and myelin basic proteins on serines 
and threonines (Mata et al., 1996). 
Studies on the ATP binding site of DLK showed that lysine-185 is important for kinase 
activity of DLK. The DLK K185A mutant, lysine-185 is mutated to alanine, has no 
autocatalytic activity and unable to phosphorylate -casein. DLK homodimerization does 
not depend on its kinase catalytic activity (Mata et al. 1996). 
Regulation of DLK activity by oligomerization and phosphorylation 
About the mechanism that relate to the activation and regulation of DLK in mammalian 
cells is little known. The oligomerization and dimerization of DLK are suggested as 
important processes leading to DLK activation. The leucine zipper domain of DLK with an 
-helical structure is necessary for DLK homodimerization. DLK P-P point mutant with 
disrupted -helical structure in which the Leu-437 and Leu-463 were replaced by proline 
residues did not interact with the leucine zipper domain of DLK (Nihalani et al. 2000). 
Homodimerization of DLK takes place through its leucine zipper domain, which leads to its 
autophosphorylation and the activation of JNK pathway (Nihalani et al. 2000).  By binding 
Introduction  
 22
to the scaffold protein JIP-1 (JNK interacting protein) and MBIP (MAPK upstream kinase 
(MUK)-binding inhibitory protein) DLK remains in its monomeric and inactive form 
(Nihalani et al. 2000, Fukuyama et al. 2000). Especially, DLK leucine zipper domain 
interacts with only the leucine zipper of DLK, not other MLKs (Nihalani et al. 2000). 
In addition, the phosphorylation status of DLK also regulates its activation. 
Oligomerization-dependent autophosphorylation of DLK results in activation of JNK signal 
pathway (Nihalani et al. 2000). Recently, Daviau et al. (2009) have observed that 
treatment of cells with vanadate, a tyrosine phosphatase inhibitor, or PDGF (platelet-
derived growth factor) results in tyrosine phosphorylation of DLK and enhances DLK 
enzymatic activity. 
In basal condition, phosphorylation of DLK is regulated by the serine/threonine 
phosphatase PP1 and PP2A: by treatment of cells with okadaic acid, an inhibitor of protein 
phosphatases PP1 and 2A, phosphorylated DLK is accummulated (Mata et al. 1996). 
Under basal condition, phosphorylation status of DLK is not effected by the calcineurin 
inhibitor Cyclosporin A (CsA). However, CsA inhibits the membrane depolarization-
dependent dephosphorylation of DLK. By this way, increased intracellular calcium 
enhances dephosphorylation of DLK via calcineurin activation-related pathway (Mata et al. 
1996). 
Regulation by interaction and degradation  
Several studies demonstrated that overexpressed DLK induces JNK activation in different 
cell lines (Fan et al. 1996; Hirai et al. 1996; Robitaille et al. 2005). In addition, DLK was 
observed to activate MKK4 (Mitogen-activated protein kinase kinase 4) and MKK7, which 
are upstream activators of JNK. Therefore, it is possible that JNK activation is modulated 
by DLK through MKK 4 and MKK7 (Hirai et al. 1997; Merritt et al. 1999). It is unclear how 
DLK induce MKK4 activation, however, MKK7 was shown to directly interact with DLK 
(Merritt et al. 1999). 
In the kidney cell line COS-7, DLK remains in its monomeric, none-phosphorylated and 
inactivated form by the interaction with the scaffold protein IB/JIP-1 (islet brain/JNK 
interacting protein-1) (Nihalani et al., 2001; 2003). Phosphorylation of IB/JIP-1 by JNK 
results in the dissociation of DLK from the complex. DLK in its homodimerized and 
autophosphorylated form become catalytic active and phosphorylate MKK7, which 
activate the downstream Kinase JNK (Nihalani et al., 2001; 2003).  
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JNK contributes to the stability of DLK by a positive feedback loop mechanism. Apoptotic 
stimuli-induced stabilization of DLK (or JIP, MLK) is prevented by inhibition of JNK 
expression or activation (Xu et al. 2001; Xu et al. 2005). 
Beside regulation by interaction, DLK was shown to undergo ubiquitination-mediated 
degradation. 
In mouse fibroblasts, DLK stability is regulated by interaction with the stress-inducible heat 
shock protein Hsp70 and its co-chaperone CHIP, an E3 ubiquitin ligase. Okadaic acid-
activated DLK wild type, not the kinase-deficient mutant, is proteasomally degraded by 
CHIP associated with Hsp70 (Daviau et al. 2006). The same regulatory process is 
conserved with DLK orthologs. In Drosophila melanogaster and Caenorhabditis elegans, 
DLK orthologs Wallenda and DLK-1, respectively, are downregulated by Highwire/RPM-1, 
an E3 ubiquitin ligase (Nakata et al. 2005; Collins et al. 2006; Wu et al. 2007). 
In addition, DLK expression is also downregulated through proteasomal degradation by 
Phr1, the mammalian homolog of Highwire/RPM-1, (Lewcock et al. 2007); however, it is 
not clear yet because Phr1 mutant mice exhibited no increase in DLK detected in the 
central nervous system (Bloom et al. 2007). 
Phenotypes 
 DLK -/- mice exhibit abnormal brain development and die perinatally due to the absence 
of anterior commissure and defects in axon growth and radial migration of neocortical 
pyramidal neurons (Hirai et al. 2006; Bloom et al. 2007). Axon degeneration induced by 
nerve injury is blocked by a gene-trap mutation of DLK in mice (Miller et al. 2009). 
By mutation of DLK-1, an ortholog of DLK, in C. elegans, the axon regeneration of injured 
neurons was impaired (Hammarlund et al. 2009). Wallenda, another DLK ortholog, was 
also found to be involved in normal axon degeneration (Miller et al. 2009) and axonal 
transport (Horiuchi et al. 2007).  
Protein Function  
Like other members of MLK, DLK is an upstream activator of JNK (Rana et al. 1996; 
Tibbles et al. 1996; Cuenda et al. 1998; Hirai et al. 1998; Merritt et al. 1999). DLK has 
been shown to be involved in various pathway and processes in different cell lines. A 
number of studies showed that DLK activates JNK signalling pathway probable by 
phosphorylation of MKK4 and MKK7 (Fan et al. 1996; Hirai et al. 1996; Robitaille et al. 
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2005; Hirai et al. 1997; Merritt et al. 1999). After membrane depolarization in the HIT T15 
cell line, DLK inhibits the transcriptional activity of CREB (Oetjen et al. 2006). In mouse 
NIH 3T3 fibroblasts, suppression of DLK by siRNA inhibits platelet derived growth factor 
(PDGF)-stimulated extracellular signal-regulated kinase (ERK) and causes Akt kinase 
activation (Daviau et al. 2009). DLK activates p46SAPK and P38 MAPK, but not ERK2 (Fan et 
al., 1996). 
By overexpression of DLK, it has been shown that DLK is involved in apoptosis of 
pancreatic beta cells (Plaumann et al. 2008) and of neurons (Xu et al. 2001; Hirai et al. 
2002; Chen et al. 2008). The terminal differentiation of human epidermal keratinocytes is 
regulated by DLK (Germain et al. 2000; Robitaille et al. 2005). Knockdown of DLK by 
siRNA blocks calphostin C-induced apoptosis of NIH 3T3 cells (Robitaille et al. 2008) or 
prevents adipocyte differentiation of 3T3-L1 cells (Couture et al. 2009). 
DLK regulates radial migration and axon projection via modulating JNK activity (Hirai et al. 
2006). DLK was demonstrated to promote degradation of injured neurons in adult mice 
(Miller et al. 2009). Two orthologs of DLK in Drosophila melanogaster and Caenorhabditis 
elegans exhibit the same feature: the DLK-deficient mutants protect injured neurons from 
degradation (Miller et al. 2009; Hammarlund et al. 2009). Additionally, a new regulatory 
feature of DLK has been indentified that it is involved in the viability of cancer cells 
(Schlabach et al. 2008). 
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Figure 6: The role of DLK in MAPK signaling pathway (Garrington and Johnson 1999) 
DLK is upstream in the MAPK pathway. By activating MKK7 DLK induces JNK-dependent 
pathways which confer different responses of the cells. Abbreviations were mentioned in 
the Abbreviation list. 
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Previous studies demonstrated that DLK reduces CRE- and CREB-directed transcription 
after membrane depolarization in the electrically excitable cell line HIT (Oetjen et al. 
2006). Since DLK decreased CBP transcriptional activity either stimulated by membrane 
depolarization or under basal conditions, it was proposed that DLK inhibits membrane 
depolarization-induced CREB activity at least in part through inhibition of CBP (Oetjen et 
al. 2006). Given that in addition to CBP the recruitment of TORC is required for CREB 
transcriptional activity (Screaton et al. 2004), besides CBP TORC might be a target of 
DLK action. Therefore, in the present study the regulation of TORC by DLK was 
investigated.   
1.5. Objectives of the study 
The present study aimed to elucidate the molecular mechanism through which DLK 
regulates the activity of TORCs 
To obtain this purpose the effects of DLK on TORCs have been investigated in aspects 
such as: the transcriptional activity, the nuclear accumulation, the phosphorylation and the 
recruitment to the promoter. Moreover, the interaction between DLK and TORC was 
examined in vitro and in vivo.  
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MATERIAL AND METHODS 
 
2. MATERIAL 
2.1. Equipments &  Consumables 
2.1.a. Equipment  
Autoclave Bioclav, Schütt Labortechnik, Göttingen, Germany 
 
Balances Sartorius AG, Göttingen, Germany 
 
Cell culture hood Lamin Air, Heraeus, Hanau, Germany 
 
Centrifuge rotors JA-20/JA-17/JA-14, Ti 70, Beckamnn GmbH, Krefeld, Germany 
 
Centrifuges Beckmann centrifuge GS-6 –Beckmann GmbH, München, Germany 
Beckmann J2HS centrifuge – Beckmann GmbH, München, Germany 
Beckmann L8-70M Ultracentrifuge – Beckmann GmbH, München, 
Germany 
Biofuge 15R – Heraeus / Thermo Electron Corp. Langenselbold, 
Germany 
Biofuge pico – Heraeus / Thermo Electron Corp., Langenselbold, 
Germany 
Eppendorf 5417R, Eppendorf GmbH, Hamburg, Germany 
Megafuge 1.0 – Heraeus Sepatech, Langenselbold, Germany 
 
Cell Disrupter Branson Sonifyer® B15 – Heinemann Ultraschall- u. Labortechnik, 
Schwäbisch Gmünd, Germany 
Dounce homogenizer (1 ml) – Kontes Glas Co., Vineland, USA 
 
DNA Sequencer ABI PRISM 3100 Genetic Analyzer – Applied Biosystems, Darmstadt, 
Germany 
ABI PRISM 7900 HT Sequence Detection System – Applied 
Biosystems, Darmstadt, Germany 
 
Electrophoresis 
power supplier 
Biometra® Standard Power Pack P25 – Whatman Biometra, 
Göttingen, Germany 
 
Electrophoresis 
chamber (DNA) 
Roth, Karlsruhe, Gemnany 
 
 
Electrophoresis 
(proteins) 
Electrophoresis chamber SE 600 – Hoefer Scientific Instruments, San 
Francisco, USA  
Mighty Small SE 250/SE 260, Hoefer Scientific Instruments, San 
Francisco, USA 
Mighty Small SE245 Dual Gel Caster, glasses, spacer, combs – 
Hoefer Scientific Intsruments, San Francisco, USA 
 
Gel Dryer  DryGel Sr Slab Gel Dryer, SE1160 - Hoefer Scientific Instruments, 
San Francisco, USA 
 
Incubators Bacteria Incubator – Heraeus / Thermo Electron Corp., 
Langenselbold, Germany 
InnovaTM4300 Incubator – New Brunswick Scientific GmbH, Nürtingen, 
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Germany 
Incubator STERI CULT 200 – Forma Scientific Inc., San Bruno, USA  
 
Luminometer AutoLumat LB 953, Berthold Technologies GmbH & Co.KG, Bad 
Wildbad, Germany 
 
Micro pipettes Gilson, France 
 
Micro plate reader 
for GFP 
FusionTM, Packard, Switzerland 
 
 
Microscope Zeiss Axiovert 200 microscope – Carl Zeiss AG, Oberkochen, 
Germany 
 
Microwave oven Phillips, Whirlpool, UK 
 
PCR cycler PCR cycler T-Gradient – Biometra, Göttingen, Germany 
PTC-200 Peltier Thermal Cycler – Biozym, Hess.-Oldendorf, Germany 
 
pH meter pH 523, Schütt Labortechnik, Göttingen, Germany 
 
Phospho Image 
Scanner 
BAS-MS 2325 phosphor-imager screen – FUJIFILM, purchased from 
raytest Isotopenmess-geräte GmbH, Straubenhardt, Germany 
BAS-1800II phosphor-imaging device – FUJIFILM, purchased from 
raytest Isotopenmess-geräte GmbH, Straubenhardt, Germany 
 
Pipetus akku Hirschmann Laborgeräte, Göttingen, Germany. 
 
Rocking platform Biometra, Göttingen, Germany 
Rocking platform Polymax 1040 – Heidolph Instruments GmbH & 
Co.KG, Schwabach, Germany 
 
Rolling platform TRM-V – IDL, Nidderau, Germany 
 
Rotator Rotator GFL 3025 – Gesellschaft für Labortechnik GmbH, Burgwedel, 
Germany 
 
Spectrophotometer Shimadzu UV-160, Duisburg, Germany 
 
Semi-dry transfer 
device 
Bender & Hobein, Switzerland 
 
 
Shaking platform Certomat®R shaking platform – Sartorius, Göttingen, Germany  
 
Temperature 
regulator 
Certomat®HK temperature-regulating device – Sartorius, Göttingen, 
Germany 
 
Thermomixer Eppendorf, Hamburg, Germany 
 
Tube Sealer Beckmann Tube Sealer – Beckmann GmbH, München, Germany. 
 
Vacuum Pump KnF Laboport, Neuberger, Germany 
 
Waterpump Schütt Labortechnik, Göttingen, Germany 
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Waterbath W. Krannich GmbH, Göttingen, Germany 
 
X-ray Cassettes  Eastman KODAK Company, New York, USA 
 
2.1.b. Consumables 
Cell culture dishes Falcon™ 6 cm cell culture dishes and 
BD Falcon™ 15 cm cell culture dishes – Schuett24 
GmbH, Göttingen, Germany 
 
Coverslips Nunc™ Thermanox Plastic Coverslips, 25 mm 
diameter – Nunc, Roskilde, Denmark 
 
Disposable cell scraper Sarstedt, Nümbrecht, Germany 
 
Dialysis tubes GIBCO BRL, Karlsruhe, Germany  
 
ECL- X ray films Amersham Biosciences, Freiburg, Germany 
 
Eppendorf tubes Eppendorf, Hamburg, Germany 
 
15, 50 ml tubes Greiner Bio-one, Solingen, Germany 
 
Filter units Sartolab, Biofiltronic GmbH, Nörten-Hardenberg, 
Germany 
 
Glass pipettes WU, Mainz, Germany 
 
Glassware Schott Duran, Mainz, Germany 
 
Gloves Paul Hartmann AG, Heidenheim, Germany 
 
Microscope slides 76x26mm Roth, Karlsruhe, Germany 
 
Microplates 96-well microplates, U-shaped bottom – Sarstedt, 
Nümbrecht, Germany 
96-well Millipore plates (Millipore-MAHV N45) – 
Millipore GmbH, Schwalbach, Germany 
384-well PCR plate – Applied Biosystems, 
Darmstadt, Germany 
 
Nitrocellulose membrane (0.45µm) Hybond™, ECL™, Amersham Biosciences 
Freiburg, Germany 
 
Parafilm Parafilm® M – Brand GmbH & Co KG, Wertheim, 
Germany 
 
Pasteur pipettes Brand, Wertheim / Main, Germany 
 
Plates (agar) Greiner, Frickenhausen, Germany 
 
Pipette tips Sarstedt, Nümbrecht, Germany 
 
Plastic tubes for luminometer (5 ml) Sarstedt, Nümbrecht, Germany 
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Quick Seal Tubes Beckmann GmbH, Munich, Germany 
 
Spectrophotometer cuvettes (plastic) Sarstedt, Nümbrecht, Germany 
 
Spectrophotometer cuvettes (quartz) Sarstedt, Nümbrecht, Germany 
 
Syringes BD Discardit II, Beckton Dickinson, Spain 
 
Syringe filters Sartorius, Göttingen, Germany 
 
Syringe needles Sterican, B/BRAUN, Melsungen, Germany 
 
Tips Tips (10 µL) - Eppendorf AG, Hamburg, Germany  
Tips (200 µL, 1 mL) - Sarstedt, Nümbrecht, 
Germany 
 
Ultracentrifuge tubes Beckman GmbH, Krefeld, Germany 
 
Whatman paper P81 Whatman, Maidstone, UK 
 
6-well plates Nunc, Roskilde, Denmark 
 
 
2.2. Chemicals  
2.2.a. Substances  
Amersham Biosciences GmbH (Freiburg, Germany): DEAE-Dextran, Sephadex G50 
AppliChem GmbH (Darmstadt, Germany): Albumin fraction V,  Acetic acid, Acrylamide, 
Agar, Ampicillin, Ammoniumpersulfate (APS), Aprotinin, ATP, Bis-acrylamide, Boric acid, 
Bromide, Bovine serum albumin (BSA), Chlorophorm, Cesium chloride, Dimethyl sulfoxide 
(DMSO), Dithiothreitol (DTT), D-saccharose, EDTA, EGTA, Ethanol, 37% formaldehyde, 
Glucose, 87% glycerol, Glycine, Glycylglycine, HEPES, Hydrochloric Acid (HCl), Imidazol , 
Iso-amylalcohol, Iso-propanol, Isopropyl-β-D-thiogalactoside (IPTG), Leupeptin, Low fat 
milk, Lysozyme, Magnesium chloride (MgCl2), Magnesium sulphate (MgSO4), Manganese 
chloride MnCl2(H2O)4, Methanol, β-Mercaptoethanol, Pepton from casein, Potassium 
chloride (KCl), Potassium diphosphate, Potassium-di-hydrogenphosphate (KH2PO4), Di-
potassium-hydrogenphosphate (K2HPO4), Pepstatin A, Pepton from casein, 
Phenylmethylsulfonylfluorid PMSF, Ponceau S solution, Potassium di-hydrogen 
phosphate (KH2PO4), Polyethylene glycol 6000 (PEG 6000), Skim milk, Sodium acetate, 
Sodium borohydrate, Sodium carbonate (Na2CO3), Sodium bicarbonate, Sodium chloride, 
Sodium-dodecylsulfate (SDS), Sodiumhydrogencarbonate (NaHCO3), Sodiumhydroxide 
(NaOH), Sodium-di-hydrogenphosphate (NaH2PO4·2H2O), Di-Sodium-hydrogenphosphate 
(Na2HPO4), TEMED, Tris base, Tween 20, Tween 80, -mercaptoethanol,  Zinc chloride. 
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Biomol GmbH (Hamburg, Germany): Phenol (liquefied and Tris saturated) 
Biontex (München, Germany): Metafectene 
Hartmann Analytics (Braunschweig, Germany): 32P]- -ATP, L-35S]-Methionine 
Invitrogen (Karlsruhe, Germany): Agarose (Electrophoresis Grade) 
Kodak AG (Stuttgart, Germany): GBX Fixation solution, LX24 x-ray developer 
MANAC Incorporated (Fukuyama, Hiroshima, Japan): Phos-tagTM Acrylamide AAL-107 
Merck (Darmstadt, Germany): n-Butanol, Nonidet-P40 
Promega GmbH (Mannheim, Germany): D-Luciferin 
Qiagen: Ni-TNT-Agarose beads 
Roche (Mannheim, Germany): ATP, GTP, CTP, TTP  
Sigma-Aldrich Chemie GmbH (Harmburg, Germany): Bromphenolblue, Sepharose CL-4B, 
Coomassie brilliant blue, Cyclosporin A, Deoxycholic acid, Ethidium bromide, Forskolin 
Glutathione-agarose beads, L-Glutathione, Lithiumchloride (LiCl), Chloroamphenicol, 25 
% glutaraldehyde, Okadaic acid, Protein A agarose, Sodium fluoride, Sodium 
orthovanadate, Triton X-100, Xylene cyanol FF 
 
2.2.b. Stock solutions and buffers 
2.2.b.I. Stock solutions 
All stock solutions were prepared in double-destilled H2O if not stated differently. 
Ampicillin    5 % (w/v) 0.5 g / 10 ml 
Aprotinin    50 g/l 5mg/100 l of 10 mM Tris/HCl pH8.0 
APS     10 % (w/v) 1 g / 10 ml  
ATP     200 M 1.1 g / 9.075 ml distilled water 
Chloroform / isoamylalcohol  1/24 (v/v) 1ml / 24 ml 
Chloramphenicol     34 mg /ml 99% EtOH 
Cyclosporin A (CsA)  830M  1mg in 0.1ml 99% EtOH, plus 20 l 
Tween 80, drop in 1ml RPMI 
Dithiothreitol (DTT)   1 M  1.542 g / 10 ml 
EDTA pH 8.0    0.5 M  46.53 g / 250 ml 
EGTA pH 7.8 – 8.0   180 mM 3.423 g / 50 ml 
Ethidium Bromide     100 mg / 10 ml 
Forskolin    10 mM  1 mg / 243.6 µl DMSO 
Hepes pH 7.5    1 M  59.58 g / 250 ml 
Glucose    0.5 M  9 g / 100 ml 
Glycine    1 M  7.507 g / 100 ml  
Glycylglycine pH 7.8   0.5 M  3.303 g / 50 ml 
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Kanamycin    5 % (w/v) 0.5 g / 10 ml 
KCl     2 M  2.98 g / 20 ml 
K2HPO4    0.5 M  4.35 g / 50 ml    
KH2PO4    100 mM 3.402 g / 250 ml 
LiCl     4 M  1.696 g / 10 ml 
Leupeptin    50 g/l 5 mg / 100 l of 10 mM Tris/HCl pH8.0 
MgCl2     1 M  5.08 g / 25 ml 
MgSO4     1 M  12.324 g / 50 ml 
MnCl2      10 mM  0.1 g of MnCl2 (H2O) 4 / 50 ml 
NaCl     0.5 M  0.292 g / 10 ml 
Na2HPO4    75 mM  1.33 g / 100 ml 
NaH2PO4    75 mM  1.33 g / 100 ml 
NaOH     1 N  4 g / 100 ml 
Phos-tagTM AAL solution  5 mM  10 mg / 3.3 ml 
Penicillin/Streptomycin  10,000 U/ml / 10,000 g/ml (ready to use solution-GIBCO) 
PMSF     200 mM 348 mg / 10 ml 99%-ethanol 
Pepstatin    50 g/l 5 mg / 100 l of 10 mM DMSO 
RNase     0.01% (w/v) 0.1 mg / ml 
SDS      10% (w/v) 25 g / 250 ml 
Tris/HCl     1 M  60.57 g / 500 ml 
(pH of Tris/HCl was adjusted to 6.8, 7.4, 7.5, or 8.0 with 6 N HCl) 
The following stocks were aliquoted and stored at -20°C: Aprotinin, APS, ATP, DTT, 
Forskolin, Leupeptin, Pepstatin, Penicillin/Streptomycin.  Cyclosporin A was kept at 4°C. 
The others were stored at room temperature. 
 
2.2.b.II. Buffers  
Routinely used buffers and media were prepared as follows: 
Stocks of Tris-base and HEPES were adjusted to different pH using hydrochloric acid 
(HCl). 
PBS pH 7.4 1x 1 L 
NaCl 140 mM 8.00 g 
KCl 2.5 mM 0.20 g 
Na2HPO4 8.1 mM 1.44 g 
KH2PO4 1.5 mM 0.24 g 
The buffer was autoclaved and stored at room temperature. 
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2.3. Biological Material  
2.3.a. Kits 
Big Dye® Terminator v1.1 Cycle Sequencing Kit – Applied Biosystems, Darmstadt, 
Germany 
Bradford Dye Reagent for Protein Assays – Biorad, München, Germany 
Easy Pure® DNA purification kit – Biozym, Hess.-Oldendorf, Germany 
ECL Western Blotting Analysis System – Amersham Biosciences, Freiburg, Germany 
TaqMan® Gene Expression Master Mix – Applied Biosystems, Darmstadt, Germany 
TNT T7 Coupled Reticulocyte Lysate System – Promega, Mannheim, Germany 
Vectashield® Mounting Medium with DAPI – Vector Laboratories, Burlingame, USA 
 
2.3.b. Procaryotic and eukaryotic cell lines 
Prokaryotic cell lines 
Chemically competent Escherichia coli strain DH5α was used for plasmid amplification. 
Chemically competent Escherichia coli strain BL-21 was used for expression of 
recombinant GST-fusion proteins and His-tagged proteins. 
Eukaryotic cell lines 
Hamster insulinoma tumor cells, clone HIT-T15 (Santerre et al., 1981), were used for all 
experiments in this thesis. 
 
2.3.c. Media and material for cell cultures  
Gibco BRL (Karlsruhe, Germany): Agar, fetal calf serum, horse serum, Penicillin / 
Streptomycin, Trypsin / EDTA, RPMI medium 
AppliChem GmbH (Darmstadt, Germany): Yeast extract 
LB medium  1000 ml  
NaCl 1 % (w/v) 10 g  
Pepton 1 % (w/v) 10 g  
Yeast extract 0.5 % (w/v)   5 g  
Ampicillin (or Kanamycin) 50 µg / ml 1000 µl 5 % stock solution
(added after autoclaving of the 
LB medium) 
 
The LB medium was autoclaved and stored at room temperature. Ampicillin or kanamycin 
was added freshly to the LB medium before use. LB medium was used for the culture of 
bacteria. 
 
Material and Methods  
 33
RPMI complete medium  500 ml 
RPMI Medium  450 ml 
Fetal calf serum 10 % (v/v)   50 ml 
Horse serum 5 % (v/v)   25 ml 
Penicillin / streptomycin 1 % (v/v)     5 ml 
The RPMI complete medium was prepared under sterile condition and stored at 4°C. 
RPMI medium was used for culture of eukaryotic cell line. 
 
2.3.d. Plasmids  
2.3.d.I. Expression vectors  
The coding sequence for human CREB is deposited in the GenBank database under 
GenBankAccession Number M27691.  
The coding sequence for mouse DLK is deposited in the GenBank database under 
GenBankAccession Number NM009582. 
The coding sequences for full lengths or fragments of human TORC1, TORC2, and 
TORC3 are based on the sequences provided kindly by Mark Labow (Novartis 
Pharmaceuticals, Suffern, NY, USA) and deposited in the GenBank database under 
GenBankAccession Numbers AY360171, AY360172, and AY360173, respectively.  
The coding sequences for full lengths of mouse TORC1 is deposited in the GenBank 
database under GenBankAccession Numbers NM_001004062. 
 
Mammalian expression vectors 
The plasmids for mammalian expression used in this work include: pcDNA3.1 (Invitrogen, 
Karlsruhe, Germany), pSG424 (Sadowski and Ptashne, 1989), pHA.CMV (Clontech, 
kindly given by Dr. Tran Ngoc Tuoc, Göttingen). 
The expression vectors for flag-TORC1 wild-type and flag-TORC1 S151A in which Ser-
151 was changed to alanine (both have mouse origin) were kindly given by Dr. Robert A. 
Screaton (University of Ottawa, Canada). Mouse TORC1 contains 630 amino acids. 
The construct TORC1 encodes for the full-length human TORC1 comprising 651 amino 
acids. The coding sequence was cloned into the mammalian expression vector pcDNA3.1 
by use of the restriction sites BamHI and XbaI (Heinrich et al., 2009).  
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The plasmids GAL4-TORC1, GAL4-TORC11-44, GAL4-TORC144, GAL4–TORC1 S167A 
encode the full-length human TORC1, the first 44 amino acids of TORC1, the truncated 
form of TORC1 without the first 44 amino acids and the full-length TORC1 with one point 
mutation where the serine at 167 was substituted by alanine, respectively, fused C-
terminally to the DNA-binding domain of the yeast transcription factor GAL4 (amino acids 
1-147). The coding sequence of TORC1, either full-length, the first 44 amino acids, the 
truncated form of TORC1 without the first 44 amino acids or the point mutation TORC1 
S167A was subcloned into the mammalian expression vector pSG424 by use of the 
restriction sites BamHI and XbaI.  
The construct HA-TORC1 encodes for the full-length human TORC1 containing a 
hemagglutinin (HA) epitope (YPYDVPDYA) between the first and the second amino acid 
of TORC1. The HA epitope was inserted by use of a modified primer. The coding 
sequence was subcloned into pHA.CMV vector using restriction sites EcoRI and XhoI. 
The expression construct GAL4-TORC2 and GAL4-TORC2 S171A encodes the full-length 
human TORC2 comprising 694 amino acids and the full-length TORC2 with one point 
mutation where the serine at 171 was substituted by alanine fused C-terminally to the 
DNA-binding domain of the yeast transcription factor GAL4 (amino acids 1-147). The 
coding sequence of TORC2 wild-type and TORC2 S171A was subcloned into the 
mammalian expression vector pSG424 by use of the restriction sites KpnI and XbaI (for 
TORC2 wild-type), and EcoRI and XbaI (for TORC2 S171A). 
The construct GAL4-TORC3 encodes the human full-length TORC3 protein comprising 
620 amino acids fused C-terminally to the DNA-binding domain of GAL4 (amino acids 1-
147). The coding sequence was subcloned into the vector pSG424 using the restriction 
sites KpnI and XbaI. 
The plasmid flag-DLK wild-type encodes the full-length mouse-DLK comprising 888 amino 
acids. The coding sequence was cloned into the mammalian expression vector pcDNA3.1 
by use of the restriction sites HindIII and XbaI (Holzman et al., 1994).  
Flag-DLK K185A encodes the full-length mouse-DLK with one point mutation where the 
lysine at 185 was substituted by alanine. The coding sequence was cloned into the 
mammalian expression vector pcDNA3.1 by use of the restriction sites HindIII and XbaI 
(Mata et al., 1996). 
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The plasmid Flag-DLK P-P encodes the full-length mouse-DLK with two point mutations 
where the leucines at 437 and 463 were substituted by prolines. The coding sequence 
was cloned into the mammalian expression vector pcDNA3.1 by use of the restriction sites 
HindIII and XbaI (Nihalani et al., 2000). 
The coding sequences of CREB wild-type and CREB R300A were used as templates in 
the TNT system-based protein synthesis. 
The pGFPtpz-cmv® control vector (Caberra-Packard, Dreieich, Germany) was used to 
check for transfection efficiency in luciferase reporter gene assays. This expression vector 
codes for the green fluorescent protein (GFP) variant topaz under control of the cyto-
megalo-virus promoter. 
The pBluescript (Stratagene, La Jolla, CA, USA) was used to adjust the amount of DNA in 
all transient transfection. 
Bacterial expression vectors 
The vectors for bacterial expression used in this work include: pGEX2T (GE Healthcare, 
Munich, Germany) and pET28b(+) (Novagene, kindly given by Prof. Dr. Frauke Melchior, 
Heidelberg). 
The construct His-TORC1 wild-type, His-TORC144, His-TORC1 S167A, His-TORC2 
wild-type and His-TORC2 S171A were used to express recombinant His-tagged proteins 
in E.coli. The coding sequences of TORC1 and TORC2 wild-type or mutants were 
amplified by PCR and subcloned into the bacterial expression vector pET28b (+) vector 
using restriction sites XbaI and XhoI. 
The   expression   construct   GST-TORC11-44 was used to express recombinant GST-
fusion protein of TORC1 (1-44) in E.coli. The coding sequences of TORC1 (1-44) was 
subcloned into the bacterial expression vector pGEX-2T using restriction sites BamHI and 
XbaI. 
 
 
 
 
 
Material and Methods  
 36
Table 1: Mammalian and bacterial expression constructs. 
The table lists all constructs used in the present work. The constructs kindly given by other authours were put 
in “provided by” column. The other constructs were generated newly using PCR cloning with primers and 
templates as indicated in table 2. 
Name of constructs Source Vector Notes provided by 
TORC1 homo sapiens pcDNA3.1 full length Annette Heinrich 
HA-TORC1 homo sapiens pHA.CMV HA-tag  
Flag-TORC1 Mus musculus   Rob Screaton 
Flag-TORC1 S151A Mus musculus   Rob Screaton 
GAL4-TORC1 homo sapiens pSG424 full length Ulrike Böer 
GAL4-TORC1 S167A homo sapiens pSG424 full length  
GAL4-TORC144 homo sapiens pSG424 aa 45-651  
GAL4-TORC11-44 homo sapiens pSG424 aa 1-44 Ulrike Böer 
His-TORC1 homo sapiens pET28b(+) His-tag  
His-TORC1 S167A homo sapiens pET28b(+) His-tag  
His- TORC144 homo sapiens pET28b(+) His-tag  
GST- TORC11-44 homo sapiens pGEX2T GST-fusion  
     
GAL4-TORC2 homo sapiens pSG424 full length Ulrike Böer 
GAL4-TORC2 S171A homo sapiens pSG424 full length  
His-TORC2 homo sapiens pET28b(+) His-tag  
His-TORC2 S171A homo sapiens pET28b(+) His-tag  
     
GAL4-TORC3 homo sapiens pSG424 full length Ulrike Böer 
     
CREB homo sapiens pcDNA3.1 aa 1-327 Ulrike Böer 
CREB-R300A homo sapiens pcDNA3.1 Arg300 --> Ala Ulrike Böer 
Flag-DLK Mus musculus pcDNA3.1 full length Lawrence Holzman 
Flag-DLK K185A Mus musculus pcDNA3.1 Lys300 --> Ala Lawrence Holzman 
Flag-DLK P-P Mus musculus pcDNA3.1 Leu437 --> Ala 
Leu463 --> Ala 
Lawrence Holzman 
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2.3.d.II. Luciferase reporter gene constructs  
The expression vector 4xsomCRE-Luc (Oetjen et al., 1994) includes four repeats of the 
CRE-containing region -58 to -31 of the rat somatostatin gene in front of the truncated 
thymidine kinase promoter (-81 to +52) of the herpes simplex virus (Nordeen, 1988).  
The plasmid G5E1B-Luc (Kruger et al., 1997) contains five repeats of an enhancer 
element, identified in yeast as binding site for the yeast transcription factor GAL4 (Webster 
et al., 1988), in front of the viral E1B TATA box (Lillie and Green, 1989; Liu and Green, 
1990).  
The plasmid -65SMSLuc (Schwaninger et al. 1993) includes the somatostatin gene 
sequence of -65SMSCAT (Powers et al., 1989) which was subcloned into the BamHI-
SmaI sites of pXP2 plasmid (Nordeen, 1988). 
 
2.3.e. Oligonucleotides 
2.3.e.I. Oligonucleotides used for PCR cloning 
The primers used to generate new constructs in the present work are listed in table 3. 
Synthetic oligonucleotides were purchased from Eurofins MWG Operon (Ebersberg, 
Germany). The sequences in 5’ – 3’ direction of the primer used for PCR cloning 
procedures (3.1.a.I) and site-directed mutagenesis (3.1.a.II) are indicated.  
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Table 2: The primer pairs (forward and reverse) used to generate the constructs in the 
present work. 
The names of plasmids are given in the construct column. Sequences of oligonucleotides are presented in 5’ – 
3’ direction. The primer direction is indicated: forward (for) and reverse (rev). The restriction sites are 
underlined and are indicated in the column restr. site. The sequences complemented with templates were 
shown in bolds and italics. The point mutation was made by substitution of nucleotides showed in bolds and 
shade. Templates were shown in the right column. 
Constructs Direction Primers Restr. 
site 
Templates 
For GCG G GAA TTC CC ATG GCG ACT TCG AAC AAT CCG  EcoRI HA-TORC1 
Rev GCG CTC GAG TTA CAG GCG GTC CAT CCG GAA GG XhoI 
TORC1 wild-
type 
For GCG GGA TCC CC ATG GCG ACT TCG AAC AAT CCG CGG  BamHI GAL4-TORC1 
S167A  (*) Rev GCG  TCT AGA  TTA  CAG  GCG  GTC  CAT  CCG  GAA  GGT XbaI 
TORC1 
S167A  
For GCG GGA TCC CC CAG CTC CAG AAA TCC CAG TAC  BamHI GAL4-TORC144 
Rev GCG  TCT AGA  TTA  CAG  GCG  GTC  CAT  CCG  GAA  GGT XbaI 
TORC1 wild-
type 
For GCG G TCT AGA ATG GCG ACT TCG AAC AAT CCG  XbaI His-TORC1 
Rev GCG CTC GAG CAG GCG GTC CAT CCG GAA GG XhoI 
TORC1 wild-
type 
For GCG G TCT AGA ATG GCG ACT TCG AAC AAT CCG  XbaI His-TORC1 
S167A Rev GCG CTC GAG CAG GCG GTC CAT CCG GAA GG XhoI 
TORC1 
S167A  
For GCG G TCT AGA CAG CTC CAG AAA TCC CAG TAC  XbaI His-TORC144 
Rev GCG CTC GAG CAG GCG GTC CAT CCG GAA GG XhoI 
TORC1 wild-
type 
For GC GGG ATC CCC ATG GCG ACT TCG AAC AAT CCG CGG  BamHI GST- TORC11-44 
Rev GCG CTC GAG CTG GAG CCG CGC GGC CCG C XhoI 
TORC1 wild-
type 
For GCG GAA TTC CCC ATG GCG ACG TCG GGG GCG AAC 
Rev CAG AGT CAG CGC TTG TCC TGT TAA GTG CAG 
EcoRI 
For CAG GAC AAG CGC TGA CTC TGC CCT TCA TAC 
GAL4-TORC2 
S171A (**) 
Rev GCG  TCT AGA  TTA  TTG GAG CCG GTC ACT GCG GAA XbaI 
TORC2 wild-
type 
For GCG G TCT AGA ATG GCG ACG TCG GGG GCG AAC  XbaI His-TORC2 
Rev GCG CTC GAG TTG GAG CCG GTC ACT GCG GAA  XhoI 
TORC2 wild-
type 
For GCG G TCT AGA ATG GCG ACG TCG GGG GCG AAC  XbaI 
His-TORC2 
S171A Rev GCG CTC GAG TTG GAG CCG GTC ACT GCG GAA  XhoI 
TORC2 
S171A 
(above) 
(*)The template TORC1 S167A was kindly given by Robert Screaton 
(**)The construct which was generated by site directed mutagenesis. 
Synthetic oligonucleotides used for site-directed mutagenesis by primerless PCR (3.1.a.II) 
were designed complementarily to each other. The mutation TORC2 S171A was made by 
substitution of the serine residue (S) at position 171 in the coding sequence of human 
TORC2 with alanine residue (A): codon TCT (S) changed to GCT (A). 
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2.3.e.II. Oligonucleotides used for quantitative real-time PCR 
Primers used for quantitative real-time PCR in ChIP-assays as well as the TaqMan™ 
probes are listed in table 7. Primers CRE_ChIP_f and CRE_ChIP_r and the TaqMan™ 
probe CRE were designed to quantify amounts of 4xsomCRE-Luc plasmid (2.3.d.II) by 
quantitative real-time PCR (3.14). The primer CRE_ChIP_f anneals upstream of the 
inserted oligomerized CRE-promoter sequence to the bases 6071 – 6086 of the pT81 
vector. The primer CRE_ChIP_r anneals downstream of the oligomerized CRE-promoter 
sequence to the bases +1 – -14 of the thymidine kinase promoter. The TaqMan™ probe 
CRE anneals to bases -46 – -24 of thymidine kinase promoter.  
Table 3: Oligonucleotides and TaqMan™ probes for quantitative real-time PCR. 
Sequences of synthetic primers and TaqMan™ probes are presented in 5’ – 3’ direction. The direction of the 
primer with respect to the coding sequence to be analyzed is indicated: forward (for) and reverse (rev). 
Labelling of the TaqMan™ probe with fluorophore and quencher is indicated. 
Name Direction Sequence 
CRE_ChIP-f for GCAATAGCATCACAAATTTCACAAA 
CRE_ChIP-r rev CCGCCCCGACTGCAT 
TaqMan™ probe CRE for CGAATTCGCCGGATCTCGAGCTC 
  modifications: 5’–Fluorescein; 3’–TAMRA 
 
2.3.f. Enzymes and buffers 
All the enzymes and buffers were purchased from Fermentas Life Sciences Ltd., St. Leon-
Rot, Germany 
Restriction enzymes  
The restriction enzymes were used in the present work include: BamHI, EcoRI, HindIII, 
KpnI, XbaI and XhoI. Each has an activity of 10 U/µl. The buffer Tango™ yellow was used 
in combination with these enzymes according to the instructions of the manufacturer. 
Modifying enzymes 
Modifying enzymes were used in the present work include: Pfu DNA Polymerase (2.5 
U/µl), T4 DNA Ligase (1 U/µl), RNase A (10 mg/ µl), Proteinase K (10 µg/µl). 
Corresponding buffers were used together with these enzymes according to the 
instructions of the manufacturer. 
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2.3.g. DNA and protein markers 
All DNA and protein markers were purchased from Fermentas Life Sciences (St. Leon-
Rot, Germany). 
DNA-ladders and loading buffer include: GeneRuler™ 100bp DNA Ladder, GeneRuler™ 
1kb DNA Ladder, 6x DNA loading buffer 
Protein markers: PageRuler™ Prestained Protein Ladder, PageRuler™ Plus Prestained 
Protein Ladder 
2.3.h. Antibodies 
The antibodies used in the present work are listed in Table 4 
Table 4: Primary and secondary antibodies. 
The basic information of antibodies used in the present work. The dilutions or amounts of the primary and 
secondary antibodies as used in the present work are given for the different application. 
Name of antibodies Source Clone Application Dilution/amount Company / reference 
panTORC (1-42) rabbit polyclonal Immuno- 
Cytochemistry and 
Western blot 
1:1,500 Calbiochem, Darmstadt, 
Germany 
TORC1 rabbit polyclonal Western blot 1:2,000 Cell signaling, Beverly, MA, 
USA 
Phospho TORC1 
(Ser-151) 
rabbit polyclonal Western blot 1:2,000 Cell signaling, Beverly, MA, 
USA 
DLK rabbit polyclonal Western blot 1:2,000 (Holzman et al. 1994) 
FLAG M2 mouse monoclonal  
CoIP 
10 µg Sigma Aldrich, Hamburg, 
Germany 
anti-HA rabbit polyclonal ChIP 10 µg Sigma Aldrich, Hamburg, 
Germany 
GAPDH (FL-335) rabbit polyclonal Western blot 1:1,000 Santa Cruz Biotechnology, 
Heidelberg, Germany 
mouse IgG-HRP 
(linked to horseradish 
peroxidase) 
sheep  Western blot 1:10,000 Amersham Biosciences, 
Freiburg, Germany 
rabbit IgG-HRP 
(linked to horseradish 
peroxidase) 
donkey  Western blot 1:10,000 Amersham Biosciences, 
Freiburg, Germany 
mouse IgG-TRITC 
(linked to 
tetramethylrhodamin-
5-isothiocyanate) 
rabbit polyclonal Immuno- 
cytochemistry 
1:50 Invitrogen, Karlsruhe, 
Germany 
rabbit IgG-Alexa®488 
(linked to AlexaFluor® 
488) 
goat polyclonal Immuno- 
cytochemistry 
1:50 Invitrogen, Karlsruhe, 
Germany 
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The panTORC (1-42) antibody is directed against the first 42 amino acids of TORC. These 
amino acids are highly conserved among the three isoforms. Therefore, all TORCs are 
recognized by this antibody.  
The TORC1 antibody was raised specifically against TORC1. 
The Phospho-TORC1 (Ser151) antibody detects specifically TORC1 phosphorylated on 
serine 151 (mouse-TORC1). In the present work, this antibody is used to detect 
phosphorylation of human-TORC1 at serine-167 (equivalent as serine-151 of mouse-
TORC1). 
The DLK antibody was raised against the C-terminal 223 amino acids of mouse DLK. 
The FLAG M2 antibody detects the proteins tagged with the FLAG epitope DYKDDDDK.  
The anti-HA antibody detects the proteins tagged with the hemagglutinin (HA) epitope 
YPYDVPDYA. 
The antibody GAPDH (FL-335) is used to detect full-length human glutaraldehyde-3-
phosphate dehydrogenase (amino acids 1-335).  
The mouse and rabbit IgG-HRP antibodies are used as secondary antibodies for 
immunolabelling in Western blots. These antibodies detect the primary ones with mouse 
and rabbit source, respectively.  
The rabbit IgG-Alexa®488 antibody was used as secondary antibody for 
immunocytochemistry assay. This antibody detects primary antibodies raised in rabbit. 
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3. METHODS 
 
 3.1. Generation of Plasmid DNA  
 3.1.a. PCR cloning and site-directed mutagenesis  
 3.1.a.II. Polymerase chain reaction (PCR)  
The DNA sequence of interest is amplified by a polymerase chain reaction (PCR) using 
specific primers and a heating program. First, by heating to 95°C, the double-strands of 
template DNA are separated. By lowering the temperature closely to the melting point of 
primers, the primers anneal with the template. Afterwards, the temperature is increased to 
72°C, the temperature at which thermostable DNA polymerase starts synthesizing new 
DNA sequences based on the template. The process is repeated several times, thereby 
amplifying the DNA exponentially. 
The PCR programme is: 
Step Reactions Time Temperature 
1. Initial denaturation 5 min 95°C 
2. Denaturation 1 min 95°C 
3. Annealing 45 sec depending on melting 
temperature of the primers 
4. Elongation 30 sec – 2min (depending on 
the length of desired DNA) 
72°C 
5. Final elongation 10 min 72°C 
6. Store  4°C 
Steps 2 to 4 were repeated 25 - 35 times. 
 
In the present work, Pfu DNA polymerase was used. PCR was performed using the 
gradient cycler T-Gradient.  
DNA templates were diluted to a concentration of 50 ng / µl using sterile H2O. The primers 
were diluted to concentration of 10 mmol / µl. 
Prepare the dNTP-mix as below: 
dNTPs 10 mM 400 µl 
dATP 10 mM 40 µl of 100 mM dATP 
dGTP 10 mM 40 µl of 100 mM dGTP 
dCTP 10 mM 40 µl of 100 mM dCTP 
dTTP 10 mM 40 µl of 100 mM dTTP 
ddH2O  add 400 µl 
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Aliquots of 10 µl were prepared and stored at -20°C. 
The PCR mixture for one reaction was as follows: 
Template DNA (50 ng/µl) 1 µl 
Forward primer (10 pmol/µl) 1 µl 
Reverse primer (10 pmol/µl) 1 µl 
DMSO  2 % (v/v) 
10x reaction buffer (plus MgCl2)  5 µl 
Pfu Turbo DNA-Polymerase  1 µl 
dNTP-Mix (10 mM) 1 µl 
ddH2O  add 50 µl 
 
The PCR mixture was briefly vortexed and centrifuged before starting the PCR program. 
The PCR products were electrophoresed on agarose gels (3.1.b) to detect the size of the 
DNA and the desired DNA fragment was purified from the gel for cloning of plasmids. 
 
 3.1.a.II. Site-directed mutagenesis primerless PCR  
In order to generate point mutation in the gene of interest, the primerless PCR was used. 
Mutations at specific sites in the coding sequence of interest are introduced by designing 
primers with the substituted nucleotides. Two sets of primer pairs were designed for two 
independent PCRs. Two different fragments were amplified by PCR, each fragment 
including an overlapping region containing the substituted nucleotides. The PCR products 
were electrophoresed on agarose-gel (3.1.b) and the fragments were purified from the gel 
(3.1.c). 1 µl of these fragments were used in a second PCR, so-called primerless PCR 
whereby the fragments served as primers and as templates. Finally, the whole DNA 
fragment is amplified by using the primers complementary at the two ends of template. 
(Fig. 7). 
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Figure 7: Site-directed mutagenesis by primerless PCR. 
Site-directed mutation was generated by independent PCRs. The first PCR generated 2 fragments with 
overlapping region and mutation sites. The second PCR, so-called primerless PCR, was performed using 2 
fragments as primers. The third PCR was done to amplify the primerless-PCR products which carried the 
desired mutations.  
 
 3.1.b. DNA gel electrophoresis 
The buffers used in DNA gel electrophoresis are described as follows: 
TAE-buffer 1x 1 l 
Tris 40 mM 4.84 g 
EDTA 1 mM 2 ml of 0.5 M stock 
Acetic acid 20 mM 1.14 ml 
 
Loading buffer (blue) 6x 10 ml 
Glycerol 30% (v/v) 3.39 ml of 87 % glycerol 
Bromophenolblue 0.25% (w/v) 0.025 g 
Xylene Cyanol FF 0.25% (w/v) 0.025 g 
 
These buffers were stored at room temperature. 
 
 
 
 
 
 
template template 
1st PCR 
2nd PCR 
3rd PCR 
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Gel preparation and electrophoresis  
During agarose gel electrophoresis, DNA fragments are separated according to their size 
and percentage of agarose (see the table bellows) (Sambrook et al., 1989) 
Percentage of agarose DNA fragments separated 
0.3 % 60 – 5 kb 
0.6 % 20 – 1 kb 
0.7 % 10 – 0.8 kb 
0.9 % 7 – 0.5 kb 
1.2 % 6 – 0.4 kb 
1.5 % 4 – 0.2 kb 
2.0 % 3 – 0.1 kb 
 
An appropriate concentration of agarose was dissolved in 1 x TAE by heating. The 
solution was cooled and ethidium bromide was added at a final concentration of 1 µg /ml. 
The solution was poured into a gel chamber with a comb and let to solidify at room 
temperature. The gel was placed in an electrophoresis chamber and covered with TAE 
buffer. 
DNA samples were mixed with the corresponding volume of 6x loading buffer and loaded 
into the wells of the gel, which were formed by the comb. Electrophoresis of DNA was 
performed by applying a constant electric field of 80V (Biometra® Standard Power Pack 
P25). 
Ethidium bromide is a fluorescent dye, which intercalates between the stacked bases of 
the DNA. This causes the dye, bound to DNA, to display an increased fluorescence yield 
compared to that of the dye in free solution under the UV-light of 366 nm wavelength. 
Analysis was perfomed using the BioDocAnalyze system including the transilluminator 
Biometra Ti1 and the software BioDocAnalyze 2.0. 
 
 3.1.c. DNA purification from agarose gels  
After electrophoresis, the bands corresponding to the DNA of interest were cut out of the 
gel and purified by using the Easy Pure® Purification Kit according the instructions of the 
manufacturer.  In brief, the agarose-gel was melted in 3 volumes of SALT-solution (100 µl 
solution per 100 mg of agarose-gel) at 55°C for 5min (Thermomixer compact) in an 1.5 ml 
Eppendorf tube; the mixture was incubated with a DNA binding solution (silica-matrix) to 
extract the DNA and pelleted by centrifugation; the pellet was washed twice with the 
WASH-solution; finally the pellet was dried in a Speed Vac, resuspended in 20 µl sterile 
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H2O and incubated for 5 min at room temperature to elute the DNA. After centrifugation, 
the supernatant containing the purified DNA was transferred to a new Eppendorf tube. 
 
3.1.d. Restriction enzyme digest of DNA 
Purified PCR-products or the corresponding vector were digested with the appropriate 
restriction endonucleases. Restriction endonucleases digest DNA specifically at 
recognized nucleotide sequences. The whole amount of purified PCR-products or 2 µg of 
plasmid DNA were digested and used in cloning. Reaction volume for digestion as 
follows: 
Total PCR-products  Plasmid DNA (2 µg) 
10x buffer TangoTM (yellow)  2.5 µl     1 µl  
Restriction endonuclease   1 µl (each)    1 µl (each) 
Sterile H2O     add to 25 µl    add to 10 µl 
The solutions were mixed in an Eppendorf tube by vortexing and spun down shortly. The 
digestion was carried out for 2 h in a waterbath at 37°C. To prepare DNA for ligation, the 
digest was carried out overnight. The samples were analyzed by agarose gel 
electrophoresis and re-purified to use for ligation. 
 
 3.1.e. Ligation of DNA 
Ligation of DNA fragments was performed with the T4 DNA ligase. The T4 DNA ligase 
catalyzes the formation of a phosphodiester bond between juxtaposed 5'-phosphate and 
3'-hydroxyl termini in double-stranded DNA.  
To estimate the amounts of DNA needed for the ligation, 3 µl aliquots of the purified and 
digested DNA samples were analysed by DNA gel electrophoresis. The insert DNA was 
employed in a ~4-fold excess over the corresponding linearized vectors. Pipeting scheme 
for the ligation reaction as follows: 
Reaction volumes: 
10x ligation buffer   1 µl 
T4 DNA ligase  1 µl 
Insert    appropriate volume (4-fold molecular excess over vector) 
Vector (linearized)  ~ 0.5 µg 
H2O     add 10 µl 
The solutions were mixed in an Eppendorf tube by vortexing and centrifuged briefly. The 
ligation reaction was carried out in a water bath at 16°C over night. 
The whole amount of the reaction was used to transform competent E.coli to amplify the 
plasmid.  
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 3.2. Amplification of plasmid DNA 
 3.2.a. Preparation of competent E.coli  
Solutions and reagents 
LB medium (2.3.c) 
Liquid nitrogen 
50 mM CaCl2  100 ml 
CaCl2 0.735 g 
Add to 100 ml with distilled water  
Autoclave 20 min at 120 oC, 15 psi.  
 
50 mM CaCl2 + 15 % glycerol  
87 % Glycerol 5.62 ml 
50 mM CaCl2 26.5 ml 
0.2 µm sterile filtered  
 
LB-agar plates (without antibiotics)   500 ml 
Agar 1.5 % (w / v) 7.5 g 
Add to 500 ml with LB medium 
Autoclave 20 min at 120 oC, 15 psi. 
  
The LB-agar was cooled to 50°C and poured into 10 cm dishes. After hardening, the agar 
plates were stored at 4°C.  
 
Procedure 
E. coli competent cells were prepared following the calcium chloride (CaCl2) procedure. 
Briefly, one colony of DH5α cells was inoculated overnight in 10 ml of LB media. From this 
pre-culture, a 100 ml LB culture was inoculated and grown at 37 oC (200 rpm) until the 
OD600 reached a value of 0.6. Cells were centrifuged for 10 min at 3,000 rpm and the 
supernatant was disposed. The pellet was resuspended in 50 ml of a cold sterile 50 mM 
CaCl2 solution and kept on ice for 30 min. The cells were centrifuged again under the 
same conditions and the pellet was now resuspended in a cold solution of 50 mM CaCl2 
containing 15 % glycerol. Cells were aliquoted into 100 µl aliquots in 1.5 ml eppendorf 
tubes. Cells were immediately frozen in liquid N2 and stored at - 80 oC. 
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 3.2.b. Transformation of competent E.coli  
Media 
LB medium (2.3.c) 
LB-agar plates (with antibiotics)  Final concentration for 500 ml 
Agar  
(add to 500 ml with LB medium autoclave 
for 20 min at 120°C 15 psi) 
1.5 % (w / v) 7.5 g 
Ampicillin (or Kanamycin) (added when the 
agar was cooled to 50°C) 
50 µg / ml 500 µl of 5% 
stock solution 
 
The LB-agar was cooled to 50°C and poured into 10 cm dishes. When hardened the agar 
plates were stored at 4°C.  
 
Procedure 
The plasmid DNA was transformed into competent E.coli by applying heat shock. 
Principally, the temperature rises quickly during the heat shock making the cell walls of 
the bacteria fragile and the plasmid DNA can be taken up. First, 30 µl of competent E.coli 
was thawed on ice.  The whole amount of ligated samples or 200 ng of DNA was used in 
transformation. The DNA and bacteria were mixed and incubated on ice for 30min. After 
incubation, the heat shock at 42°C was performed for 90 sec (Thermomixer compact). 
The suspension was quickly immersed on ice for 2 min. 500 µl of LB-medium (without 
ampicillin) was added to the suspension. The mixture was incubated for 2 h at 37°C 
(Thermomixer compact, agitating at 500 rpm). Afterwards 200 µl of suspension were 
plated on a LB-agar plate (with appropriate antibiotic) and incubated over night at 37°C in 
an incubator.  
 
 3.2.c. Small scale DNA preparation (Mini-prep) 
Buffers and solutions  
Buffer M1     100 ml       
Tris/HCl pH 8.0  25 mM  2.5 ml of 1 M Tris/HCl pH 8.0 stock solution 
Glucose   50 mM  10 ml of 0.5 M Glucose stock solution 
EDTA pH 8.0   10 mM  2 ml of 0.5 M EDTA pH 8.0 stock solution 
add fresh before use: 
Lysozyme     2 mg / 1 ml buffer M1 
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Buffer M2     5 ml       
NaOH    0.2 N  1 ml 1 N NaOH stock solution 
SDS    1%  500 µl 10%-SDS stock solution  
H2O sterile     3.5 ml 
 
Buffer M3     20 ml       
Na acetate pH 4.8  3 M  8.165 g / 20 ml 
 
Procedure 
Mini preparation of plasmid DNA was used to confirm the identity of the construct. The 
process was performed with several colonies of every construct. The single colonies were 
picked and grown over night in 3 ml LB media using 15 ml blue-cap tubes (Greiner bio-
one, Solingen, Germany) at 37°C, shaking 200 rpm. 1.5 ml of the over-night bacteria 
culture was centrifuged in an Eppendorf tube for 2 min at 6000 rpm at 4°C.  After 
discarding the supernatant the pellet was resuspended in 150 µl buffer M1 and kept on ice 
for 10 min. Next, addition of 200 µl buffer M2 was done quickly to lyse the cells. The 
suspension was inverted several times for mixing and left for 5 min on ice. 150 µl of buffer 
M3 was added and the suspension was stored on ice for 5 min to neutralize the lysate. 
The sample was centrifuged for 10 min at 14,000 rpm at 4°C. The resulting supernatant 
was transferred to a new Eppendorf tube and the plasmid-DNA was extracted by addition 
of 200 µl phenol plus 200 µl chloroform-isoamylalcohol (24:1). The suspension was mixed 
by vortex and different phases were separated by centrifugation at 14,000rpm at 4°C for 5 
min. The DNA-containing aqueous phase was transferred to a new Eppendorf tube. DNA 
was precipitated by addition of 1/10-sample volume buffer M3 and 2-sample volumes ice-
cold 99 %-ethanol and storage at -20°C for 15min. Subsequently, the DNA was 
centrifuged for 30 min at 14000 rpm, 4°C. After discarding the supernatant the pellet was 
washed with 500 µl cold 70 %-ethanol and again centrifuged for 5 min at 14,000 rpm at 
4°C. The acquired pellet was dried and solved in RNase solution. The RNase-digest was 
applied for 30 min in a water bath at 37°C. 
The DNA products from mini-prep were digested with the appropriate restriction enzymes 
and applied on an agarose electrophoresis to analyse. 
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 3.2.d. Large scale DNA preparation (Maxi-prep) 
Buffers and solutions 
0.5M EDTA pH 8.0 (2.2.b.I) 
LB medium (2.3.c) 
Ethidium bromide    10 mg/ml  
CsCl      10.9 g 
STE Buffer                                                    100 ml 
1 mM EDTA     0.2 ml / 0.5 M 
25% Saccharose    25 g 
50 mM Tris-HCl pH 8.0   5 ml / 1 M 
 
Triton-Mix                                                      100 ml 
60 mM EDTA pH 8.0    12 ml / 0.5 M 
50 mM Tris-HCl pH 8.0   5 ml / 1 M 
0.1 % Triton X-100    0.1 ml 
 
PEG solution                                                100 ml 
1.5 M NaCl     30 ml / 5 M 
30% PEG 6000    30 g 
 
TNE Buffer                                                   100 ml 
1 mM EDTA     0.2 ml / 0.5 M 
10 mM NaCl     0.2 ml / 5 M 
10 mM Tris-HCl pH 8.0   1 ml / 1 M 
 
TE Buffer                                                      1L 
1 mM EDTA pH 8.0    2.0 ml / 0.5 M 
10 mM Tris-HCl pH 8.0   10 ml / 1 M 
 
Lysozyme                                                      7 ml 
60 mg/ ml Lysozyme    420 mg 
Add to 7 ml of STE buffer 
 
Maxi-preparation procedure 
After identification of the desired plasmid by mini-prep, a maxi-preparation of DNA was 
performed by using ultracentrifugation of bacterial lysate in a cesium chloride (CsCl) 
gradient. The process was performed as described by Sambrook et al. (1989). Briefly, the 
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culture given high yield of desired plasmid was inoculated into 30 ml LB medium 
containing a final concentration of 50 g/ml ampicillin or kanamycin (depending on the 
antibiotic resistance of the plasmid). The bacteria were grown overnight at 37oC with 
agitation (225 rpm). In the next morning, the suspension was inoculated in 1 L LB medium 
containing the appropriate antibiotics. The culture was grown under the same condition 
until it reached an OD600 around 0.6-0.8. Chloramphenicol was added to a final 
concentration of 200 mg/L of the culture. After growing for 12 h, the bacteria were 
harvested by centrifugation (15 min at 6,000 rpm at 4oC). From now on, all steps were 
conducted on ice. After discarding the supernatant the pellet was resuspended in 45 ml 
ice-cold STE buffer. Lysis of the bacteria was carried on in 3 ml of a lysozyme solution for 
20 min. The lysis was stopped by adding 3.6 ml of 0.5 M EDTA and incubating for 5 min. 
In the next step, the suspension was incubated with 28.8 ml of Triton mix solution for 30 
min (shaking the mixture every 5 min). After centrifugation of the mixture for 1 h at 14,000 
rpm at 4oC, the supernatant was transferred into a new tube and incubated for 1 h with 40 
ml of a 30% PEG solution. Centrifugation for 10 min at 10,000 rpm at 4oC followed and 
the supernatant was removed. The pellet was dried and resuspended in 10 ml of TNE 
buffer together with 10.9 g of CsCl and 150 l of a 10 mg/ml ethidium bromide solution. 
The suspension was transferred to ultracentrifuge tubes which were weighted (the 
difference between the weights were not more than 0.05 g) to keep balance before 
centrifugation. The samples underwent ultracentrifugation for 20 h at 60,000rpm at 20oC. 
After ultracentrifugation the band containing plasmid DNA was sucked out with a needle 
and a syringe. The samples were washed with isoamylalcohol to remove ethidium 
bromide (until the solution was colorless). CsCl was removed by dialyzing each sample in 
2 L of TE buffer during 24 h at 4oC. Afterwards, the DNA concentration and purity were 
measured (OD260, OD 280) (3.2.f) and the identity of plasmids were checked by enzymatic 
restriction (3.1.d) 
 
3.2.e. Sequencing  
The newly generated expression vector was sequenced. The DNA sequence was 
determined by the chain-termination method (Sanger et al., 1977) using the sequencing 
kit Big Dye® Terminator v1.1 Cycle Sequencing Kit. This kit contains fluorescently labeled 
didesoxynucleotides (ddATP, ddGTP, ddCTP and ddTTP) which lead to a termination of 
the DNA synthesis after incorporation. These ddNTPs are mixed with dNTPs in a relation 
that statistically allows the synthesis of fragments of all possible sizes. The PCR for 
sequencing was performed using the PTC-200 Peltier Thermal Cycler. 
The following components were used for the reaction: 
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DNA 300 ng 
Primer 10 pmol 
BigDye® Mix 1.8 µl 
DMSO 0.5 µl 
dd H2O ad 10 µl 
 
The PCR program used for the sequencing as follows: 
1. 2 min of initial denaturation 94°C 
2. 15 sec of denaturation 96°C 
3. 15 sec of annealing 56.5°C 
4. 4 min of elongation 60°C 
5. 7 min of final elongation 72°C 
Steps 2 – 4 were repeated 24 times.  
 
After amplification of DNA the PCR fragments were purified by gel filtration 
chromatography. The samples were filled with dd H2O to a final volume of 40 µl. The 
Sephadex (Sephadex G50, Amersham Biosciences) was preswollen in a 96-well Millipore 
plate (Millipore-MAHV N45) and washed once with H2O. The samples were added on top 
of the sephadex and were purified by centrifugation for 5 min at 150xg (Beckmann GS-6). 
Afterwards the samples were analyzed by capillary electrophoresis with respect to their 
size and the nucleotides were determined by fluorescence analysis using the ABI PRISM 
3100 Genetic Analyzer. 
 
3.2.f. Quantification of DNA concentration 
The concentration and purity of DNA was determined by UV-absorption at 260 nm using a 
UV-visible recording spectrometer (Shimadzu UV-160). The measurement was performed 
in quartz cuvettes in a total volume of 1 mL TE-buffer (3.2.d)  
Following is the formula used to calculate DNA concentration  
 
c (µg / µL) = OD260 x 50 x dilution factor of  DNA  
 
The ratio between the absorption at 260 nm and at 280 nm gives a measure of the purity 
of the plasmid DNA. The ratio should range between 1.8 and 2.0. 
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 3.3. Analysis of proteins  
 3.3.a. Quantification of proteins  
 3.3.a.I. Bradford assay 
The Bradford assay was used to determine the concentration of proteins in solution. In this 
assay, the Dye Reagent For Protein Assays (Biorad) containing the Coomassie Brilliant 
Blue G-250 is red. When binding to a protein, the dye changes its colour to blue. The 
intensity of blue colour correlates with the amount of the protein in solution (Bradford, 
1976). Briefly, the Dye Reagent was diluted 1:5 in H2O. BSA was used to generate a 
standard curve ranging from 0.5 µg to 20 µg.  1 µl of the protein solution was added to 1 
ml of diluted reagent. The mixture was vortexed in a cuvette. The OD value of the protein 
solution was determined by photometric measurement at 550 nm using a 
spectrophotometer (Shimadzu UV-160, Duisburg). The concentration of protein was 
calculated based on a standard curve. 
 
 3.3.a.II. Semi-quantitative SDS-PAGE 
Different volumes of protein solutions and defined amounts of BSA (100 – 2,000 ng) were 
denatured in sufficient amount of 2x Laemmli loading buffer (Laemmli, 1970). The 
samples were electrophoresed by SDS-PAGE (3.3.b) and the gel was stained with 
Coomassie (3.3.c). 
 
 3.3.b. SDS-PAGE  
 
 Buffers and solutions  
Stacking-gel buffer     200 ml      
Tris/HCl pH 6.8  0.5 M   12.144 g  
SDS    0.4 % (w/v)  8 ml 10 %-SDS solution 
 
Resolving-gel buffer     200 ml      
Tris/HCl pH 8.8  1.5 M   36.342 g 
SDS    0.4 % (w/v)  8 ml 10 %-SDS solution 
 
Acryl-amide solution     250 ml      
Acryl amide   29.2 % (w/v)  73 g 
Bis-acryl amide  0.8 % (w/v)  0.82 g 
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Tank buffer      1L      
Tris    25 mM   3.09 g 
Glycine   192 mM  14.41 g 
SDS    0.1 % (w/v)  10 ml 10 %-SDS solution 
 
Lämmli-loading buffer 2x   100 ml      
Tris/HCl pH 6.8  160 mM  16 ml 1 M Tris/HCl pH 6.8 stock 
SDS    4 % (w/v)   4 g 
Glycerol   10 % (v/v)  11.4 ml 87.5-% solution 
Bromphenolblue  0.05 % (w/v)  50 mg 
β-Mercaptoethanol  10 % (v/v)  10 ml 
 
 Gel preparation   
The gel caster Mighty Small SE245 Dual Gel Caster and the corresponding glasses, 
spacer and combs were used to cast the gels. 
8% and 10%-acryl amide resolving gels and 4%-acryl amide stacking gels were prepared 
as follows: 
Resolving gel:  1 gel (10%) 1 gel (8%) Stacking gel:  1 gel  
Separating-gel buffer  2.5 ml   2.5 ml Stacking-gel buffer  1.25 ml 
H2O  4.2 ml  4.8 ml  3.13 ml 
Acryl-amide solution 3.3 ml  2.7 ml  620 µl 
Temed   15 µl  15 µl   7.5 µl 
APS-stock solution 100 µl 100 µl  50 µl 
        
After casting the resolving gel n-butanol was applied to the upper layer to release air 
bubbles and to smooth the edge between resolving gel and stacking gel. n-butanol was 
removed after gel polymerisation. The stacking gel was cast on top of the resolving gel; 
the comb was inserted. 
To separate the phospho-proteins from their isotypes, the Phos-tag SDS-PAGE was used. 
The acrylamide gel was supplemented with 50 µM Phos-tagTM AAL-107, a ligand of 
acrylamide which is able to bind to the phospho groups of the proteins, thereby retarding 
the migration of phosphorylated proteins (Kinoshita et al., 2008). 
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Electrophoresis of proteins 
Proteins were separated by SDS-poly-acrylamide gel electrophoresis. The comb was 
removed from the gel. The gel was placed in gel-electrophoresis chamber (Mighty Small 
SE250/SE260 Mini Vertical Unit) filled with tank buffer. Equal amounts of protein from 
different samples were used. The proteins were denatured by boiling the samples for 10 
min at 95°C (Thermomixer compact) in 2x Lämmli-loading buffer. Denatured proteins were 
loaded onto the gel. Electrophoresis of proteins through the stacking gel was conducted 
by applying a current of 15 mA per gel using the power supply Biometra® Standard Power 
Pack P25. As the lowest migrated band of bromphenolblue reached the resolving gel the 
current was adjusted to 25mA per gel until the samples passed the whole length of the 
gel. 4 µl of the PageRulerTM Prestained Protein Ladder was loaded onto the gel to 
estimate the molecular weight. 
 
 3.3.c. Detection of proteins with Coomassie stain 
 
 Buffers and solutions  
Coomassie-stain solution     1 L      
Bromphenolblue  0.25 % (w/v)  2.5 g 
Methanol   40 % (v/v)  400 ml 
Acetic acid   10 % (v/v)  100 ml 
 
Destain solution     1 L      
Iso-propanol   25 % (v/v)  250 ml 
Acetic acid   10 % (v/v)  100 ml 
Methanol   10 % (v/v)  100 ml 
 
 Procedure  
After electrophoresis, the stacking gel was removed and the resolving gel containing  
proteins was stained for 20 min in coomassie-stain solution and destained over night with 
destain solution. 
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 3.3.d. Western blot 
 Buffers and solutions  
Buffer A   1 L 
Tris, pH 11.3 300 mM 36.3 g 
Methanol 20% (v/v) 200 ml 
H2O  add to 1L 
Buffer B   1 L 
Tris, pH 10.5 25 mM 3.03 g 
Methanol 20% (v/v) 200 ml 
H2O  add to 1L 
Buffer C   1L 
Tris, pH 9.0 25 mM 3.03 g 
Methanol 20% (v/v) 200 ml 
Adjust pH with boric acid   
H2O  add to 1L 
TBS-T    10x 1 L 
NaCl 1.5 M 80 g 
Tris 100 mM 24.2 g 
Adjust pH to 7.5   
H2O  add to 1L 
 
TBS-T    
 
1x 1 L 
TBS 10x  100 ml  
Tween 20 0.1 % (v / v) 1 ml 
H2O  add to 1L 
Blocking solution  50 ml 
Skim milk powder 5% (w/v) 2.5 g 
TBS-T  add to 50 ml 
Antibody solution  10 mL 
Skim milk powder 1% (w/v) 0.1 g 
TBS-T  add to 10 ml 
 
Material and Methods  
 57 
 Blotting  
After SDS-PAGE was performed, the resolving gel was incubated for 20 min in buffer C 
and the nitrocellulose membrane was incubated for 10 min in buffer B. Proteins were 
transferred from the gel to the membrane using a semi-dry electroblotting chamber. The 
arrangement of the blotting stacks was as follows (starting from the cathode- bottom to the 
anode-top): 2x whatman papers in buffer A, 2x whatman papers in buffer B, membrane in 
buffer B, gel in buffer C and finally 4x whatman papers in buffer C. A roller was used to 
avoid formation of bubbles. The transfer was done for 1 h 10 min at a constant current of 
1.2 mA / cm2. 
 
 Immunodetection  
In order to avoid unspecific protein binding, after blotting, the membrane was blocked for 1 
h at RT in blocking solution under constant rocking. After three washing steps, 5 min each, 
with TBS-T, the required dilution of the primary antibody was added in a 5 % skim milk-
TBS-T solution. The membrane in the solution of primary antibody was incubated 
overnight at 4oC with gentle rocking. Next day, the membrane was washed three times, 5 
min each, with TBS-T at room temperature. Then the membrane was incubated for 1 h at 
room temperature with the secondary antibody (anti-rabbit or mouse horseradish 
peroxidase-HRP) at 1: 10,000 dilution. After three washing steps of 5 min with TBS-T, the 
membrane was ready for protein detection. The antibody-antigen complex was detected 
with Immun-Star WesternC Kit (Bio-Rad Laboratories, Munich, Germany) using the 
VersaDoc system. 
 
3.3.e. Analysis of radioactively labeled proteins 
In case radioactively labelled proteins were to be detected, after electrophoresis, the 
stacking gels were removed. The separating gels were placed on Whatman paper and 
covered with plastic film. The gels were dried by heating to 60°C and applying vacuum 
using a gel dryer (DryGel Sr Slab Gel Dryer SE1160). To analyse radioactively labeled 
proteins the dried gels were exposed to a phosphor-imager screen (BAS-MS 2325, 
FUJIFILM). The exposure time was from overnight to several days depending on the 
incorporated isotope. The phosphor-imager screen was scanned using the phosphor-
imager device BAS-1800II (FUJIFILM) and the software AIDA Version 4.15.025.  
 
 3.4. Purification of GST-fusion and His-tagged proteins 
 3.4.a.  Screening for inducible clones expressing GST- and His-fusion proteins 
The coding sequences of interest were subcloned into the bacterial expression vector 
pGEX2T or pET28b downstream of the lac operon to result in the expression of 
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glutathione S-transferase (GST) or His-fusion proteins, respectively. In E.coli the lac 
operon controls the expression of sugar-metabolizing enzymes, which depend on the 
presence of lactose in the media. In case that there is no lactose in the media, the lac 
operon encoding protein called repressor which in turn binds to the site of transcription 
initiation on the lac operon. This inhibits transcription. The lac operon genes expression 
can be induced by lactose or other structurally similar molecules, like isopropyl-β-D-
thiogalactoside (IPTG), added to the media. These molecules bind to the lac repressor, 
which results in its release from the DNA; and therefore the gene transcription under the 
control of lac operon is activated. By using IPTG as inducer, the production of GST-fusion 
or His-tagged proteins can be enhanced. 
To screen for the colonies expressing high yield of interested proteins nine colonies 
containing the same transformed construct were picked and left for growing over night at 
37°C in 2 ml LB-media. Next morning, 100 µl of every bacteria suspension was inoculated 
in another 2 ml LB-media. The bacteria were cultured again for about 2 h at 37°C, until the 
OD600 reaches 0.6-0.8. Then 500 µl per sample was collected and stored on ice. To the 
remaining 1.5 ml bacteria suspension 1 mM IPTG was added and incubated for further 3 h 
at 37°C to produce the GST- or His-fusion proteins. From every sample, 200 µl was taken 
and the remaining suspension was stored at 4°C. The samples taken before and after 
induction were centrifuged for 2 min at 7,000 rpm (4,000xg) at 4°C (Eppendorf centrifuge 
5417R). The supernatant was discarded and the pellet was denatured in 50 µl 2x Lämmli-
loading buffer. The samples were analysed by SDS-PAGE and coomassie-staining to 
identify the potentially inducible clones. 
 
 3.4.b.  Purification of GST- and His-fusion proteins 
Buffers and solutions  
Buffer A1     1 L       
HEPES pH 7.5  20 mM  20 ml of 1 M Hepes pH 7.5 stock 
NaCl    1 M  58.44 g 
add fresh before use from stock-solutions: 
DTT    1 mM  10 µl 1 M DTT / 10 ml buffer A 
PMSF    1 mM  50 µl 200 mM PMSF / 10 ml buffer A 
 
Buffer A2     1 L       
Tris-HCl pH 8.0  20 mM  20 ml of 1 M Tris-HCl pH 8.0 stock 
NaCl    1 M  58.44 g 
Glycerol   20% (v/v) 200 ml 
Tween 20   0.1% (v/v) 1 ml 
Material and Methods  
 59 
ZnCl2    10 µM  10 ml of 1 mM ZnCl2  
Imidazol   40 mM  40 ml of 1 M Imidazol 
add fresh before use from stock-solutions: 
DTT    1 mM  10 µl 1 M DTT / 10 ml buffer A 
PMSF    1 mM  50 µl 200 mM PMSF / 10 ml buffer A 
 
Buffer A2-plus: contains all the components with the same concentration as buffer A2, 
except NaCl 2M 
 
Reaction buffer     1 L      
NaCl    100 mM 5.844 g 
EDTA    1 mM  2 ml of 0.5 M EDTA pH 8.0 stock 
Tris/HCl pH 7.5  20 mM  20 ml 1 M Tris/HCl pH 7.5 stock 
Nonidet-P40    0.5 % (v/v) 5 ml 
add fresh before use from stock-solutions: 
DTT    1 mM  10 µl 1 M DTT / 10 ml Na+- Buffer 
PMSF    1 mM  50 µl 200 mM PMSF / 10 ml Na+- Buffer 
 
Preparation of glutathione- and NTA-Ni-agarose beads 
Relying on the affinity of the beads described in the protocols supplied by the producers 
sufficient amounts of glutathione-agarose or NTA-Ni-agarose beads were employed for 
purification of GST- or His-proteins, respectively. The agarose beads were pre-swollen 
overnight in 8 ml PBS at 4°C. The suspension was centrifuged in the next day for 3 min at 
900 rpm (150xg) at 4°C using the centrifuge Sigma 4K1. After discarding the supernatant 
the beads were washed with 10 ml buffer A1 or A2, for glutathione- or NTA-Ni-agarose, 
respectively, followed by 3 min centrifugation at 900 rpm (150xg) at 4°C. The washing 
step was repeated once. Afterwards, 0.5 ml buffer A1 or A2 was added to the glutathione- 
or NTA-Ni-agarose, respectively, making a total volume of 1 ml. 
 
Purification of GST-fusion and His-tagged proteins 
The colony given highest yield of GST- or His-proteins was inoculated overnight at 37°C in 
100 ml of LB media. The next morning, the suspension was spun down for 2 min at 3,000 
rpm. The bacteria pellet was inoculated in 1 L of LB-media and grown until an OD 600 of 
0.5 – 0.6. At this phase the bacteria were growing logarithmically and were induced by 
adding 1 mM IPTG. The culture was grown overnight at 25°C. Afterwards, the bacteria 
pellet was obtained by 15 min centrifugation at 3,500 rpm (2,000xg) at 4°C (Beckmann 
centrifuge J2-HS), followed by discarding the supernatant. 
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The obtained pellets were resuspended in 10 ml buffer A1 or A2, corresponding to GST- 
or His-proteins, respectively. Corresponding samples were pooled in a 50 ml tube (Greiner 
bio-one, Solingen, Germany) and kept on ice. The bacteria walls were disrupted by 
sonication using the Branson Sonifyer® Cell Disrupter B15, applying 5 cycles of 10 s 
sonication and 20 s break at 70 % duty cycle. To prevent overheating and protein 
degradation during sonication the tube was kept in an ice-methanol bath.  
The suspension of disrupted bacteria was centrifuged for 10 min at 10000 rpm (12000xg) 
at 4°C (Beckmann centrifuge J2-HS). The supernatant was transferred into a new 50 ml 
blue cap tube which contained 1 ml prepared glutathione-agarose or NTA-Ni-agarose 
beads. To promote binding the mixture was slightly rotated for 2h at 4°C on a rolling 
platform (TRM-V). Subsequently, the samples were centrifuged 3 min at 900 rpm (150xg) 
at 4°C (Sigma 4K1), the supernatant was discarded and the pellets were washed 4 times 
in 10 ml buffer A1 or buffer A2-plus, corresponding to GST- or His-proteins, respectively. 
Afterwards, the GST- or His-fusion proteins bound to glutathione-agarose beads or NTA-
Ni-agarose beads were added with reaction buffer to form slurry of 50 % and stored on ice 
at 4°C. 
 
3.5. Labelling of proteins with [35S]-Methionine 
The [35S]-labeled proteins were synthesized in vitro by using the TNT® T7 Coupled 
Reticulocyte Lysate System following the manufacturer’s instructions and using the 
delivered solutions.  
The synthesis reaction was performed in an Eppendorf tube, as follows:  
TNT® Rabbit Reticulocyte Lysate    25 µl 
TNT® Reaction Buffer        2 µl 
TNT® RNA Polymerase T7       1 µl  
Amino acid mixture minus methionine  1 mM     1 µl 
Template          1 µg 
RedivueTM L-[35S] methionine  10 µCi / µl   3 µl 
H2O sterile      add to  50 µl 
The reaction solution was mixed by vortex and incubated for 90 min at 30°C with agitating 
at 900 rpm in a heat block (Thermomixer compact). Afterwards the synthesized proteins 
were stored on ice at 4°C for later use in GST- and His-pull down assays. 
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 3.6. GST- and His- pull-down assay  
The coding sequences of the proteins of interest were used as templates for in vitro 
transcription/translation with TNT® T7 coupled reticulocyte lysate system. 30 µCi of L-
35S methionine was used to label the in vitro transcribed / translated proteins in a 50 µl 
reaction mixture (3.5). 
To exclude unspecific binding, NTA-Ni-agarose or glutathion-S-transferase (GST) was 
used as control in His- or GST- pulldown assay, respectively. Equal amount of the His-
tagged or GST-fusion proteins and GST were employed in the assay (controlled by SDS-
PAGE analysis (3.3.a.II)); equal volumes were achieved by filling with corresponding 
agarose beads which were pre-washed and equilibrated to reaction buffer (3.4.b). The 
samples were centrifuged for 2 min at 800 rpm (70xg) at 4°C (Eppendorf centrifuge 
5417R). After discarding the supernatant the pellet was washed with 200 µl of the reaction 
buffer. Pellet and solution were mixed by tipping on the Eppendorf tube. The supernatant 
was discarded after applying again 2 min centrifugation at 800 rpm (70xg) at 4°C 
(Eppendorf centrifuge 5417R). In the final reaction, the proteins bound to beads were 
incubated with 250 µl of reaction buffer and 4 µl of [35S] radioactively labelled proteins 
overnight at 4°C on a rocking platform (Polymax 1040). Next day, the proteins bound to 
beads were centrifuged 2 minutes at 800 rpm (60xg) at 4°C (Biofuge 15R). The samples 
were washed 4 times, each with 400 µl reaction buffer followed by 2 min centrifugation at 
800 rpm (60xg) at 4°C (Biofuge 15R) and discarding of the supernatant. Finally, SDS-
sample buffer was added to the samples, boiled at 950C for 5 minutes and loaded on a 
SDS-PAGE for analysis. 1 µl of [35S] proteins (25%) were used as inputs for analysis. The 
gels were dried and the radioactively labelled proteins were visualized by exposure to a 
phosphor-imager screen (3.3.e). The bands corresponding to [35S] proteins recovered 
from GST alone, GST fusion protein or His-tagged proteins were evaluated by 
densitometric analysis (3.3.e).  
 
3.7. Culture of HIT-T15 cells 
HIT-T15 cells were cultured under sterile conditions. Filter- or autoclave-sterilized 
solutions were pre-warmed in water bath at 37oC before use. All glassware items were 
autoclaved. Before putting equipment or handling in the sterile hood, all outside surfaces 
were wiped with 70 % isopropanol solution.  
The culture of HIT-T15 cells monolayers was performed in 30 ml of RPMI complete 
medium (2.3.c) on 15-cm (150 x 25 mm) plates. The cells were incubated at 37oC in a 5 % 
CO2, 95 % humidity atmosphere (Steri-Kult Incubator, Labotect GmbH, Göttingen). Once a 
week, the cells were propagated when they reach 80-90 % confluence (~35 x 106 cells). 
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The propagation process was performed as follows: the plate was washed with 10 ml 1X 
PBS solution. The cells were incubated in 3 ml of Trypsin/EDTA solution (GIBCO BRL, 
Karlsruhe) for 2-3 min at 37oC. The plates were shaken to detach the cells. Cells were 
resuspended in 7 ml of RPMI medium and transferred into a 50 ml tube (Blue Max, 
Falcon, Becton). The suspension was centrifuged for 2 min at 310xg (Megafuge 1.0) and 
washed once with RPMI complete medium. The cells were seeded at a density of ~0.5 x 
106 cells / cm2. After three days the medium was changed. 
 
3.8. Transient transfection of HIT-T15 cells 
Buffers and solution 
RPMI complete medium   (2.3.c) 
RPMI uncomplete medium  (without supplement of serum and antibiotics)  
DEAE-Dextran solution (30 ml) 
60 mg/ml DEAE-Dextran   1.8 g 
Add to 30 ml with distilled water 
Filtrate through a 0.45 m syringe filter 
 
TD Buffer  500 ml 
0.7 mM K2HPO4    0.35 ml  of 1 M stock solution 
5 mM KCl      2.5 ml of 1 M stock solution 
140 mM NaCl     70 ml of 1 M stock solution 
25 mM Tris-HCl pH 7.4  12.5 ml of 1 M stock solution 
dd H2O Add to 500 ml  
Autoclave 20 min at 120oC at 15 psi.  
 
3.8.a.Transfection using DEAE Dextran 
First, the medium was sucked off and the plate was washed with 10 ml 1X PBS solution. 
The cells were incubated with trypsin-EDTA for 3 min at 37oC and the plate was shaken to 
detach the cells. The cells were resuspended in 7 ml of uncomplete RPMI. The 
suspension was centrifuged and the medium was disposed. Cell pellets were washed 
twice in 10 ml TD buffer. After centrifugation, cells were resuspended in 1 ml of TD 
buffer/dish and 5 l/dish of a 60 mg/ml DEAE-Dextran solution was added. This cell 
suspension was then mixed with the desired plasmids. 2 g of DNA plasmid/dish was 
used. To estimate the transfection efficiency, 0.5 g of the plasmid pGFPtpz-cmv[R] /dish 
was used. After 15 min incubation of the mixture at room temperature, the transient 
transfection was stopped by adding complete RPMI medium. The cells were centrifuged 
and the supernatants were removed. This washing step was repeated twice with complete 
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RPMI medium. Finally, appropriate volumes of complete RPMI medium (5 ml/dish) were 
added and 5 ml of cell suspension were seeded into 60 x 15 mm polystyrene tissue 
culture dishes. Incubation of cells was performed at 37oC under 5 % CO2 atmosphere until 
treatment and harvest were performed. 
 
 3.8.b. Transfection using Metafectene 
In order to get high transfection efficiency for further experiments, transfection with a 
polycationic transfection reagent, Metafectene (Biontex, Munich), was performed 
according to the manufacturer's protocol. This method was used to transfect the HIT-T15 
cells once they reached 80-90% confluency.  
DNA mixture and Metafectene mixture were separately prepared in the Eppendorf tubes 
with 300 µl of RPMI uncomplete medium (without serum and antibiotics). The ratio of 
DNA:Metafectene was 1:2 (w/v). The HIT-T15 cells on 15-cm plate were washed with 15 
ml of 1 x PBS, then 3 ml of trypsin / EDTA solution was applied. After incubation for 2 - 3 
min at 37C, the plate was shaken to detach the cells. The cells were washed with RPMI 
uncomplete medium and transferred to a 50 ml tube. After centrifugation, the cell pellet 
was resuspended in the appropriate amount of RPMI complete medium and plated out 
(4.5 ml per 6-cm plate). Subsequently, DNA/medium mix was added to the 
metafectene/medium mix and incubated for 25 min at RT. The DNA/Metafectene complex 
was added to the 6 cm plate. 
 
3.9. Treatment of HIT-T15 cells  
Depending on the purpose of different experiments, HIT-T15 cells were treated with KCl, 
Forskolin, a combination of KCl and Forskolin, or Cyclosporin A (an immunosuppressive 
agent) in different concentration and time course. The basic principles were as follows: 
Treatment with KCl leads to membrane depolarization of HIT-T15 cells and opening of 
voltage-gated calcium channels of the L-type resulting in an increase in the intracellular 
calcium concentration.  
The treatment of cells with forskolin (FSK) increased the intracellular cAMP level as FSK 
is a potent activator of the adenylyl cyclase.  
By treatment with Cyclosporin A, the phosphatase calcineurin was inhibited. 
In luciferase reporter-gene assays, the cells were treated with a final concentration of 45 
mM KCl, 10 µM FSK, or the combination of 45 mM KCl and 10 µM FSK. These treatments 
were performed for 6 h before harvest of cells and measuremet of luciferase activity. 
For immunocytochemistry experiments, cells were treated with 45 mM KCl for 30 min. 
For analysis of in vivo phosphorylation of the proteins of interest, HIT-T15 cells were 
treated with 5 µM CsA for 15 min, or with the combination of 45 mM KCl and 10 µM FSK 
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for 15 min.  
For chromatin immunoprecipitation assays, HIT-T15 cells were treated for 30 min with the 
combination of 45 mM KCl and 10 µM FSK. 
 
3.10. Preparation of cell lysates for Western blot 
 
Cell lysis buffer  50 ml 
HEPES pH 7.5 50 mM 2.5 ml of 1 M stock 
NaCl 150 mM 1.5 ml of 5 M stock 
MgCl2 1.5 mM 75 µl of 1 M stock 
EGTA 1 mM 50 µl of 1 M stock 
Triton X-100 1 % (v/v) 500 µl 
NP-40 0.5 % (v/v) 250 µl 
The following inhibitors was added freshly before use   
phosphatase inhibitors   
Na3VO4 0.1 mM 5 µl of 1 M stock 
-glycerophosphate 20 mM  2 ml of 0.5 M stock 
NaF 1 mM 50 µl of 1 M stock 
PMSF 1 mM 250 µl of 0.2 M stock 
protease inhibitor   
Pepstatin 1 µg/ml 1 µl of 50 µg/µl stock 
Leupeptin 1 µg/ml 1 µl of 50 µg/µl stock 
Aprotinin 1 µg/ml 1 µl of 50 µg/µl stock 
 
Procedure 
The cell lysates were prepared for Western blot to analyze proteins. In brief, the cells were 
harvested 48 h after transfection. Cells in 6 cm-dishes were washed with cold 1X PBS. To 
each dish 100 µl of cell lysis buffer was added. Cells were scraped from the plates and 
transferred to 1.5 ml eppendorf tubes. Cells were mechanically disrupted 4 to 5 times with 
a syringe and a needle (27 G x ¾”, Sterican, B/BRAUN). The suspensions were incubated 
on ice for 30 min. After centrifugation for 10 min at 13,000 rpm, the supernatant was 
transferred to new eppendorf tubes. Protein concentration was measured using Bradford 
assay (3.3.a.I). Equal amounts of proteins from different samples were aliquoted for 
analysis. Equal volumes of 2X Laemmli buffer (pre-heated at 95oC) were added and 
samples were then heated on a thermo block at 95oC for 5 min. SDS-PAGE analysis was 
performed (3.3.b). 
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3.11. Immunocytochemistry 
 
 Buffers and solutions  
Quenching buffer  50 mL 
Sodium borohydride 0.1% (w/v) 0.05 g 
PBS  50 mL 
Blocking buffer  50 mL 
BSA 1% (w/v) 0.5 g 
Horse Serum 10% (v/v) 5 mL 
PBS  44.5 mL 
Antibody-dilution buffer  1.4 mL 
BSA 1% (w/v) 0.014 g 
PBS  1.4 mL 
 
Staining procedure  
To investigate the effect of DLK on the location of endogenous TORC proteins under 
basal or KCl-treated condition, immunocytochemistry experiments were performed. Cells 
were grown on coverslips in 6-well plates (0.962cm² per well) and plated ~2 x 106 cells per 
well. Cells were transfected by metafectene (with ratio µl metafectene: µg DNA = 2:1).  48 
h after transfection, cells were treated for 30 min with 45 mM KCl. After that, the coverslips 
were transferred to new 6-well plates and washed once with 4 ml 1x PBS per well at room 
temperature. PBS was aspirated off completely and the cells were immediately fixed by 
immersing the coverslips in 4 ml per well of -20°C precooled 100 % methanol, for 10 min. 
Next, the coverslips were rinsed 3 times for 5 min each with 4 ml PBS per well at room 
temperature, agitating gently. The cells were quenched in 4 ml (per well) fresh 0.1 % 
sodium borohydride in PBS (quenching buffer) for 5 min while agitating. Subsequently, the 
coverslips were washed 3 times for 5 min each with 4 ml PBS per well at RT, agitating. 
The PBS was aspirated off completely. Incubation of coverslips in 4 ml blocking buffer per 
well was performed for 45 min. To reduce background by removing any aggregated 
material, before staining the cells, the antibodies were centrifuged for 20 min at 12000 x g. 
The primary antibodies were diluted with antibody-dilution buffer (flag mouse antibody 
1:50, pan TORC antibody 1:1,500). A sheet of parafilm was placed in a 15-cm dish. 50 µl 
of diluted antibodies mixture was pipetted on the parafilm and the coverslip was placed on 
(the surface containing cells was turned bottom). The 15-cm dish was covered with 
aluminium foil and cells were incubated with primary antibody overnight at 4°C (paper 
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soaked with PBS was also placed in the dish to keep the environment humid). On the next 
day, the coverslips were placed again into the 6-well plate (the cell-containing surface was 
on top). A washing step was carried on 3 times with all coverslips using 4 ml PBS per 
coverslip, agitating for 5 min each. Next, the secondary antibodies were diluted in 
antibody-dilution buffer (TRITC-tetramethylrhodamin-5-isothiocyanate- linked anti-mouse 
IgG 1:200;and fluorophore Alexa488®-linked rabbit IgG antibody 1:50). The cells were 
incubated with the diluted secondary antibody on parafilm as performed with the primary 
antibody. This incubation was carried out for 30 min at room temperature in the dark 
(cover the plate with aluminium foil). Afterwards, the coverslips were washed 3 times with 
4 ml PBS at room temperature, agitating for 5 min each. Finally, the coverslips were 
mounted on slides using the Vectashield® Mounting Medium with DAPI (4',6-Diamidino-2-
phenylindol) and were sealed with nail polish. The samples were kept in the dark at 4oC 
for later microscopic analysis. 
 
 Fluorescence microscopic analysic  
The cells were observed at 63x magnification (Zeiss, LD Achroplan 63x) using the Zeiss 
Axiovert 200 microscope. The Software OpenLab™ 3.1 (Improvision Ltd.) was used to 
operate the device. Excitation/emission wavelengths for the fluorophores were: 495 nm / 
519 nm for AlexaFluor® 488; 555 nm / 580 nm for TRITC; and 360 nm / 460 nm for DAPI. 
 
3.12. Co-immunoprecipitation assay 
 
Immunoprecipitation  
HIT cells were transfected with expression vectors as indicated using metafectene 
(Biontex, Germany). 48 h after transfection, cells were lysed for 30 min in lysis buffer 
(3.10). Lysates were centrifuged for 10 min at 13,000 rpm, 4°C. The concentration of total 
protein in the supernatant was quantified using Bradford protein assay (Bio-Rad 
Laboratories, München). 500 µg of protein extract was incubated overnight on a rotator, at 
4°C with the primary antibody and protein A-agarose beads. The proteins bound to the 
beads were collected by centrifugation (13,000 rpm, 4°C for 1 min) and washed three 
times with the lysis buffer. The immunoprecipitates were used for in vitro kinase assays or 
co-immunoprecipitation assays.  
 
Co-immunoprecipitation assays 
To investigate the interaction between DLK and TORC in HIT-T15 cell, the HIT cells were 
co-transfected with expression vectors for flag-tagged DLK wild-type or mutants and a 
vector expressing TORC1 wild-type. The immunoprecipitation was performed 48 h after 
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transfection using the anti-flag M2 antibody (Sigma, Taufkirchen, Germany). The Western 
blot was performed to investigate whether flag-tagged DLK co-immunoprecipitated TORC 
1 wild-type.  
 
3.13. In vitro kinase assay 
 Buffers and solutions  
Kinase buffer   50 ml 
HEPES pH 7.5 1 M 25 mM 1.25 ml of 1M HEPES pH 7.5 
NaCl 5 M 100 mM 1 ml of 5 M NaCl  
MgCl2 1 M 10 mM 0.5 ml of 1M MgCl2 
Na3VO4 1 M 0.1 mM 5 µl of 1M Na3VO4 
Add freshly before use    
PMSF 200 mM 1 mM 250 µl of 200 mM PMSF 
ATP 200 mM 50 µM 125 µl of 200 mM ATP 
protease inhibitor    
Pepstatin 5 mg/ml 1 µg/ml 1 µl of 50 µg/µl stock 
Leupeptin 5 mg/ml 1 µg/ml 1 µl of 50 µg/µl stock 
Aprotinin 5 mg/ml 1 µg/ml 1 µl of 50 µg/µl stock 
 
His-tagged TORC proteins were prepared as described in (3.4.b) 
HIT cells were transfected with expression vectors for flag-tagged DLK wild-type or DLK 
K185A, respectively. The flag epitope-tagged DLK or its mutant were immunoprecipitated 
as described above (3.12). Immunoprecipitated flag-tagged DLK was washed three times 
with kinase buffer. The immunocomplex was incubated in kinase buffer for 3 h at room 
temperature with 25 µmol/l ATP, 2 µg of dephosphorylated casein (Sigma, Taufkirchen, 
Germany) as control or equal amount of His-tagged TORCs bound to Ni-agarose beads 
which have been washed 3 times with kinase buffer, and 3 µCi -32P]-ATP (3,000 
Ci/mmol) in a total volume of 200 µl, gently shaking. The reaction mixture was centrifuged 
for 1 min at 2000 rpm. After discarding the supernatants SDS-sample buffer were added 
to the pellets and boiled at 950C for 10min. Samples were subjected to SDS-PAGE. The 
phosphorylation of proteins was detected by a PhosphorImager. For the determination of 
the amount of immunoprecipitated DLK, a Western blot was performed using the antibody 
against C-terminal 223 amino acids of mouse DLK.  
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3.14. Chromatin-immunoprecipitation (ChIP)  
 
 Buffers and solutions  
Cell lysis buffer  100 ml 
Tris/HCl pH 8.0 10 mM 1 ml of 1 M stock 
NaCl 10 mM 200 µl of 5 M stock 
Nonidet-P40 0.2 % (v/v) 2 ml of 10% Nonidet-P40 
Protease inhibitors 1x 200 µl of 50x protease inh. mix / 10 ml 
Nuclei lysis buffer  100 ml 
Tris/HCl pH 8.0 50 mM 5 ml of 1 M stock 
EDTA 10 mM 2 ml of 0.5 M stock 
SDS 1 % (w/v) 10 ml of 10% SDS 
Protease inhibitors 1x 200 µl of 50x protease inh. mix / 10 ml 
 
Wash buffer I  50 ml 
Tris/HCl pH 8.0 20 mM 1 ml of 1 M stock 
NaCl 150 mM 1.5 ml of 5 M stock 
EDTA 2 mM 0.2 ml of 0.5 M stock 
SDS 0.1 % 0.5 ml of 10% SDS 
Triton X100 1% (v/v) 0.5 ml 
Wash buffer II  50 ml 
Tris/HCl pH 8.0 20 mM 1 ml of 1 M stock 
NaCl 500 mM 5 ml of 5 M stock 
EDTA 2 mM 0.2 ml of 0.5 M stock 
SDS 0.1 % 0.5 ml of 10% SDS 
Triton X100 1% (v/v) 0.5 ml 
Wash buffer III  50 ml 
Tris/HCl pH 8.0 10 mM 0.5 ml of 1 M stock 
EDTA 1 mM 0.1 ml of 0.5 M stock 
LiCl 0.25 M 3.125 ml of 4 M stock 
Nonidet-P40 1 % (v/v) 0.5 ml 
Deoxycholic acid 1 % (w/v) 500 mg 
   
Material and Methods  
 69 
 
Elution buffer I 
 
10 ml 
Tris/HCl pH 8.0 10 mM 100 µl of 1 M stock 
EDTA 1 mM 20 µl of 0.5 M stock 
SDS 1 % (w/v) 1 ml of 10 % SDS 
Elution buffer II  10 ml 
Tris/HCl pH 8.0 10 mM 100 µl of 1 M stock 
EDTA 1 mM 20 µl of 0.5 M stock 
SDS 0.67 % (w/v) 670 µl of 10 % SDS 
TE buffer  50 ml 
Tris/HCl pH 8.0 10 mM 0.5 ml of 1 M stock 
EDTA 1 mM 0.1 ml of 0.5 M stock 
 
Chromatin immunoprecipitation assay 
To investigate the effect of DLK on the recruitment of TORC to a CRE-containing 
promotor, the chromatin immunoprecipitation assay was performed. The assay was 
performed as described by Heinrich et al., 2009. 
HIT cells on 10-cm plates were co-transfected using Metafectene with expression vectors 
for DLK wild-type/K185A/NLS1 or NLS2 and HA-tagged TORC1, and with p4xsomCRE. 
48h after transfection, cross-linking of proteins and DNA was achieved by adding 1 % 
formaldehyde to the plates and agitating for 20 min at room temperature. The cross-linking 
reaction was stopped by addition of glycine to a final concentration of 0.125 M and 
agitating the plates for 5 min at room temperature. The media was discarded and cells 
were rinsed twice with 5 ml of ice-cold PBS. Cells were scraped in 1.5 ml PBS and 
centrifuged for 2 min at 1,700xg, 4°C. Cell pellets were lysed in 800 µl cell lysis buffer. 
Samples were frozen and thawed (in liquid N2 and 37°C waterbath, respectively) 3 times. 
Disrupted cells were homogenized in a 1 ml douncer 20 times. After leaving on ice for 10 
min, the samples were centrifuged 5 min at 2,700xg, 4°C. The pellets were added with 
300 µl nuclei lysis buffer, mixed and incubated 10 min on ice. Samples were applied to 
sonication 5 times (each 5 seconds, 30 sec break with output control 6, duty cycle 50 %). 
The disrupted nuclei were centrifuged 10 min at 18,000xg, 4°C. 10 % of the supernatants 
were used as input. The remaining supernatants were incubated on a rotator overnight at 
4°C with 30 µl protein A agarose slurry (containing 50 % beads) which were already 
equilibrated overnight with nuclei lysis buffer plus 0.1 % BSA and with 10 µg (2 µl) anti-HA 
antibody (Sigma). Subsequently, the samples were centrifuged 1 min at 18,000xg, 4°C. 
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The washing steps were performed as follows: twice with washing buffer 1, once with 
washing buffer 2, once with washing buffer 3 and once with TE buffer. Each washing step 
was repeated with 5 min rotation, 2 min centrifugation at 1,700xg, 4°C and followed by 
discarding the supernatants. Afterwards, the agarose pellets were added to 100 µl elution 
buffer 1 and incubated for 15 min at 65°C. The samples were centrifuged 3 min at 
18,000xg, 4°C. The supernatants were transferred into new eppendorf tubes. To the 
pellets 150 µl elution buffer 2 were added and the incubation and centrifugation were 
repeated. The supernatants were transferred into the corresponding eppendorf tubes. The 
inputs were added with 10 % SDS and filled up to 250 µl with TE buffer. All samples and 
inputs were incubated overnight at 65°C while agitating. In the next day, to each sample 
250 µl TE buffer plus 100 µg Proteinase K was added and incubated for 2 h at 37°C. After 
addition of 55 µl 4 M LiCl, the DNA was extracted twice with 500 µl Phenol and once with 
500 µl chloroform/isoamylacohol (24/1), each step was performed with 2 min 
centrifugation at 18,000xg, room temperature and taking the upper phase. The DNA was 
precipitated by addition of 1 µl glycogen and 900 µl 100 %-EtOH, cooled down at -20°C 
for 30 min. The samples were centrifuged 30 min at 18,000xg, 4°C. The pellets were 
washed with 500µl 70% EtOH and centrifuged 10 min at 13,000 rpm, 4°C. Afterwards, the 
pellets were dried and resuspended in 20 µl TE buffer. The samples were used for 
quantitative real-time PCR using the ABI PRISM 7900 HT Sequence machine and the 
primers described before (2.3.e.II) 
 
Quantitative real-time PCR  
The DNA samples resulting from ChIP assays were analyzed quantitatively by real-time 
PCR using TaqMan™ probes. The oligonucleotide TaqMan™ probe is labeled with a 
fluorescent dye at its 5’ end and carries a quencher at its 3’ end. The probe is 
complementary to the nucleotides of the sequence of the specific DNA template. 
Normally, the fluorescene of the probe is quenched. The probe is disabled from 3’ 
extension by a 3’ phosphate. During the PCR, the probe hybridized to the DNA is digested 
by the polymerase due to its 5’-3’ exonuclease activity. The digestion of quencher-
nucleotides leads to the enhancement of fluorescence intensity (Lee et al., 1993). 
Spectrophotometric measurement of the fluorescence during PCR determines the 
amounts of DNA template present in the sample.  
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3.15. Luciferase reporter-gene assay  
 
 Buffers and solutions  
Scraping Buffer (500 ml) 
1 mM EDTA     1 ml  of 0.5 M EDTA  
150 mM NaCl     75 ml of 1 M NaCl 
40 mM Tris HCl pH 7.5   20 ml of 1 M Tris-HCl pH 7.5 
 
Potassium phosphate buffer pH 7.8 (500 ml) 
Solution 1: 100 mM K2HPO4   8.71 g in 400 ml water 
Solution 2: 100 mM KH2PO4   1.36 g in 100 ml water 
Adjust the pH of solution 1 to pH 7.8 with solution 2. Add to 500 ml with distilled water. 
 
Potassium phosphate buffer + DTT (5 ml) 
Phosphate buffer pH 7.8   5 ml 
1 mM DTT     5 l of 1 M DTT 
 
0.5 M Glycylglycin (100 ml) 
Glycylglycin     6.6 g 
Add to 100 ml with distilled water 
 
Glycylglycin Buffer (100 ml) 
4 mM EGTA     2.22 ml of 180 mM EGTA 
25 mM Glycylglycine (pH 7.8)  5 ml of 0.5 M Glycylglycin 
15 mM MgSO4    1.5 ml  1 M MgSO4 
Adjust pH to 7.8 with NaOH 
Keep at 4oC 
 
Luciferin  
10 mM DTT       275 mg 
Glycylglycin buffer     178.5 ml 
1 mM Luciferin     50 mg 
Dissolve DTT with glycylglycin buffer on ice 
Add the luciferin in the dark 
Make 1.4 ml aliquots and freeze at -80oC 
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Luciferase assay mix (LAM) Buffer (for 25 samples) 
2 mM ATP      100 l of 200 M ATP 
1 mM DTT      10 l of 1 M DTT 
82.4 % (v/v) Glycyglycin buffer   7.5 ml 
16.5 mM Potassium phosphate buffer pH 7.8 1.5 ml 
 
Luciferin Mix (LM) Buffer (for 25 samples) 
10 mM DTT      56 l 
Glycyglycin buffer     5.6 ml 
1 mM Luciferin     1.4 ml 
 
Cell extract preparation procedure 
Cells were harvested 48 h after transfection. Briefly, the cells were washed once with 1X 
PBS solution. The cells were detached in 750 l/dish of scraping buffer using a scraper. 
Cell suspensions were pipetted into 1.5 ml eppendorf tubes (on ice). The dish was 
washed with another 750 l/dish of scraping buffer and the suspension was collected into 
the same tube. Cells were centrifuged for 5 min at 5,200 x g and the supernatant was 
sucked off using a water pump. Cell pellets were resuspended in 150 l of potassium 
buffer containing DTT and were subjected to 3 times freezing with liquid N2 followed 
thawing in water bath at 37oC. The suspensions were centrifuged for 5 min at 20,800 x g. 
The supernatant was used as cell extract for luciferase reporter and GFP assays. 
 
Luciferase assay procedure 
In the presence of ATP the substrate luciferin is adenylated by the enzyme luciferase 
isolated from the firefly Photinus pyralis. The luciferyl-adenylate undergoes an oxidative 
decarboxylation which produces light. As long as the substrate luciferin is present in 
excess, the production of light is proportional to the amount of luciferase in the reaction 
mixture (de Wet et al., 1987). By determining the luciferase activity in luciferase reporter-
gene assays the promoter activity is estimated. 
 
Luciferase activity from cell extracts prepared from transiently transfected cells was 
measured. Briefly, 50 l of every cell extracts was pipetted into 5 ml plastic tube (75 x 12 
mm diameter - Sarstead, Nümbrecht) and 368 l of the LAM buffer were added. 50 l of 
the potassium phosphate buffer containing DTT were used as a blank. The samples were 
shortly vortexed and placed in a Luminometer (AutoLumat LB 953, E&G Berthold). The 
luciferin mix (LM) was stored in the dark and was placed in the automatic injector of the 
luminometer. 200 µL of the luciferin solution were injected automatically to the samples 
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and the light emission was measured at 560 nm for 20 sec. The raw data were expressed 
as relative light units.  
 
GFP reporter gene assay procedure 
Green fluorescent protein (GFP) containing a chromophore possessing visible absorption 
and fluorescence under aerobic conditions was isolated from the jellyfish Aequorea 
Victoria. GFP topaz (GFPtpz) is a variant of GFP containing 4 point mutations which 
modify the chromophore and thereby change the emission spectrum to yellow (Tsien, 
1998). To control for transfection efficiency during luciferase reporter-gene assay the 
pGFPtpz-cmv® control vector was cotransfected. The expression of GFPtpz is under 
control of a potent CMV-promoter.  
Micro plate reader for GFP (FusionTM, Packard, Switzerland) was used for measurement 
of GFP. 50 l of the cell extract were pipetted into every other well of a 96 U-shaped well 
plate. 50 l of the potassium phosphate buffer containing DTT were used as a blank. The 
fluorometer Fusion (Canberra-Packard) performed 1 sec measurement at excitation 
wavelength of 485 nm and emission at 530 nm. The device was operated using the 
software Fusion InstrumentControl Application version 3.50 (Canberra-Packard). The final 
GFP values are the result of the subtraction of the GFP measurements from the average 
of three blank values. 
 
3.16. Statistics 
The data were analyzed by one-way or two-way analysis of variance (ANOVA) followed by 
Student’s t-test using the software STATISTICA (Statsoft, Hamburg, Germany). 
Significance level was set at p  0.05. 
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4. RESULTS 
 
4.1. Effect of DLK on the transcriptional activity conferred by the three TORC 
isoforms 
TORC transactivating capacity of CREB directed gene transcription is regulated by its 
cellular localization and presumably by its own transcriptional activity (Bittinger et al. 2004; 
Screaton et al. 2004; Heinrich et al. 2009). To examine the effect of DLK on TORCs 
transcriptional activity, the GAL4 system was used. An expression vector encoding either  
TORC1, TORC2 or TORC3 fused to the DNA binding domain (DBD) of the yeast 
transcription factor GAL4 (GAL4-TORC) was transiently co-transfected (§3.8.a) into the 
electrically excitable β-cell line HIT-T15 together with a luciferase reporter gene, 
consisting of five copies of the GAL4 DNA binding sites placed in front of a minimal viral 
E1B promotor (pG5E1B) (Fig. 8). Through the GAL4-DBD GAL4-TORC fusion proteins 
are tethered to the promoter of the G5E1B-Luc, thereby activating transcription of the 
luciferase gene. Thus, luciferase activity can be considered as a measure of TORC 
transcriptional activity. Cells were also co-transfected with expression vectors of DLK wild-
type or DLK K185A. In this mutant, lysine-185 is changed to alanine resulting in the loss of 
ATP binding and thus enzymatic activity. 48 h after transfection cells were harvested and 
luciferase assay was performed (§3.15) to determine the transcriptional activity of TORC.  
 
 
 
 
 
 
 
Under the basal condition, DLK wild-type and DLK K185A reduced the transcriptional 
activity of TORC1 to 18.2  0.6% (n=6, p<0.0029) and 41.5  4.6% (n=6, p<0.01), 
respectively (Fig. 9A). They reduced TORC2 activity to 59.5  2.8% (n=6, p<0.001) and to 
80  4.5% (n=6, p<0.01), respectively (Fig. 9B). The transactivating capacity of TORC3 
was decreased by DLK wild-type and the kinase dead DLK mutant to 41.6  1.7% (n=6, 
p<0.001) and 73.7  4.7% (n=6, p<0.0026), respectively (Fig. 9C). In all cases, DLK wild-
type and DLK K185A significantly inhibited all three TORC isoforms (Fig. 9A-C). 
In each group, the inhibitions of TORC transcriptional activities caused by DLK wild-type 
or by its kinase dead mutant were significantly different. The enzymatic dead DLK mutant 
had less inhibitory effect than the wild-type form of DLK (Fig. 9A-C). In the presence of 
overexpressed DLK K185A TORC1 and 3 activities were about 2-fold higher than their 
GAL4 binding domain TORC 
1 147 
5 x GAL4 binding sites -38 
+1 
Luciferase 
+250 E1B Adenovirus promotor 
G5E1B 
GAL4-TORC 
Figure 8: The sketch of plasmid 5xGal4E1BLuc and expression vector of GAL4-TORC 
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activities in the presence of overexpressed DLK wild-type (n=6, p<0.0038 and n=6, 
p<0.001, respectively) (Fig. 9A, C). TORC2 activity was also significantly different 
between DLK wild-type presenting group and the group of kinase dead DLK mutant (60% 
and 80% (n=6, p<0.004), respectively) (Fig. 9B). 
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Figure 9: The effect of DLK on unstimulated 
transcriptional activity of TORC isoforms  
HIT-T15 cells were transiently transfected with the 
luciferase-reporter gene G5E1B under control of five 
repeats of the GAL4 DNA-binding site. Co-transfected 
was an expression plasmid encoding TORC1, TORC2 or 
TORC3 fused to the DNA-binding domain of GAL4. The 
cells were co-transfected with expression vectors for DLK 
wild-type or its kinase dead mutant DLK K185A as 
indicated and incubated for 48 hours before harvesting 
and measurement of luciferase activity. A schematic 
illustration of the constructs is shown above the graphs. 
The luciferase activity in cells transfected with the 
reporter gene, the expression vector for the GAL4-TORC 
fusion protein and Bluescript was considered as control. 
Relative luciferase activity values are means ± SEM of 
three independent experiments performed in duplicate, 
and are expressed in percent of control. Statistical 
analysis was performed by two-way ANOVA followed by 
Student’s t-test: **p ≤ 0.01, ***p ≤ 0.005. 
9A-C: upper panels depict expression vectors used in 
experiments. 
9A-C: lower panels are graphs of result corresponding to 
TORC1, TORC2 and TORC3, respectively. 
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CREB-directed gene transcription is regulated by nucleo/cytosolic shuttling of TORC. 
Under resting conditions phosphorylated TORC is sequestered in the cytoplasm by 
binding to 14-3-3 proteins. By an increase of intracellular Ca2+ and cAMP levels TORC is 
dephosphorylated and translocated to the nucleus (Bittinger et al., 2004; Screaton et al., 
2004). The effect of DLK on the transcriptional activity of TORC proteins after treatment 
with KCl and forskolin (a bicyclic diterpene) was examined using reporter gene assays. 
KCl treatment of cells results in its membrane depolarization thereby increasing 
intracellular Ca2+ levels by activation of the voltage-gated calcium channel of the L-type.  
 
The calcium/calmodulin-dependent phosphatase calcineurin is activated by high 
concentration of Ca2+, which was shown to dephosphorylate TORC (Bittinger et al., 2004; 
Screaton et al., 2004). Forskolin treatment of cells activates the enzyme adenylyl cyclase 
thereby increasing intracellular cAMP level and activation of PKA. PKA inhibits SIK, 
thereby reducing the phosphorylation of TORC (Katoh et al., 2004; Takemori and 
Okamoto, 2008). To understand the effect of DLK on TORCs under the stimulated 
condition, HIT-T15 cells were transiently co-transfected with the luciferase reporter gene 
G5E1B and expression vectors encoding GAL4-TORC1, -TORC2 or -TORC3 fusion 
proteins. The cells were co-transfected with expression vectors for DLK wild-type or its 
kinase dead mutant DLK K185A as indicated and cultured for 48 hours before harvesting 
and the measurement of luciferase activity. Cells were treated with 45 mM KCl, 10 µM 
forskolin, or a combination of both 6 hours prior to harvest. The same principle of GAL4 
system and luciferase reporter gene assay (§3.15) was applied. 
 
Forskolin and KCl enhanced the transcriptional activity of TORC1 approximately 4.5-fold, 
each, and the combined stimuli increased the activity 8-fold (Fig. 10A). TORC2 activity 
was enhanced by KCl, Forskolin and their combination 1.7-, 2- and 2.3-fold, respectively 
(Fig. 10A). TORC3 activity was not enhanced by KCl and slightly increased by treatment 
of forskolin or the combination of KCl and forskolin (Fig. 10A).  
As seen in Fig. 10B-D, under the treatment with KCl, DLK wild-type reduced the 
transcriptional activities of TORC1, TORC2 and TORC3 to 35.3  4.1% (p<0.001), 54.3   
1.6% (p<0.001) and 44.4   1.8% (p<0.001), respectively. TORC1, TORC2 and TORC3 
activities were reduced by DLK K185A to 67.5  1.4% (p<0.001), 81.4  2.6% (p<0.001) 
and 73.2  4.8% (p<0.001), respectively. In the condition of membrane depolarization, the 
inhibition effected by DLK K185A on TORC1, 2 and 3 were significantly different from the 
effect caused by DLK wild-type (Fig. 10B-D). 
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After treatment with forskolin, TORC1, TORC2 and TORC3 activities were decreased in 
the presence of DLK wild-type to 43.1  1.8% (n=6, p<0.001), 66.7  3.9 (n=6, p< 0.001) 
and 52.5  0.9% (n=6, p<0.001), respectively, whereas DLK K185 reduced the activities of 
TORC1, TORC2 and TORC3 to 54.7  1.6% (n=6, p<0.001), 75.3  4.7% (n=6, p<0.0036) 
and 80.4  5.5 (n=6, p<0.017), respectively (Fig. 10B-D). Under these experimental 
conditions, the inhibitory effects caused by DLK wild-type on TORC1 or 3 were 
significantly different from the effects resulted from overexpression of DLK K185A (Fig. 
10B-D). After treatment with forskolin DLK wild type reduced TORC2 activity more than 
DLK K185 did, even though their effects were not significantly different in these 
experiments. 
 
The combined treatment with KCl plus forskolin did not change much the inhibitory effect 
on three TORC isoforms caused by DLK wild-type or its enzymatic dead mutant, as 
compared to other single treatments. In this condition, only on TORC3 DLK wild-type and 
its mutant exerted significantly different inhibition (Fig. 10D). The transcriptional activity of 
TORC1 was reduced by DLK wild-type and DLK K185A to 55.3  3.1% (n=6, p<0.001), 
61.0  2.2% (n=6, p<0.001), respectively (Fig. 10B). The presence of overexpressed DLK 
wild-type and DLK K185A also resulted in a reduction of TORC2 or TORC3 transcriptional 
activities to 69.5   4.5% (n=6, p<0.001) and 75.6  2.3% (n=6, p<0.001) or 52.9  2.8% 
(n=6, p<0.001) and 69.8  4.8% (n=6, p<0.001), respectively (Fig. 10C, D). 
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Figure 10: Effect of DLK on the stimulated transcriptional activity of TORC isoforms 
A luciferase reporter fusion gene under the control of five DNA binding sequences for the yeast transcription 
factor GAL4 (plasmid G5E1B.Luc) was transiently co-transfected into HIT cells with an expression vector for 
fusion proteins consisting of DNA binding domain of GAL4 and TORC1, TORC2 or TORC3. The cells were co-
transfected with expression vectors for DLK wild-type (wt) or DLK K185A as indicated and incubated for 48 hours. 
Treatment of cells with 40 mM KCl or 10 µM forskolin was performed 6 hours prior to harvesting and measuring 
luciferase activity. The luciferase activity in cells transfected with the reporter gene, the expression vectors for 
GAL4-TORC fusion protein and Bluescript was considered as control. Relative luciferase activity values are 
means ± SEM of three independent experiments performed in duplicate, and are expressed in percent of control. 
Statistical analysis was performed by two-way ANOVA followed by Student’s t-test: *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 
0.005.  
The most upper panel depicts a scheme of the expression vectors used in experiments 
10A: Effect of KCl and forskolin on the transcriptional activities of TORC1, TORC2 and TORC3. The control 
groups under basal condition were set as 100%. 
10B-D: Effect of DLK on stimulated transcriptional activity of TORC isoforms (B: TORC1; C: TORC2; D: TORC3). 
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4.2. Comparison of the inhibitory effect of DLK on the transcriptional activity of 
three TORC isoforms 
In order to investigate which TORC isoform was most inhibited by DLK, the reporter gene 
assay using the GAL4 system was used. HIT-T15 cells were transiently co-transfected 
(§3.8a) with the reporter gene plasmid pG5E1B and GAL4-TORC 1, -TORC2 or -TORC3. 
Increasing amounts of the expression vector for DLK were transiently co-transfected as 
indicated. Cells were harvested and luciferase assays (§3.15) were performed after 48h. 
Increasing amounts of the expression vector for DLK showed that TORC1 activity was 
most intensively inhibited as compared to TORC2 and 3 activities (Fig. 11). The amount of 
expression vector for DLK wild-type from 0.6µg to 2µg significantly decreased 
transcriptional activity of TORC1 from 30% to 55%. Meanwhile the similar amounts of DLK 
expressing vector significantly inhibited TORC3 and TORC2 activities from 20% to 40% 
and 15% to 35%, respectively (Fig. 11). The results indicated that the inhibitory action of 
DLK on the transcriptional activity of TORC was enforced by increasing amounts of the 
expression vector for DLK wild-type. Inhibition of TORC1 transcriptional activity was the 
most pronounced. 
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Figure 11: Increasing amount of overexpression vector for DLK enhances the inhibitory effect on TORCs 
The effect of increasing amount (0; 0.2; 0.6 and 2 µg) of the expression vector for DLK on different TORC 
isoforms was investigated. The vector for Bluescript was used to keep the amount of transfected DNA 
constant among the experimental groups.  2µg of GAL4-TORC1, -TORC2 or -TORC3 was co-transfected 
with a total of 2µg of the expression vectors for DLK and Bluescript into HIT cells. Each TORC activity in   
the absence of DLK was considered as control (100%) for its own group. Luciferase activity is expressed 
relative to the activity of the control (Gal4-TORC only) in the absence of DLK. Relative luciferase activity 
values are means ± SEM of three independent experiments performed in duplicate. Statistical analysis was 
performed by two-way ANOVA followed by Student’s t-test:  ***p ≤ 0.005. 
The upper panel depicts expression vectors used in the experiments. 
The lower panel is the graph of the results. 
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4.3. Mapping of TORC1 domains inhibited by DLK 
 
TORC proteins activate transcription by interaction with the bZip domain of CREB. 
Structurally, the coiled-coil sequence of mouse TORC 1 located at aa 1-42 is (Conkright et 
al., 2003a) involved in this interaction. In addition, the C-termini of TORCs were shown to 
have transactivating potency (Iourgenko et al., 2003). In order to study which domain of 
TORC mediates the inhibitory action of DLK, a reporter gene assay using the GAL4 
system was employed. HIT-T15 cells were transiently co-transfected (§3.8a) with the 
reporter gene pG5E1B, the expression vectors for GAL4 fusion proteins containing either 
TORC1 full length, or its deletions (C-terminus TORC1 aa44-651 (44) or N-terminus 
TORC1 aa1-44) and expression vector for DLK wild-type or DLK K185A. 48 h after 
transfection cells were harvested and luciferase assays (§3.15) were performed. 
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Figure 12: Effect of DLK on the transcriptional activity of TORC1 domains 
Vector for Bluescript was used to keep the amount of transfected DNA constant among the 
experimental groups. 2µg of either GAL4-TORC1 full-length (FL), GAL4-TORC144 or GAL4-
TORC11-44 were co-transfected with 2µg of DLK wild-type or DLK K185A or Bluescript 
vectors into HIT cells. After 48 h, cells were harvested and luciferase activity was measured. 
The luciferase activity is expressed relative to the activity of TORC1 full length in the 
absence of DLK wild-type or DLK K185A. Relative luciferase activity values are means ± 
SEM of three independent experiments performed in duplicate, and are expressed in 
percent of control. Statistical analysis was performed by two-way ANOVA followed by 
Student’s t-test: ** p ≤ 0.01, * p ≤ 0.05.   
The upper panel depicts expression vectors used in the experiments. 
The lower panel is the graph of results. 
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In Fig. 12, the deletion of N-terminal 44 amino acid of TORC1 increased transcriptional 
activity 3-fold. Its activity was inhibited by both DLK wild-type and DLK K185A, whereby 
both DLK mutant and wild-type reduced the transcriptional activity to the same extent. In 
the presence of DLK wild-type and its kinase dead mutant, TORC144 transcriptional 
activity (294.9  40.4%) were decreased nearly by half, with p<0.014 and p<0.027, 
respectively. The 44 N-terminal amino acid of TORC1 showed a decreased transcriptional 
activity which was inhibited neither by DLK wild-type nor by the kinase dead mutant of 
DLK (Fig. 12).  
 
4.4. Effect of DLK on the transcriptional activity of TORC1 S167A and of TORC2 
S171A 
The above results (Fig. 9) suggested that the enzymatic activity of DLK is partly involved 
in the inhibition of TORC transcriptional activity. The phosphorylation of Ser-167 in 
TORC1 and of Ser-171 in TORC2 enhancing the interaction of TORC protein with the 14-
3-3 protein and thus preventing the nuclear localization of TORC is considered as the key 
switching “on” and “off” the transactivating potency of TORC protein. Therefore, the effect 
of DLK on the transcriptional activity of TORC1 S167A and TORC2 S171A was 
investigated using the GAL4 system. HIT cells were transiently co-transfected (§3.8a) with 
the luciferase reporter gene pG5E1B, expression vectors for GAL4-TORC1 S167A or 
GAL4-TORC2 S171A fusion proteins, and DLK wild-type or DLK K185A as indicated. The 
transcriptional activity of the TORC mutants was measured by luciferase assay (§3.15) 
which was perfomed 48 hours after transfection. GAL4-TORC 1 or 2 wild-types were used 
as controls. 
 
Both TORC1 S167A and TORC2 S171A exhibited 3- and 5-fold enhanced transcriptional 
activity when compared to their respective wild-types (Fig. 13A, B). In the experimental 
condition, the inhibitory effects on TORC1 and TORC 2 (wild-type) caused by DLK wild-
type were different from the effects resulting from overexpression of DLK K185A. TORC1 
S167A activity was increased to 315.3  30.5% when compared to TORC1, whereas this 
activity was slightly changed to 293.8  27.6% or 333.0  39.6% by overexpression of 
DLK wild-type or DLK K185A, respectively. However, these changes were not significant. 
The transcriptional activity of TORC2 S171A was also enhanced to 541  53.1% when 
compared to TORC2, whereas this activity was not inhibited in the presence of 
overexpressed DLK wild-type or insignificantly reduced to 509.6  90.6% by 
overexpression of DLK K185A. The results indicated that overexpression of DLK wild-type 
or its kinase dead mutant resulted in an inhibition of TORC1- and TORC2-dependent gene 
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transcription, whereas the transcriptional activities of the TORC1 and 2 mutants were no 
longer reduced by DLK (Fig. 13A, B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.5. Effect of a dimerization-deficient DLK mutant on the transcriptional activity of 
the TORC isoforms 
DLK P-P, in which the leucines 437 and 463 are changed into prolines, is a dimerization 
deficient mutant of DLK (Nihalani et al. 2000). Since homodimerization of DLK is required 
for its kinase activity, this mutant lacks enzymatic activity (Nihalani et al. 2000; Nihalani et 
al. 2003). It is possible that DLK may exert in part the inhibition on TORC through the 
zipper domain. The effect of DLK P-P on the transcriptional activity of TORC isoforms was 
Figure 13: Effect of DLK on the transcriptional activity of TORC1S167A and TORC2 S171A. 
A luciferase reporter fusion gene under the control of five DNA binding sequences for the yeast 
transcription factor GAL4 (plasmid G5E1B.Luc) was transiently transfected into HIT cells with an 
expression vector for a fusion protein consisting of DNA binding domain of GAL4 and TORC1 or 
TORC2 wild-type or mutants (TORC1 S167A or TORC2 S171A). The cells were co-transfected with 
expression vectors for DLKwt or DLK K185A as indicated and incubated for 48 hours before 
havesting and measuring luciferase activity. The luciferase activity in cells transfected with the 
reporter gene, the expression vectors for GAL4-TORC fusion protein and Bluescript was considered 
as control. Relative luciferase activity values are means ± SEM of three independent experiments 
performed in duplicate, and are expressed in percent of control. Statistical analysis was performed 
by two-way ANOVA followed by Student’s t-test: ***p ≤ 0.005, **p ≤ 0.01.  
The most upper panel depicts expression vectors used in experiments 
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tested. To perform the investigation, HIT cells were transiently co-transfected with the 
reporter gene pG5E1B and vectors for GAL4-TORC1, -TORC2 or -TORC3 fusion proteins 
and DLK wild-type or DLK P-P, as indicated. The luciferase assay (§3.15) was performed 
48 hours after transfection. 
As shown in Fig. 14, DLK wild-type significantly reduced the transcriptional activities 
conferred by TORC1, TORC2 and TORC3 to 62.5  4.2% (p<0.001), 90.4  5.3% 
(p<0.05) and 66.6  3.6% (p<0.001), respectively, whereas overexpression of the DLK P-
P mutant did not decrease the transcriptional activities conferred by the three TORC 
isoforms.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.6. Overexpression of DLK wild-type and its mutants in HIT cells 
In order to investigate whether the differences in the inhibitory effect of DLK wild-type and 
its mutants (the kinase dead or the dimerization deficient) on TORCs resulted from 
differences in the expression levels of DLK proteins, HIT cells were transiently transfected 
(§3.8b) with expression vector for DLK wild-type or its mutants. Cells were incubated for 
14 
Figure 14: The dimerization-deficient DLK has no inhibitory effect on TORC 
A luciferase reporter fusion gene under the control of five DNA binding sequences for yeast transcription factor 
GAL4 (plasmid G5E1B.Luc) was transiently co-transfected into HIT cells with an expression vector for a fusion 
protein consisting of DNA binding domain of GAL4 and TORC1, -TORC2 or -TORC3. The cells were co-
transfected with expression vectors for DLK wild type or its dimerization-deficient mutant DLK P-P as indicated 
and incubated for 48 hours prior to harvesting and measuring luciferase activity. The luciferase activity in cells 
transfected with the reporter gene, the expression vectors for GAL4-TORC fusion protein and Bluescript was 
considered as control. Relative luciferase activity values are means ± SEM of three independent experiments 
performed in duplicate, and are expressed in percent of control. Statistical analysis was performed by two-way 
ANOVA followed by Student’s t-test: ***p ≤ 0.005, **p ≤ 0.01, *p ≤ 0.05.     
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48h before harvesting and lysis (§3.10). Cell lysates were analyzed by Western blot 
(§3.3d). DLK proteins were detected by using the antibody against the C-terminus of DLK. 
DLK wild-type and its mutants were differerently overexpressed in HIT cells (Fig. 15).  
When compared to DLK wild-type, the overexpression of DLK K185A resulted in 87  
4.3% (p<0.021) and the overexpression of DLK P-P resulted in 131.3  13.2% of DLK 
content (p<0.046). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.7. Interaction between DLK and TORC as revealed by an in vitro assay 
TORCs dependent transcription was reduced in part by the enzymatic activity of DLK. In 
addition, the kinase-dead DLK mutant showed also less inhibitory effect than the wild-type 
(Fig. 9). Therefore, it was investigated whether DLK interacts with TORC. 
To investigate the interaction between DLK and TORC, an in vitro protein interaction 
assay (§3.6) was conducted. In principle, GST-TORC11-44 fusion proteins or His-tagged 
TORC1 full length and His-tagged TORC144 proteins were bacterially expressed and 
purified using glutathione- or NTA-Ni-agarose beads (§3.4), respectively. The GST alone 
or NTA-Ni agarose beads were used as background control for GST-TORC1-44 or His-
tagged TORC fusion proteins. These on-beads immobilized proteins were incubated with 
[35S] radio-labeled proteins (DLK wild-type, DLK K185A, DLK P-P, CREB wild-type or 
CREB R300A) (§3.5). If the radio-labelled proteins interact with the immobilized proteins, 
a complex will be formed on the agarose beads. Afterwards, the complex was separated 
from unbound proteins by several washing steps. The protein complex bound to agarose 
beads were eluted and subjected to SDS-PAGE for detection of the radio-labelled protein 
R
el
at
iv
e 
op
tic
al
 d
en
si
ty
 (%
 o
f D
LK
 w
ild
 ty
pe
)
0
20
40
60
80
100
120
140
160
DLK
wild type
DLK
K185A
DLK
P-P
*
*
Figure 15: Expression levels of DLK wild-type and 
its mutants in HIT cells 
Expression vectors for DLK wild-type, DLK K185A 
or DLK P-P were transfected into HIT cells. Cells 
were harvested after 48 hours. Cells were lysed 
and a Western blot was performed. The optical 
density of band representing DLK wild-type or its 
mutants was corrected for the optical density of 
the GAPDH representing band. The values are 
expressed relative to the mean value ± SEM of the 
optical density of the DLK wild-type representing 
band in each experiment in five independent 
experiments each done in duplicate. 
Upper panel: The typical Western blot showing 
overexpressed DLKs and GAPDH. 
Lower panel: graph showing quantitative 
evaluation of the expression levels of DLK proteins 
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(§3.6). Equal volume of input of [35S] proteins was loaded on the same SDS-PAGE to 
calculate results. 
Calculation: 
Density of interacting [35S] protein = (density of band presenting [35S] protein interacting 
with GST-or His- protein) – (density of band presenting the corresponding [35S] protein 
interacting with GST or NTA-Ni agarose beads alone)/density of band presenting the 
corresponding [35S] protein input. 
 
4.7.a. Purification of bacterially expressed proteins 
His-tagged TORC1 full length and His-tagged TORC44 (a N-terminal deleted TORC1 
mutant, lacking the interaction domain with the dimerized leucine zipper of CREB 
(Screaton et al. 2004)) were bacterially expressed and purified using NTA-Ni-agarose 
beads (§3.4 a, b). The GST protein or GST-TORC1-44- (C-terminal deleted TORC1 mutant 
consisting of the interaction domain with CREB) fusion protein were bacterially expressed 
and purified using glutathione agarose beads (§3.4 a, b).  
The extracts from different steps of protein expression and purification were run on a SDS 
PAGE and stained with coomasive dye to detect the purified proteins. Consistent with the 
calculated molecular weight, His-tagged TORC 1 and His-tagged TORC144 proteins 
migrated at 70 kD and 65 kD, respectively (the arrows in lanes 5 and 6, Fig. 16). GST-
TORC1-44 and GST proteins were the bands migrating at 31 kD and 26 kD (the arrows in 
lane 6 and 7, Fig. 17), respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16: Purification of His tagged TORC1 full length and His-tagged TORC144 proteins 
The following protein extracts were run on the SDS-PAGE (8% acrylamide) and stained with coomassie dye. The 
bands at 70 kD and 65 kD indicated purified His-tagged TORC full length and His-tagged TORC44  (arrows). 
1. Cell extract before induction with IPTG 
2. Supernatant after induction with IPTG and cell disruption 
3. Pellet after induction with IPTG and cell disruption 
4. Supernatant after incubating with Ni-agarose beads 
5. 5µl of proteins bound to Ni-agarose beads 
6. 10µl of proteins bound to Ni-agarose beads 
1 2 3 4 5 6 
His-TORC1  
full length 
1 2 3 4 5 6 
His-TORC1 44 
72 kD- 
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To estimate the amounts of the purified protein used in in vitro protein interaction assay, a 
semi-quantitative analysis of proteins (3.3.a.II) was performed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17: Purification of GST protein and GST-TORC11-44 fusion protein 
The following protein extracts were subjected to SDS-PAGE (12% acrylamide) and stained with coomassie 
dye. The bands at 31 kD and 26 kD indicated purified GST- TORC11-44 and GST (arrows), respectively. 
1. Cell extract before induction with IPTG  
2. Cell extract after induction with IPTG 
3. Supernatant after induction with IPTG and cell disruption 
4. Pellet after induction with IPTG and cell disruption 
5. Supernatant after incubating with Ni-agarose beads 
6. 15 µl of proteins bound to Ni-agarose beads 
7. 5 µl of proteins bound to Ni-agarose beads 
1 2 3 4 5 6 
GST-TORC1 1-44 
7 1 2 3 4 5 6 
GST 
7 
25 kD- 
35 kD- 
70 kD- 
55 kD- 
40 kD- 
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17 
Figure 18: Semi-quantification of purified proteins 
Different amounts and volume of BSA protein and purified proteins, respectively, as indicated were subjected 
to SDS-PAGE (8% acrylamide) and stained with coomassie dye. The marker bands at 55 and 36 kD 
overlapped. The bands at about 60 kD correspond to BSA (lane 1-5). GST protein and GST-TORC11-44 
fusion protein migrated at 26 kD and 31 kD, respectively. His-tagged TORC1 full length and His-tagged 
TORC144 proteins migrated at 70 kD, and 65 kD, respectively. 
Lane 1: 0.1 mg BSA  
Lane 2: 0.2 mg BSA 
Lane 3: 0.5 mg BSA 
Lane 4: 1 mg BSA 
Lane 5: 2 mg BSA 
Lane 6: 5 µl of GST protein bound to glutathione agarose beads 
Lane 7: 5 µl of GST-TORC11-44 fusion protein bound to glutathione agarose beads 
Lane 8: 15 µl of His-TORC1 full length fusion protein bound to Ni-agarose beads 
Lane 9: 15 µl of His- TORC144 fusion protein bound to Ni-agarose beads 
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In Fig. 18, equal volumes of GST and GST-TORC11-44 proteins and of His-tagged TORC1 
full length and His-tagged TORC144 proteins were loaded. The band representing GST-
TORC11-44 was fuzzy due to the expression of GST protein in the same selected bacterial 
clone. In this 8% acrylamide gel, the low-weight proteins were not well separated. 
Therefore, the marker bands at 55 kD and 36 kD overlapped and both GST and GST- 
TORC11-44 migrated at the same size. 
 
4.7.b. In vitro interaction of proteins 
4.7.b.I. Interaction between TORC1 full length and DLK wild-type or DLK mutants. 
Bacterially expressed His-tagged TORC1 full length protein bound to NTA-Ni agarose 
beads (§4.7.a, Fig. 16) was used in this experiment. The NTA-Ni agarose beads served 
as background control. DLK wild-type, its kinase-dead DLK K185A mutant and the 
dimerization-difficient DLK P-P mutant were labelled by in vitro transcription and 
translation using 35S-methionine (§3.5). Radio-labelled CREB wild-type and its mutant 
CREB R300A served as positive and negative controls, respectively. In vitro protein 
interaction assays were performed as described before (§3.6) 
 
The upper panels of Fig. 19A and B represent typical gels showing the interaction 
between TORC1 full length and DLK wild-type or CREB wild-type. As seen in lane 7 and 8 
(upper panel, Fig. 19A), the interaction between TORC1 and DLK wild-type or DLK 
K185A was stronger than the interaction between TORC1 and the dimerization-deficient 
DLK mutant (lane 9). In the control experiment (upper panel, Fig. 19B), CREB wild type 
(lane 5) interacted more with TORC1 full length than the CREB R300A (lane 6).  
 
The lower panels of Fig. 19A and B are graphs showing the quantitative evaluation of the 
interaction assays. The kinase dead DLK mutant interacted a slightly better with TORC1 
full length (121.3   19.1%) when compared to DLK wild-type (lower panel, Fig. 19A). 
However, this difference was not significant. The interaction between TORC1 full length 
and the dimerization deficient DLK mutant was reduced to 62.5  5.3% compared to that 
of the wild-type form (p<0.04) (lower panel, Fig. 19A). As positive control, under the same 
experimental condition, CREB R300A (unable to interact with TORC (Screaton et al., 
2004) exhibited less interaction intensity with TORC1 full length (19.8   1.5%, p<0.01) 
than CREB wild-type did (lower panel, Fig. 19B). 
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Figure 19: In vitro interaction between DLK/CREB and TORC1 full length 
His-tagged TORC1 full length was expressed in E.coli, purified by affinity chromatography and 
immobilized on NTA-Ni agarose. NTA-Ni agarose alone was used as background. DLK wild-type 
and its mutants or CREB wild-type and CREB R300A were labelled with [35S]methionine by in vitro 
transcription and translation. The amount of [35S]DLK or [35S]CREB proteins recovered from His-
tagged protein was analyzed by SDS-PAGE followed by autoradiography and densitometric 
analysis of the bands corresponding to [35S]DLK or [35S]CREB. Typical gels are shown above the 
graphs. 
The data are mean values ± SEM of three independent experiments and are expressed in percent 
of DLK wild-type (A) or CREB wild-type (B). Statistical analysis was performed by two-way ANOVA 
followed by two-sided paired Student’s t-test: : **p ≤ 0.01, *p ≤ 0.05.     
 
Figure 19A:  
The upper panel 
Lane 1, 2 and 3: 25% input of DLK wild-type, DLK K185A and DLK P-P, respectively. 
Lane 4, 5 and 6: Interaction between NTA-Ni Agarose and DLK wild-type, DLK K185A and DLK P-
P, respectively. These were used as corresponding backgrounds in calculation. 
Lane 7, 8 and 9: Interaction between His-TORC1 full length and and DLK wild-type, DLK K185A 
and DLK P-P, respectively. 
The lower panel 
Graph of result showing interaction between DLK proteins and TORC1 full length 
 
Figure 19B:  
The upper panel 
Lane 1 and 2: 25% input of CREB wild-type and CREB R300A, respectively. 
Lane 3 and 4: Interaction between NTA-Ni Agarose and CREB wild-type and CREB R300A, 
respectively. These were used as corresponding backgrounds in calculation. 
Lane 5 and 6: Interaction between His-TORC1 full length and CREB wild-type and CREB R300A, 
respectively. 
The lower panel 
Graph of result showing interaction between CREB proteins and TORC1 full length 
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4.7.b.II. Interaction between TORC11-44 and DLK wild-type or DLK mutants 
The N-terminal coiled-coil domain of TORC was shown to interact with the dimerized 
leucine zipper domain of CREB (Conkright et al. 2003; Iourgenko et al. 2003; Screaton et 
al. 2004). In order to investigate whether DLK interacts with this region of TORC, the N-
terminal 44 amino acid peptide of TORC1 in fusion with GST bound to glutathione 
agarose beads (§4.7.a, Fig. 17) was used in the in vitro protein interaction assay (§3.6). 
GST alone bound to glutathione agarose beads (Fig. 17) was used as background 
control. DLK and CREB proteins were radio-labelled and used as described above 
(4.7.b.I). 
As shown in the typical gel (upper panel, Fig. 20A), the N-terminal domain of TORC1 
interacted less with DLK P-P (lane 9) than with DLK wild-type (lane 7) or DLK K185A (lane 
8). In Fig. 20B (upper panel), the N-terminus of TORC1 also interacted more with CREB 
wild-type (lane 5) than with CREB R300A (lane 6). 
Analysis of the optical density of the pulled down [35S] proteins shown in Fig. 20A 
indicates that DLK wild-type and DLK K185A interacted to the same extent with TORC11-
44. DLK P-P interacted with the C-terminal-deleted TORC1 about 30% less than the wild-
type form (Fig. 20A). However, no significant differences of interaction among those 
groups were observed. In the same experimental condition, CREB wild-type and R300A 
interacted with TORC1 1-44 (lower panel, Fig. 20B).  
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Figure 20: In vitro interaction between DLK/CREB and TORC11-44 
GST-TORC11-44 fusion protein or GST alone was expressed in E.coli, purified by affinity 
chromatography and immobilized on glutathione agarose. GST alone was used as background. 
DLK wild-type, DLK mutants, CREB wild-type or CREB R300A were labelled with 
[35S]methionine by in vitro transcription and translation. The amount of [35S]DLK or [35S]CREB 
proteins recovered from GST alone or GST fusion protein was analyzed by SDS-PAGE followed 
by autoradiography and densitometric analysis of the bands corresponding to [35S]DLK or 
[35S]CREB. Typical gels are shown above the graphs. 
The data are mean values ± SEM of three independent experiments and are expressed in 
percent of DLK wild-type (A) or CREB wild-type (B). Statistical analysis was performed by two-
way ANOVA followed by two-sided paired Student’s t-test: *p ≤ 0.05.     
Figure 20A:  
The upper panel  
Lane 1, 2 and 3: 25% input of DLK wild-type, DLK K185A and DLK P-P, respectively. 
Lane 4, 5 and 6: Interaction between GST and DLK wild-type, DLK K185A and DLK P-P, 
respectively. These were used as corresponding backgrounds in calculation. 
Lane 7, 8 and 9: Interaction between GST-TORC11-44 fusion protein and and DLK wild-type, 
DLK K185A and DLK P-P, respectively. 
The lower panel 
Quantitative evaluation of the interaction between DLK proteins and TORC11-44 
Figure 20B: 
The upper panel 
Lane 1 and 2: 25% input of CREB wild-type and CREB R300A, respectively 
Lane 3 and 4: Interaction between GST and CREB wild-type and CREB R300A, respectively. 
These were used as corresponding backgrounds in calculation. 
Lane 5 and 6: Interaction between GST-TORC1 1-44 and CREB wild-type and CREB R300A, 
respectively. 
The lower panel 
Quantitative evaluation of the interaction between CREB proteins and TORC11-44 
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4.7.b.III. Interaction between TORC144 and DLK wild-type or DLK mutants 
The His-tagged TORC144 (§4.7.a, Fig. 16) was used to check if the C-terminus of TORC1 
interacts with the radio-labelled DLK proteins. NTA-Ni agarose served as background 
control. 
As seen in Fig. 21, the deletion of 44 N-terminal amino acids of TORC resulted in almost 
no interaction with DLK wild-type, DLK K185A or DLK P-P (Fig. 21) 
 
 
 
 
 
 
4.7.b.IV. Interaction between DLK wild-type and different domains of TORC 
In order to identify the region of TORC which interacts with DLK wild-type, a pull down 
assay was performed using bacterially expressed His-tagged TORC1 full length protein, 
His-tagged TORC144 protein, GST-TORC11-44 and [35S] labelled DLK wild-type. 
All tested TORC1 proteins interacted with DLK wild-type, albeit to a different extent (Fig. 
22). As demonstrated in the typical gel (the upper panel, Fig. 22), DLK wild-type 
interacted more with the N-terminal domain of TORC1 (lane 6) than the others. DLK wild-
type interacted to a higher extent with TORC1 full length protein (lane 5) than with the C-
terminus of TORC1 (lane 4). 
The quantitative evaluation is shown in the graph (lower panel, Fig. 22). As compared to 
the interaction with TORC1 full length, the interaction between DLK wild-type and 
TORC144 was reduced significantly to 64.2  1.9% (p<0.006), whereas the interaction 
between DLK wild-type and TORC11-44 was about 6-fold (p<0.03) increased. 
 
 
 
 
 
Figure 21: Interaction between the N-terminal deleted TORC1 and DLK wild-type, DLKK185A or 
DLKP-P.  
His-tagged TORC144 was expressed in E.coli, purified by affinity chromatography and 
immobilized on NTA-Ni agarose. NTA-Ni agarose alone was used as background. DLK wild-
type and its mutants were labelled with [35S]methionine by in vitro transcription and translation. 
The amount of [35S]DLK proteins recovered from His-tagged protein was analyzed by SDS-
PAGE followed by autoradiography and densitometric analysis of the bands corresponding to 
[35S]DLK. Typical gel is shown. 
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4.8. Interaction between DLK and TORC in HIT cells 
The pull down assay showed that DLK interacted with TORC1. To investigate whether 
TORC1 interacts with DLK in a cellular context, a co-immunoprecipitation assay (§3.12) 
was performed. HIT cells were transiently co-transfected (§3.8a) with an expression vector 
for TORC1 full length and with flag epitope tagged expression vectors for DLK wild-type or 
its mutants. An equal overexpression of the proteins was tested by Western blot (§3.3d) 
using primary antibodies against DLK or TORC1 (Fig. 23). DLK or its mutants were 
immunoprecipitated using an antibody against the flag epitope, and co-
immunoprecipitated TORC1 was detected by the antibody specifically against TORC1 
(Fig. 24).  
As demonstrated in Fig. 23, DLK wild-type, its mutants and TORC1 were overexpressed 
in HIT cells (lane 4, 6 and 8, Fig. 23). The expression levels of DLK proteins in the cells 
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Figure 22: Interaction between TORC1 full length, TORC144, TORC11-44 and DLK wild-type. 
GST-TORC11-44 fusion protein, GST alone, His-tagged TORC1 full length, His-tagged TORC44 
were expressed in E.coli, purified by affinity chromatography and immobilized on appropriate 
agarose beads. GST alone and NTA-Ni agarose were used as background for GST-TORC1-44 
and His-tagged TORC proteins, respectively. DLK wild-type was labelled with [35S]methionine 
by in vitro transcription and translation. The amount of [35S]DLK recovered from GST alone, 
GST fusion protein or His-tagged proteins was analyzed by SDS-PAGE followed by 
autoradiography and densitometric analysis of the bands corresponding to [35S]DLK. Typical 
gel is shown above the graph. 
The data are mean values ± SEM of three independent experiments and are expressed in 
percent of TORC1 full-length. Statistical analysis was performed by two-way ANOVA followed 
by two-sided paired Student’s t-test: ***p ≤ 0.005, *p ≤ 0.05.     
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co-transfected with TORC1 (lanes 4, 6 and 8, Fig. 23, upper panel) were less than in cells 
without TORC1 cotransfection (lanes 3, 5 and 7, Fig. 23, upper panel). Due to the 
reduced expression level of DLK wild-type or its mutants in the presence of overexpressed 
TORC1, co-immunoprecipitated TORC1 was corrected for the amount of the 
corresponding immunoprecipitated DLK.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In the co-immunopreciptation assay, no TORC1 was detected in samples without 
overexpression of flag epitope tagged DLK (lanes 1 and 2, upper panel, Fig. 24) 
In the presence of DLK wild-type or its mutants, overexpressed TORC1 co-
immunoprecipitated with DLK wild-type and its mutants (lane 4, 6 and 8, upper panel, Fig. 
24); however, as observed in the in vitro pull down assay, the interaction between TORC 
and the dimerization-deficient DLK mutant was somewhat less than its interaction with 
DLK wild-type (lane 8 and 4, upper panel and the graph, Fig. 24), which was about 77.2  
13.2% of DLK wild-type. This difference was not significant, however, the T-test with p = 
0.12 implied the trend of a difference. The interactions of TORC with DLK wild-type or 
kinase dead DLK mutant were not significant different.  
 
 
 
 
 
 
 
 
Figure 23: Overexpression of DLK wild-type, DLK K185A, DLK P-P and TORC1 in HIT cells 
Expression vectors for flag-tagged DLK wild-type, DLK K185A or DLK P-P were co-transfected with the 
expression vector for TORC1 into HIT cells. Cells were harvested after 48 hours. Cells were lysed and the 
extracts were analyzed by western blot using antibodies against TORC1 and the C-terminal 223 aa of 
DLK.  
The typical Western blot showing overexpression of TORC1 and DLK proteins: The bands at 130 kD 
represent DLK wild-type (lane 3, 4), DLK K185A (lane 5, 6) and DLK PP (lane 7, 8). The bands at 90 kD 
represent TORC1 (lanes 2, 4, 6 and 8) 
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4.9. Effect of DLK on the nuclear localization of TORC 
TORC nuclear localization is required for CRE/CREB-directed gene transcription and its 
cellular localization is regulated by diverse signals (Bittinger et al. 2004; Screaton et al. 
2004). The shuttling of TORC between nucleus and cytoplasm depends at least in part on 
its phosphorylation status. Therefore, the effect of DLK on the nuclear localization of 
TORC was investigated by immunocytochemistry (§3.11). The expression vector for flag 
epitope tagged DLK or its kinase-dead mutant were transiently transfected (§3.8b) into 
HIT cells. Cells were treated with 45 mM KCl for 30 min, as indicated. The overexpressed 
DLK protein and endogenous TORC protein were detected by the primary antibodies 
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Figure 24: Interaction of TORC1 with DLK wild-type, DLK K185A and DLK P-P in HIT cells 
Expression vectors for flag-epitope tagged DLK wild-type or its mutants were co-transfected with vector for 
TORC1 into HIT cells. Cells were harvested after 48 hours. Cells were lysed and flag epitope tagged DLK 
proteins were immunoprecipitated using anti-flag antibody and protein A agarose. TORC1 co-
immunoprecipitated with DLK proteins was detected by Western blot using the antibodies against TORC1 
and the C-terminal 223 aa of DLK.  
Cells transfected with the empty vector pcDNA3 (EV) were used as negative control. The interaction 
between DLK wild-type and TORC1 was considered as 100%. All results are expressed as means ± SEM 
of five independent experiments. 
Calculation: interaction level = (the density of band representing coimmunopreciptatated TORC) / (the 
density of band representing corresponding immunoprecipitated DLK) 
The upper panel: Typical Western blot showing DLKs co-immunoprecipitated with TORC1 
Immunoprecipitated DLKs migrated at 130 kD (lane 3-8) 
Co-immunoprecipitated TORC1 was corresponding to the band migrating at 90 kD (lane 4, 6 and 8) 
The lower panel: Quantitative evaluation of the co-immunoprecipitation assays.  
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against the flag epitope and against TORC, respectively, and the secondary anti-mouse 
protein TRITC labeled and anti-rabbit protein Alexa Fluor 488 labeled antibodies, 
respectively. Cell nuclei were stained with DAPI. The cells showing a nuclear localization 
of TORC in DLK-positive were counted manually using fluorescent microscopic analysis 
(§3.11). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25: Typical pictures showing subcellular localization of TORC in the presence of overexpressed 
DLK wild-type (A) or overexpressed DLK K185A (B). 
HIT cells were transiently transfected with expression vectors for flag-epitope tagged DLK wild-type or 
flag-epitope tagged DLK K185A. Cells were stained with anti-flag epitope antibody (mouse), anti-TORC 
antibody (rabbit) and with DAPI (stain nucleus with blue colour). The secondary antibodies were anti-
mouse protein_TRITC (red colour) and anti-rabbit protein_Alexa Fluor 488 (green colour). In the 
pictures, flag-epitope tagged DLK proteins were stained with red colour, endogenous TORC proteins 
were stained with green colour, and the nuclei were blue. 
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Figure 26: Effect of DLK on the nuclear localization of 
TORC 
HIT cells were transiently transfected with expression 
vectors for flag-epitope tagged DLK wild-type or flag-
epitope tagged DLK K185A. Cells were treated with 45 
mM KCl for 30 min, as indicated. Cells were stained 
with anti-flag epitope antibody (mouse), anti-TORC 
antibody (rabbit) and with DAPI (stain nucleus with blue 
colour). The secondary antibodies were anti-mouse 
protein_TRITC (red colour) and anti-rabbit 
protein_Alexa Fluor 488 (green colour). In each single 
experiment about 30-80 DLK-positive cells were 
randomly selected and the number of cells presenting 
TORC in the nucleus was counted. The percentage of 
cells with nuclear TORC within the number of DLK-
positive cells was calculated. All results are expressed 
as means ± SEM of three independent experiments, 
each done in duplicate. Statistical analysis was 
performed by two-way ANOVA followed by two-sided 
paired Student’s t-test:  **p ≤ 0.01, ***p ≤ 0.005.     
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In the presence of DLK wild-type already 60% of cells exhibited nuclear localization of 
TORC (Fig. 25A and Fig. 26), which was further increased in the presence of DLK K185A 
(Fig. 25B and Fig. 26). In detail, endogenous TORC was observed in nuclei of about 61.9 
 5.4% of DLK wild-type-positive cells (Fig. 26). Treatment of KCl increased significantly 
the nuclear localization of TORC within the DLK-positive cells (85.1  3.7%, p<0.006, as 
compared to the basal condition of overexpressed DLK wild-type) (Fig. 26). Under basal 
or KCl treatment condition, up to 90% of DLK K185A-positive cells showed a nuclear 
localization of TORC, which was significant different from the percentage of DLK wild-type 
showed nuclear localization of TORC in the basal condition (p<0.001 or p<0.002, 
respectively) (Fig. 26). 
 
4.10. Effect of DLK on the phosphorylation of TORC in an in vitro assay 
The phosphorylation of TORC 1 and TORC2 at Ser-167 and Ser-171, respectively, is a 
decisive point in the process regulating TORC transactivating capacity (Screaton et al. 
2004, Katoh et al. 2004, Bittinger et al. 2004). To study whether DLK phosphorylates 
TORC1 and TORC2 at these residues, an in vitro kinase assay (§3.13) was performed 
using the bacterially expressed His-tagged TORC proteins (§3.4) as subtrates and the flag 
epitope tagged DLK proteins which were overexpressed in HIT cells and purified by 
immunoprecipitation (§3.12a) as kinase. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27A: TORC proteins were expressed and purified from E.coli. The proteins were subjected to SDS-
PAGE (8% acrylamide) and stained with coomassie dye. The bands migrated between 70 kD and 74 kD 
(arrow) indicate the purified His-tagged TORC proteins (wt: wild-type). 
 
Figure 27B: Western blot to check the bacterially expressed His-tagged TORC proteins and 
immunoprecipitated DLK proteins. The first four lanes from left to right show His-tagged TORC1 wild-type, 
TORC1 S167A, TORC2 wild-type and TORC2 S171A, respectively. The next two lanes show DLK wild-
types and DLK K185A. 
TORC proteins were expressed and purified from E.coli. DLK proteins were immunoprecipitated from HIT 
cells. Those proteins were applied to SDS-PAGE and followed by Western blot. TORCs and DLK were 
detected with anti-Pan TORC antibody and antibody against the C-terminal 223 aa of DLK, respectively. The 
double bands representing TORCs migrated between 70 kD and 74 kD, whereas DLK migrated at 130 kD. 
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As shown in Fig. 27A and B, all TORC proteins used were successfully expressed and 
purified from bacteria. The equal amount of TORC1 wild-type and TORC1 S167A or 
TORC2 wild-type and TORC2 S171A were used (Fig. 27A). TORC proteins were 
detected at the region between 70 kD and 74 kD by Western blot (Fig. 27B). The flag-
epitope tagged DLK wild-type and DLK K185A were overexpressed and 
immunoprecipitated from HIT cells (Fig. 27B)  
 
 
 
 
 
 
 
 
 
 
 
 
 
The bands at 130 kD showed that DLK was autophosphorylated. Casein was 
phosphorylated by DLK wild-type (Fig. 28). However, no phosphorylation of TORC 
proteins was detected in this in vitro kinase assay.  
4.11. Effect of DLK on the phosphorylation of TORC in HIT cells 
The in vitro kinase assay provided no evidence that DLK directly phosphorylated TORC. 
To study whether DLK indirectly, i.e. via its downstream kinases, enhances the 
phosphorylation of TORC, the effect of DLK on the phosphorylation of TORC in HIT cells 
was investigated. To this aim, HIT cells were transiently co-transfected with expression 
vectors for DLK wild-type or DLK K185A and human TORC1 full length. 48 h after 
transfection, the cells were treated with CsA, or combination of KCl and Forskolin, as 
indicated. CsA enhances the phosphorylation of TORC, whereas KCl and forskolin 
treatment reduce the phosphorylation of TORC (Bittinger et al. 2004, Screaton et al. 2004, 
Katoh et al. 2004, Takemori and Okamoto, 2008). Cells were harvested, lysed (§3.3d) and 
a Western blot (§3.10) was performed. The phosphorylation of TORC1 was detected 
using an antibody specifically against on Ser-151 phosphorylated murine (m) TORC1 
(equivalent to Ser-167 human (h) TORC1). 
Figure 28: In vitro kinase assay 
The immunoprecipitated DLKs were incubated with the bacterially expressed TORC proteins, as indicated, 
in kinase buffer supplemented with [32P] labelled -ATP. After incubation for 3h at room temperature, the 
samples were subjected to SDS-PAGE and the intensity of phosphorylated proteins was evaluated using 
phosphor-imager scanner. The phosphorylation of the general substrate casein by DLK served as positive 
control. 
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In these experiments, human TORC1 was used, whereas the antibody is against the Ser-
151 phosphorylated TORC1 of mouse. Therefore, first, the specificity of the antibody 
against on Ser-151 phosphorylated mTORC1 was tested if it is able to detect on Ser-167 
phosphorylated hTORC1. As shown in Fig. 29, this antibody was able to detect hTORC1 
wild-type (lane 1) which was phosphorylated at Ser-167 and was unable to detect 
mTORC1 S151A (lane 2) in which the Ser-151 was changed to alanine. 
 
 
 
 
 
 
 
 
 
In Fig. 30 a typical Western blot showing the effect of DLK on the phosphorylation of 
TORC1 on Ser-167 is depicted. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29:  Western blot: Control of the antibody specifically against Ser-151 phospho-mTORC1 
(equivalent to Ser-167 hTORC1 
HIT cells were transiently transfected with expression vectors for human (h) TORC1 wild-type (wt) or 
mouse (m) TORC1 S151A. After 48 hours of incubation, cells were harvested and lysed in lysis buffer an 
a Western blot was perfomed using the antibody specifically against Ser-151 phospho-mTORC1 and an 
antibody against GAPDH. 
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Figure 30: Typical Western blot: The effect of DLK on the phosphorylation of TORC on Ser-167 
HIT cells were co-transfected with expression vectors for DLK wild-type or DLK K185A and human TORC1 wild-
type. 48h after transfection, cells were treated with 5 µM CsA, or a combination of 45 mM KCl (K) and 10 μM 
forskolin (F) for 15 minutes. Cells were harvested and lysed in lysis buffer supplemented with phosphatase 
inhibitors. A Western blot was performed using antibodies specifically against GAPDH, Ser-167 phospho-TORC1 
and TORC1.  
No overexpression of DLK (lane 1-3): CsA (lane 2) enhanced, whereas KCl and forskolin (lane 3) reduced the 
phosphorylation of TORC1 on Ser-167, as compared to basal condition (lane 1). 
Overexpression of DLK wild-type (lane 4-6): CsA (lane 5) enhanced, whereas KCl and forskolin (lane 6) reduced 
the phosphorylation of TORC1 on Ser-167, as compared to basal condition (lane 4). 
Overexpression of DLK K185A (lane 7-9): CsA (lane 8) enhanced, whereas KCl and forskolin (lane 9) reduced 
the phosphorylation of TORC1 on Ser-167, as compared to basal condition (lane 7). 
In basal condition (lanes 1, 4, 7): Overexpression of DLK wild-type (lane 4) enhanced the phosphorylation of 
TORC on Ser-167, as compared to the non-overexpression group (lane 1) or the overexpression of DLK K185A 
(lane 7). 
Treatment of CsA (lanes 2, 5, 8): Overexpression of DLK wild-type (lane 5) enhanced the phosphorylation of 
TORC on Ser-167, as compared to the non-overexpression group (lane 2) or the overexpression of DLK K185A 
(lane 8). 
The combined treatment of KCl and forskolin (lanes 3, 6, 9): no pronounced difference was observed among 
groups. 
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Independent of the overexpression of DLK wild-type or its mutant, CsA enhanced the 
phosphorylation of TORC1, whereas the combination of KCl and forskolin reduced it (see 
the legend, Fig. 30). Overexpression of DLK wild-type enhanced the phosphorylation of 
TORC1 on Ser-167 both in the basal condition (compare lane 4 with lane 1) and in the 
presence of CsA (compare lane 5 and lane 2) (Fig. 30). Overexpression of DLK K185A 
did not result in differences under both basal condition (compare lane 7 with lane 1) and 
CsA-treated condition (compare lane 8 and lane 2) (Fig. 30). Notably, in different 
experiments, in the presence of overexpressed DLK wild-type plus CsA, the band 
representing on Ser-167 phosphorylated TORC1 (lane 5, Fig. 30) migrated slower than 
the others.  
 
Quantitative evaluation of five independent experiments and statistical analysis showed 
that under basal condition, DLK wild-type significantly enhanced the phosphorylation of 
TORC1 on Ser-167 to 191.1  41.4% (p<0.046), whereas the kinase dead DLK mutant did 
not significantly increase the amount of on Ser-167 phosphorylated TORC1 (Fig. 31). 
Treatment with CsA increased the phosphorylation of TORC1 significantly from 187.5  
15.2% (in the absence of overexpressed DLK wild-type) to 267.1  20.7% (in the presence 
of overexpressed DLK wild-type) (p<0.017, Fig. 31). However, treatment of KCl plus 
forskolin did not significantly change the level of on Ser-167 phosphoylated TORC1 (Fig. 
31). 
 
 
 
 
 
 
 
 
 
 
 
 
In order to confirm that the shift of the band representing phospho-TORC in the sample 
with overexpression of DLK wild-type plus CsA treatment was due to the phosphorylation 
of TORC1 on additional sites (see Fig. 30), a Phos-tag SDS-PAGE was used. In Phos-tag 
SDS-PAGE, the acrylamide gel was supplemented with Phos-tagTM AAL-107, a ligand of 
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Figure 31: DLK wild-type induced the phosphorylation of 
TORC 
HIT cells were co-transfected with expression vectors for 
DLK wild-type or DLK K185A and TORC1 wild-type. 48h 
after transfection, cells were treated with 5 µM CsA, or a 
combination of 45 mM KCl (K) and 10 μM forskolin (F) for 
15 minutes. Cells were harvested and lysed in lysis buffer 
supplemented with phosphatase inhibitors. A Western 
blot was performed using antibodies specifically against 
GAPDH, Ser-167 phospho-TORC1 and TORC1, 
respectively.  
To evaluate the phosphorylation of TORC, the density of 
the band representing phospho-TORC was normalized to 
the corresponding band representing TORC. The 
samples without transfection of DLK in basal condition 
were considered as control. All values are expressed as 
means ± SEM of five independent experiments. Statistical 
analysis was performed by two-way ANOVA followed by 
two-sided paired Student’s t-test: *p ≤ 0.05.  
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acrylamide which is able to bind to the phospho groups of the proteins, thereby further 
retarding the migration of phosphorylated proteins (Kinoshita et al., 2008).  
As shown in Fig. 32, the phosphorylated TORC1 was clearly detected as two shifted 
bands. CsA treatment in addition with the overexpression of DLK wild-type (lane 4, Fig. 
32) resulted in the slower migration of the band representing on Ser-167 phosphorylated 
TORC1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
JNK is the kinase downstream of DLK. To study whether JNK is involved in the 
phosphorylation of TORC, a Western blot analysis of phospho-TORC employing the 
antibody specifically against on Ser-151 phosphorylated mTORC1 (equivalent to Ser-167 
phospho-hTORC1) was conducted. HIT cells were transfected with expression vectors for 
DLK wild-type and TORC1, as indicated. Cells were treated with a combination of KCl and 
forskolin, CsA or SP600125 (an inhibitor specific for JNK – Bennett et al., 2001) as 
indicated. 48 h after transfection, cells were harvested and lysed. The lysates were 
subjected to Phos-tag SDS-PAGE and a Western blot was perfomed. 
 
A typical Western blot is shown in Fig. 33. Treatment with KCl plus forskolin (lane 2) 
reduced the amount of phosphorylated TORC1 (compared to non-treatment sample, lane 
1). CsA increased the phosphorylation of TORC1 (lane 3) and this enhancement was 
more pronouced in the presence of overexpressed DLK (lane 6). The treatment of the JNK 
inhibitor SP600125 decreased pronoucedly the phosphorylation of TORC1 and prevented 
a slower migration of the phosphorylated TORC1 both in the absence or the presence of 
overexpressed DLK (lane 4 and 7, respectively, Fig. 33). 
 
Figure 32: Typical Western blot: The shift of of TORC1 protein phosphorylated on additional residues 
HIT cells were transfected with expression vectors for DLK wild-type (wt), DLK K185A and hTORC1 wild-type 
(wt) or mTORC1S151A (equivalent to hTORC1 S167A). Cells were grown for 48h after transfection before 
harvest. Cells were treated, as indicated, with 5 µM CsA or a combination of 45 mM KCl (K) and 10 µM 
forskolin (F) for 15 min. Cells were lysed and the lysates were subjeted to phos-tag gel (8% acrylamide 
supplemented with 50 µM Phos-tagTM AAL-107). A Western blot was performed using antibody specically 
against on Ser-151 phosphorylated mTORC1 and an antibody against GAPDH. 
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4.12. Effect of DLK on the recruitment of TORC to a CRE-containing promoter 
The interaction with and the phosphorylation of TORC by DLK might result in decreased 
recruitment of TORC to a CRE-containing promoter. To investigate the effect of DLK on 
the recruitment of TORC to a CRE-containing promoter, a reporter gene assay (§3.15) 
was performed whereby a luciferase reporter gene controlled by the minimal promoter of 
the rat somatostatin gene (-65 SomCRE.Luc), containing a high affinity binding site for 
CREB (Oetjen et al. 1994), was transiently co-transfected into HIT cells with an 
expression vector for TORC1 (§3.8a). DLK wild-type or its mutants were overexpressed to 
observe their effect on TORC-induced CRE-dependent gene transcription. The cells were 
treated with a combination of KCl and forskolin, as indicated, to enforce the nuclear 
localization of TORC. By this way the nuclear translocation and an increased recruitment 
of TORC to the promoter can be demonstrated (Boer et al. 2007).  
 
 
 
 
 
 
 
 
Figure 33: Typical Western blot: Putative involvement of JNK in DLK-induced phosphorylation of 
TORC1 
HIT cells were transfected with expression vectors for DLK wild-type and mouse TORC1. Cells 
were grown for 48 h after transfection before harvest. Cells were treated, as indicated, with 5 µM 
CsA or a combination of 45 mM KCl (K) and 10 µM forskolin (F) for 15 min or with 25 µM JNK 
inhibitor SP600125 (SP) for 12 h before harvest. Cells were lysed and the lysates were subjected 
to phos-tag gel (8% acrylamide supplemented with 50 µM Phos-tagTM AAL-107). A Western blot 
was performed using an antibody specically against on Ser-151 phosphorylated mTORC1 
(equivalent to Ser-167 phosphorylated hTORC1) and an antibody against GAPDH. 
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Of note, KCl plus forskolin treatment increased the TORC1 dependent CRE directed gene 
transcription to about 170-fold (data not shown).  DLK wild-type, but not its kinase dead 
mutant, significantly inhibited this transcriptional activity in the presence of KCl plus 
forskolin treatment (Fig. 34). 
 
To further elucidate the effect of DLK on TORC promoter recruitment a chromatin 
immunoprecipitation assay (§3.14) was employed. HIT cells were transfected (§3.8b) with 
a promoter containing four copies of the CRE of the rat somatostatin promoter and an 
expression vector for HA epitope tagged TORC1. In addition, the expression vector for 
DLK wild-type was co-transfected (§3.8b). DNA and proteins were cross-linked and 
immunoprecipitated with an antibody against the HA epitope. The amount of precipitated 
DNA was determined by qRT-PCR (Heinrich et al. 2009). Treatment of the cells with 
membrane depolarization and forskolin which enhance the amount of TORC protein 
recruited to CRE promoter was used as a positive control. 
 
Figure 34: Effect of DLK on TORC dependent CRE-directed gene transcription under combined 
treatment of KCl and forskolin. 
A luciferase reporter fusion gene under the control of the minimal promoter of the rat 
somatostatin gene (-65 SomCRE.Luc), containing a high affinity binding site for CREB, was 
transiently co-transfected with an expression vector for TORC1. The cells were co-transfected 
with expression vectors for DLKwt or its kinase dead mutant as indicated and incubated for 48 
hours prior to harvesting and measuring luciferase activity. Treatment of cells with a combination 
of 45 mM KCl and 10 μM forskolin was applied 6 hours before harvesting. The luciferase activity 
in cells transfected with the reporter gene, the expression vector for TORC1 protein and 
Bluescript were considered as control. Relative luciferase activity values are means ± SEM of 
three independent experiments performed in duplicate, and are expressed in percent of control. 
Statistical analysis was performed by two-way ANOVA followed by Student’s t-test: ***p ≤ 0.005.    
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Fig. 35 shows the results of the ChIP assay. The combined stimulation with KCl and 
forskolin significantly increased the amount of precipitated DNA to 131.5  1.7% 
(p<0.0001, Fig. 35). Overexpression of DLK wild-type significantly reduced the amount of 
precipitated DNA by 28% (p<0.018, Fig. 35).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 35: Effect of DLK on the recruitment of TORC to a CRE-containing promotor 
HIT cells were transfected with a promoter containing four copies of the CRE of the rat somatostatin 
promoter and an expression vector for HA epitope tagged TORC1. In addition, the expression vector for 
DLK wild-type was co-transfected. The schemes of plasmids used in the experiment are depicted in the 
upper pannel. 48h after transfection, cells were treated with 45 mM KCl plus 10 µM forskolin for 30 min 
before performing the ChIP assay. DNA and proteins were cross-linked with 1% formaldehyde, the 
complexes were precipitated by an antibody against the HA epitope. The amount of precipitated DNA 
was determined by qRT-PCR. Cells transfected with vectors for TORC1, Bluescript and 4xsomCRE.Luc 
were used as control. The precipitated amount of DNA is expressed relative to the mean value of the 
control ± SEM. Values represent three independent experiments, each done in duplicate. Statistical 
analysis was performed by two-way ANOVA followed by Student’s t-test: ***p ≤ 0.005, **p ≤ 0.01.   
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5. DISCUSSION 
 
In the present study the molecular mechanism by which the Dual Leucine Zipper-bearing 
Kinase (DLK) regulates the activity of Transducer of regulated CREB (TORC) in HIT cells 
was investigated. DLK was demonstrated to inhibit the transcriptional activity of the three 
isoforms of TORC under both the basal and stimulated condition. The inhibitory action of 
DLK on TORC can be explained first by indirect enhancement of the phosphorylation of 
TORC1 on Ser167; second, direct interaction between DLK and TORC1 may contribute to 
the reduction of TORC activity; finally, the ways by which DLK inhibits the transcriptional 
activity of TORC were further interpreted by the cytosolic accumulation of TORC and the 
reduction of TORC recruitment to a CRE-containing promoter.  
 
5.1. DLK inhibits the transcriptional activity of TORC proteins 
A huge number of cell signaling pathways converge on the transcription factor CREB 
which enables the cell to adapt to various environmental changes or demands of the 
organism. Many components of the transcriptional machinery, like CBP, TAFII130/ TAFIID, 
TORC, interact with CREB and activate the gene transcription (Mayr and Montminy, 2001; 
Shaywitz and Greenberg, 1999; Nakajima et al., 1997). Among these, CREB’s 
coactivators CBP and TORC which are regulated by diverse signals are most examined. 
By distinct regulations on the action of CBP and TORC, CREB-directed gene transcription 
is sophistically modulated (Screaton et al. 2004; Zhou et al. 2004; Oetjen et al. 2005; 
Jansson et al. 2008; He et al. 2009). Especially, the transcriptional activity of TORC is 
modulated in a more complicated way, including the processes such as the 
phosphorylation of TORC, the shuttling of TORC between the nucleus and the cytoplasm, 
and the interaction between TORC and the CBP/CREB complex (Katoh et al. 2004, 
Takemori and Okamoto 2008, Screaton et al. 2004, Ravnskjaer et al. 2007, Xu et al. 
2007). The regulation of TORC action by phosphorylation or translocation is, therefore, 
crucial for CREB-dependent gene transcription. The present study shows for the first time 
that TORC is a target of the inhibitory action of DLK.  
By using the reporter gene assay combined with the Gal4 system, whereby TORC is 
artificially recruited to the promoter, the effect of DLK on all three isoforms of TORC was 
investigated in the HIT-T15 cell line under basal condition. Over expression of DLK 
inhibited the transcriptional activity of all three TORC isoforms to various extents, whereby 
the inhibition of TORC1 transcriptional activity was most pronounced (Fig. 9A-C).  
Treatment of HIT cells with KCl and Forskolin enhanced pronouncedly the 
transactivational activity of TORC1 and TORC2 (Fig. 10A), which is consistent with 
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previous studies (Bittinger et al., 2004; Screaton et al., 2004, Katoh et al., 2004; Takemori 
and Okamoto, 2008). Under these conditions, the transcriptional activity of TORC3 was 
slightly increased (Fig. 10A). Therefore, other KCl or forskolin-dependent signaling 
cascades might result in a further activation of the transcriptional activities of TORC1 and 
TORC2 in HIT cells – not or less so of TORC3. The stimulated transcriptional activities of 
three TORC isoforms were inhibited to the same extent as the basal activities by DLK 
(Fig. 10B-D).  
By increasing the amount of the expression vector for DLK, the inhibition of TORC was 
shown to be dependent on the amount of DLK expression vector. Among the three TORC 
isoforms, TORC1 is inhibited most pronouncedly by DLK (Fig. 11). It is not clear at the 
moment why DLK inhibited different TORC isoforms at distinct levels. 
The result of the mapping experiments to identify a DLK-responsive domain within TORC 
was not clear for the short 44 aa N-terminus of TORC1 due to its low transcriptional 
activity. The C-terminus lacking in the first 44 aa of TORC1 but containing the 
transactivation domain (Conkright et al., 2003, Siu et al., 2009) was inhibited by DLK (Fig. 
12). It is noteworthy that phosphorylation of TORC1 on the C-terminal 220 aa containing 
transaction domain by MEKK1 promotes TORC’s nuclear translocation and recruitment to 
CRE-containing promoter in HEK293 cells (Siu et al., 2009). By this way, MEKK1 
activates TORC, which is in contrast to the inhibitory effect of DLK on TORC. MEKK1 and 
DLK might act on TORC through different pathways and differently in distinct cell lines, 
even though they are considered belonging to the big family of MAPKKK. 
 
5.2. DLK enhances the phosphorylation of TORC on the regulatory sites 
A comparison between the effect of DLK wild-type and its kinase dead mutant showed 
that the later one exhibited less inhibition on TORC than the wild-type form (Fig. 9A-C). 
However, the kinase dead DLK mutant was less overexpressed than DLK wild-type in HIT 
cells (Fig. 15). These results can be interpreted by two possibilities: first, the lower amount 
of DLK K185A protein results in less inhibitory effect as compared to DLK wild-type; 
second, even though DLK K185A is less overexpressed than the wild-type form, however, 
an equal amount of DLK wild-type or DLK K185A protein are involved in all the 
biochemical reactions leading to the reduction of TORC transcriptional activity. The 
second possibility implies that DLK-induced TORC inhibition depended at least in part on 
the enzymatic activity of DLK.  
The experiments, in which TORC transcriptional activity was stimulated by KCl and 
forskolin confirmed the findings in basal condition. In both conditions, DLK exerted a 
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reduction of the transactivating capacity of TORC depending on its an enzymatic activity 
(Fig. 10B-D). As a kinase, it is possible that DLK directly phosphorylates TORC or DLK 
may induce other kinases to participate in this process, which might reduce the nuclear 
localization of TORC.  
It has been shown that the phosphorylation of TORC 1 and TORC2 on Ser-167 and Ser-
171, respectively, is a pivotal step in the TORC regulating signalling pathways (Screaton 
et al., 2004; Katoh et al., 2004, Bittinger et al., 2004). By assuming that the enzymatic 
activity of DLK may contribute to the inhibition of TORC through the phosphorylation on 
these residues, the reporter gene assay using the GAL4 system and TORC1 and TORC2, 
carrying the mutations of Ser-167 and Ser-171 to alanine, respectively, was performed. 
Mutation of TORC1 and 2 at Ser-167 and Ser-171 to alanine increased their 
transcriptional activity 3 and 5 folds (Fig. 13A, B), respectively. This might be explained 
that, the lack of the serine residues results in the constitutive nuclear localisation and thus 
activation of TORC1 and TORC2. These results are consistent with the findings before 
which demonstrated that the phosphorylation of TORC1 and TORC2 at Ser-167 and Ser-
171, respectively, switches off their transcriptional activity (Screaton et al., 2004; Katoh et 
al., 2004 & 2006). On the other hand, it is assumed that the DNA binding domain of GAL4 
efficiently translocates fusion proteins to the nucleus (Silver et al., 1984). The enhanced 
transcriptional activity conferred by the TORC1 S167A and TORC2 S171A mutants (Fig. 
13A, B), respectively, suggests that the phosphorylation of these residues has additional 
inhibitory effects i.e. a reduced interaction with components of TFIID (Conkright et al. 
2003). Under the same experimental condition, DLK was shown to decrease the activity of 
TORC1 and TORC2 wild-type but exhibited no effect on both TORC1 S167A and TORC2 
S171A mutants (Fig. 13A, B). This indicates that DLK-induced inhibition of TORC 
transcriptional activity depended at least in part on the phosphorylation on Ser-167 or Ser-
171 residues of TORC1 or TORC2, respectively. 
In line with the hypothesis assuming DLK may contribute to the phosphorylation of TORC, 
the in vitro kinase assay was performed using recombinant bacterially expressed TORC1 
wild-type, TORC1 S167A, TORC2 wild-type and TORC2 S171A as substrates. In this 
experimental condition DLK was shown to phosphorylate casein and to be auto-
phosphorylated (Fig. 28), as observed before by Mata et al. (1996). This evidence 
indicates that the enzymatic activity of immunoprecipitated DLK was intact. However, it 
directly phosphorylated neither the recombinant TORC1 nor TORC2 (Fig. 28). 
There might be a possibility that in the cellular environment DLK downstream kinases are 
involved in the phosphorylation of TORC to some extent. Indeed, in HIT cells 
overexpressing DLK the analysis of the phosphorylation level of TORC by Western blot 
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showed that DLK induces the phosphorylation of TORC1 on Ser-167 (Fig. 30 and Fig. 
31). Especially, treatment of cells with CsA in the presence of overexpressed DLK 
resulted in a phosphorylation of TORC1 on Ser-167 and on other as yet unidentified 
residues, as suggested by the band shift of phosphorylated TORC1 on the Western blot 
using SDS-PAGE (Fig. 30).  
A Western blot using a SDS-PAGE supplemented with Phos-tagTM AAL-107 resulting in an 
improved separation of the phosphoprotein isotypes (Kinoshita et al., 2008) revealed that 
the overexpression of DLK wild-type cooperated with CsA treatment to induce a 
hyperphosphorylation of TORC1, which was observed clearly by the retardation of the 
band representing phosphorylated TORC1 (Fig. 32). CsA was shown to enhance the 
kinase activity of DLK (Plaumann et al., 2008) and thereby possibly increasing the 
phosphorylation of TORC on other sites. Besides Ser-167 or Ser-171 on TORC1 or 
TORC2, Jansson et al. (2008) identified Ser-275 of TORC2 as another regulatory 
phosphorylation site. Low level glucose-induced activation of MARK2 results in 
phosphorylation of TORC specifically on Ser-275 and on Ser-171, leading to TORC2 
interaction with 14-3-3 proteins and attenuation of CREB-dependent gene transcription in 
beta-cells (Jansson et al. 2008). In the same way, Ser-261 of TORC1 has possibly the 
same function: when phosphorylated on Ser-261, TORC1 might be sequestered in the 
cytosol and thereby attenuating the transcriptional activation. Possibly DLK enhanced 
phosphorylation of TORC1 on both Ser-167 and Ser-261.  
The regulation of CREB-dependent gene transcription is critical for islet cell proliferation 
and survival (Jhala et al., 2003; Hussain et al., 2006; Inada et al., 2004). Phosphorylation 
of TORC2 on Ser-171 and Ser-275 block this process by attenuating the transcriptional 
activity of CREB (Jansson et al. 2008). In addition, the MARK2-/- -mice displayed an 
increased metabolic rate and insulin hypersensitivity (Hurov et al., 2007). By acting in the 
same way as MARK2, activation of DLK in pancreatic islets might inhibit the proliferation 
and survival of beta-cells. 
Although DLK enhanced the phosphorylation of TORC in HIT cells, neither TORC1 nor 
TORC2 are direct substrates of DLK, since both coactivators were not phosphorylated in 
the in vitro kinase assay (Fig. 28). This indicates that DLK downstream-kinases like JNK 
or p38 confer DLK-induced TORC phosphorylation (Fan et al. 1996; Gallo and Johnson 
2002). In line with this deduction, treatment of cells with SP600125, a JNK-specific 
inhibitor (Bennett et al., 2001), resulted in a reduction of phosphorylation of mouse 
TORC1 on Ser-151 (equivalent to Ser-167 of human TORC1) in both the presence and 
absence of overexpressed DLK, as compared with the basal condition (Fig. 33). These 
findings indicate that DLK presumable through activation of its down-stream kinase JNK 
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results in the phosphorylation of TORC. Since JNK is able to translocate to the nucleus 
(Chang and Karin 2001) this phosphorylation can either occur in the cytoplasm, thereby 
preventing TORC nuclear translocation or in the nucleus, thereby advancing TORC’s 
nuclear exclusion.  
In hepatocytes, phosphorylation of TORC2 on Ser-171 is a key point in the regulation of 
gluconeogenesis (Koo et al., 2005; Dentin et al., 2007, 2008; Jansson et al., 2008). SIK’s 
activity is inhibited by cAMP-responsive PKA, which is activated by glucagon in condition 
of low circulating glucose (Screaton et al., 2004; Katoh et al., 2006). In response to the 
fasting condition, the SIK-induced Ser-171 phosphorylation of TORC2 is inhibited through 
glucagon and thereby leading to the transcriptional activation of gluconeogenic genes 
such as PEPCK and G6Pase. Hyperglucagonemia leading to fasting hyperglycaemia due 
to elevated gluconeogenesis is often present in individuals with type 2 diabetes. In 
contrast, SIK is activated by insulin-induced AKT activation which results in the 
phosphorylation of TORC2 and abolishment of gluconeogenic gene transcription (Dentin 
et al., 2007). However, low energy conditions, or low ATP level, also activate AMPK which 
bring about the phosphorylation of TORC2 on Ser-171 and block the transcription of 
gluconeogenic genes (Koo et al., 2005). AMPK plays a role as negative regulator of 
gluconeogensis in hepatocytes. Of note, DLK transcripts were detected in liver of the adult 
mouse (Blouin et al. 1996). It is not known at the moment if DLK, acting similar to AMPK, 
enhances the phosphorylation of TORC proteins on inhibitory sites and thereby inhibits 
gluconeogenesis in hepatocytes.  
 
5.3. DLK may inhibit TORC through direct interaction 
Besides the kinase activity, the ability of DLK to homodimerize via its leucine zipper 
domain was also demonstrated to contribute to the inhibitiory action on TORC. Under the 
same conditions, DLK wild-type but not DLK P-P, a dimerization deficient mutant of DLK 
(Nihalani et al. 2000), reduced the transactivating ability of TORC (Fig. 14), although DLK 
P-P was overexpressed to a higher extent than DLK wild-type in HIT cells (Fig. 15). This 
observation indicated that the dimerization ability of DLK is one of the essential 
characteristics contributing in DLK-induced reduction of TORC transcriptional activity. 
Because the homodimerization of DLK is required for its kinase activity (Nihalani et al. 
2000; Nihalani et al. 2003), the dimerization deficient mutant has no longer an enzymatic 
function. This result is, therefore, consistent with the above finding about the role of 
enzymatic activity of DLK on inhibition of TORC. Furthermore, it seems that when DLK 
wild-type or its mutants were overexpressed in HIT cells, the differences in the 
overexpression level of DLK proteins were not the reason causing different levels of 
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inhibition. In these cases, the amounts of overexpressed DLK proteins were possibly 
enough to mediate the inhibitory reactions. By reasoning like this, the difference in 
inhibition of TORC caused by DLK wild-type and DLK K185A, as mentioned above, was 
due to the enzymatic activity of DLK, not to the difference levels of overexpression. 
In addition to phosphorylating TORC, the present work has demonstrated that DLK 
directly interacts with TORC. As shown by in vitro pull down assays, this interaction 
depended on DLK’s ability to homodimerize, since the DLK P-P mutant bound to a lesser 
extent to the immobilized His-TORC fusion proteins (Fig. 19A and Fig. 20A). In addition, 
in the coimmunoprecipitation assays, overexpressed TORC1 was coimmunoprecipitated 
to a slightly lesser extent by DLK P-P, than by DLK wild-type or its kinase dead mutant 
(Fig. 24). However, homodimerisation is a prerequisite for the enzymatic activity of DLK 
as well (Nihalani et al. 2000). The finding that both DLK wild-type and its kinase-dead 
mutant bound to the same extent to immobilized His-TORC fusion proteins (Fig. 19A and 
Fig. 20A) indicates that indeed the formation of a leucine zipper structure is required for 
the TORC-DLK interaction. The coiled-coil structure formed by the N-terminal domains of 
tetramerized TORCs seems to be required for the interaction with the leucine zipper of 
DLK since GST-TORC1-44 fusion protein interacted with DLK wild-type to a larger extent 
than the binding between DLK wild-type and His-TORC full length or His-TORC44 (Fig. 
22). Thus, besides the leucine zipper of CREB TORC interacts with other proteins able to 
form this structure like the transcription factor AP-1 (Canettieri et al. 2009b). Given that 
TORC and DLK are able to translocate to the nucleus (Bittinger et al. 2004; Screaton et al. 
2004, unpublished results of the group) it is unclear in which cellular compartment this 
interaction occurs.  
By acting as a coactivator of CREB TORC proteins have been shown to mainly regulate 
metabolic control in various tissues (Wang et al., 2010; Canettieri et al. 2005; Koo et al. 
2005; Wu et al. 2006; Altarejos et al. 2008), to promote β-cell survival (Jansson et al. 
2008) and to be involved in hippocampal long-term synaptic plasticity (Kovacs et al. 2007).  
Mucoepidermoid carcinomas are associated with a chromosomal translocation, t(11;19) 
which results in the formation of the oncoprotein CRTC1-MAML2. This oncoprotein 
consists of the N-terminal 42 aa of TORC1 fused to the C-terminal 981 aa of the Notch 
coactivator MAML2 (Tonon et al. 2003). The oncogenic capacity of this fusion protein is 
due to its ability to interact via its TORC1 fraction with CREB and with AP-1, both of them 
promoting cell proliferation (Coxon et al. 2005; Wu et al. 2005; Siu and Jin 2007; 
Canettieri et al. 2009a; Canettieri et al. 2009b). Given that DLK interacts with the N-
terminal domain of TORC and reduces the recruitment of TORC to CREB, an 
accumulation of DLK might prevent the cell proliferation.   
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5.4. DLK inhibits the nuclear translocation of TORC and recruitment of TORC to a 
CRE-containing promoter 
In normal condition, TORC is located to some extent in the nucleus. Enhancement of 
phosphorylated TORC is generally assumed to result in the cytoplasmic retention or the 
nuclear exclusion of TORC  (Bittinger et al. 2004; Screaton et al. 2004; Canettieri et al. 
2005; Koo et al. 2005; Katoh et al. 2006; Jansson et al. 2008; Takemori and Okamoto 
2008).  
Indeed, in the present study, the immunocytochemistry analysis showed that DLK 
depending on its enzymatic activity prevented the nuclear localization of TORC in basal 
condition (Fig. 25A, B and Fig. 26). Treatment of cells with KCl enhanced the amount of 
TORC in nucleus regardless of overexpression of DLK (Fig. 26). KCl treatment increased 
the activation of calcineurin thereby dephosphorylating TORCs and leading to TORC 
nuclear localization (Bittinger et al., 2004; Screaton et al., 2004). Moreover, intracellular 
calcium might enhance dephosphorylation of DLK via calcineurin activation-related 
pathway (Mata et al. 1996), which reduces the enzymatic activity of DLK, decreases the 
phosphorylation of TORC and thereby elevating the nuclear localization of TORC. 
The chromatin-immunoprecipitation (ChIP) assay in the present study showed that 
overexpression of DLK wild-type reduced the amount of CRE-containing promoter 
precipitated by TORC (Fig. 35). As shown in the in vitro interaction assay and the 
immunocytochemistry experiments, DLK interacted with TORC and reduced the nuclear 
localization of TORC, respectively. By this way, overexpression of DLK wild-type resulted 
in a decreased recruitment of TORC to the CRE-promoter. The dimerized DLK might 
interact with TORC via its N-terminus in the nucleus, thereby preventing the recruitment of 
TORC to the promoter.  In the same line with this finding, DLK wild-type was also 
observed to reduce the TORC dependent CRE-directed gene transcription in the reporter 
gene assay (Fig. 34). Taken together, DLK was demonstrated to inhibit the recruitment of 
TORC to a CRE-containing promoter and thereby reducing the transactivating potency of 
TORC on CRE-directed gene transcription. 
A recent report showed the activation of TORC1 by the mitogen activated kinase kinase 
kinase MEKK1 (Siu et al. 2008). Like DLK MEKK1 can activate the down-stream kinases 
JNK and p38 (Chang and Karin 2001; Gallo and Johnson 2002), but MEKK1 was 
demonstrated to directly phosphorylate a region encompassing the aa 431 to 650 of 
TORC1, to enhance TORC nuclear localization and thus CRE-dependent IL-8 gene 
transcription (Siu et al. 2008). MEKK1 is a potent activator of the AP-1 transcription factor 
complex (Chang and Karin 2001), and TORC1 was shown to promote cell proliferation 
and transformation via AP-1 (Canettieri et al. 2009b). Like AP-1 CREB confers cell 
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proliferation (Mayr and Montminy 2001) and might contribute to the pathogenesis of 
cancer (Siu and Jin 2007; Canettieri et al. 2009a). It is tempting to speculate that TORC 
activating signals will promote cell proliferation through the interaction with DNA-bound 
CREB and AP-1. Conversely, signals inhibiting TORC might prevent cell proliferation and 
even result in apoptosis. In line with this, overexpression of DLK did not enhance c-Jun 
transcriptional activity whereas overexpression of MEKK1 enhanced it 9-fold (unpublished 
observation, G. Ficz and E. Oetjen) although both kinases activate the c-Jun kinase JNK 
(Chang and Karin 2001). Furthermore, overexpression of DLK induced apoptosis in 
neuronal cells and in a β-cell line (Xu et al. 2001; Plaumann et al. 2008) and the 
adenoviral delivery of dominant-negative DLK mutants had antiapoptotic and trophic 
effects on dopamine neurons of the substantia nigra in mice (Chen et al. 2008).  These 
findings suggest that the activation of DLK leading to the inhibition of TORC and thereby 
to the inhibition of CREB- and AP-1- dependent gene transcription has anti-proliferative 
effects.   
The balance of beta-cell replication and apoptosis is critical for beta-cell mass and 
function. Disruption of this balance results in reduced beta-cell mass and reduced insulin 
secretion, contributing to the pathogenesis of type 2 diabetes (Butler et al., 2003). 
Therefore, the DLK-induced inhibition of TORC is a newly identified pathway which may 
govern the apoptosis and proliferation of beta-cells, and thereby represent possibly a new 
target for the treatment of diabetes. 
Taken together, the present study shows that TORC is a target of the inhibitory action of 
DLK in beta-cells. DLK acts on TORC at distinct levels: (1) it enhanced the 
phosphorylation of TORC and (2) interacted with TORC and (3) prevented the nuclear 
translocation of TORC, the recruitment of TORC to CRE-containing promoter and 
ultimately the stimulus-induced CREB transcriptional activity. This action of DLK might 
contribute to its inhibitory effect on CREB dependent gene transcription. Fig. 36 describes 
a putative mechanism by which TORC is inhibited by DLK. 
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Figure 36: DLK inhibits transcriptional activity of TORC at distinct levels: (1) indirect 
enhancement of phosphorylation and (2) direct interaction and (3) prevention of the nuclear 
translocation of TORC, the recruitment of TORC to CRE-containing promoter and ultimately the 
stimulus-induced CREB transcriptional activity. The inhibitory action may take place in the 
nucleus or in the cytoplasm. 
In the cytoplasm, DLK interacts with TORC and plays a role as a docking protein. DLK also 
induces the phosphorylation of TORC presumably through JNK, thereby increasing the 
cytoplasmic localization of TORC through interaction with 14-3-3 proteins. These activities result 
in reduced CREB-dependent gene transcription. 
In the nucleus, on one hand DLK enhances the phosphorylation of TORC possibly through JNK, 
which reduces the number of TORC molecules in the nucleus due to the cytoplasmic 
retranslocation. On the other hand DLK interacts with TORC, thereby reducing number of TORC 
recruited to CRE-promotor and attenuating CREB-dependent gene transcription.  
14-3-3 
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6. SUMARY AND CONCLUSION 
 
The ubiquitously expressed transcription factor CREB is involved in numerous cell 
signalling pathways including metabolic process, cell cycle or survival, cell growth and 
immune regulation. Recently, the three isoforms of Transducer of Regulated CREB 
(TORC) have been identified as additional CREB co-activators. TORC2 phosphorylated 
on Ser-171, or TORC1 phosphorylated on Ser-167, is retained in the cytosol by binding to 
the 14-3-3 proteins. Upon dephosphorylation of TORC on these residues, TORC 
translocates to the nucleus, interacts with the dimerized leucine zipper of CREB and 
confers transcriptional activity to CREB-dependent genes. A previous study showed that 
the dual leucine zipper kinase DLK inhibits membrane depolarization-induced CREB 
transcriptional activity in a beta-cell line. The recruitment of TORC is required for CREB 
transcriptional activity. Therefore, TORC might be a target of DLK action. In the present 
study the effect of DLK on the regulation of TORC activity was investigated. 
 
To this aim the effect of DLK on the transcriptional activity of TORC in the beta-cell line 
HIT-T15 was examined using luciferase reporter gene assays. The interaction between DLK 
and TORC was tested by in vitro protein interaction assays and by co-immunoprecipitation 
assays. Whether DLK is able to result in phosphorylation of TORC was elucidated by 
Western blot and in vitro kinase assays. Finally, the effect of DLK on the nuclear 
translocation of TORC and the recruitment of TORC to a CRE-containing promoter were 
investigated by immunocytochemistry and by chromatin-immunoprecipitation assay in 
cooperation with luciferase reporter gene assays.  
 
DLK inhibited the transcriptional activities of all three TORC isoforms. This inhibitory 
action was dependent on the ability of DLK to homodimerize via its leucine zipper domain 
as well as on its enzymatic activity. Neither TORC1 nor TORC2 were direct substrates of 
DLK, since both coactivators were not phosphorylated in the in vitro kinase assay. 
However, the Western blot analysis showed that DLK induced the phosphorylation of 
TORC1 on Ser-167 and presumably on other as yet unidentified residues, as suggested 
by the retarded migration of TORC1. Interestingly, treatment of HIT cells with SP600125, 
a JNK inhibitor, reduced pronouncedly the Ser-167 phosphorylation of TORC1 regardless 
of the presence or absence of overexpressed DLK. Taken into account that DLK is able to 
phosphorylate and thus to activate JNK, these findings indicate, that DLK presumable 
through activation of its down-stream kinase JNK results in the phosphorylation of TORC. 
Besides induction of TORC phosphorylation, DLK directly interacts with TORC as shown 
by in vitro pull down assays and co-immunoprecipitation assays. This interaction 
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depended on DLK’s ability to homodimerize, since the DLK-PP mutant bound to a lesser 
extent to the immobilized His-TORC fusion protein. The finding that both DLK wild-type 
and its kinase-dead mutant bound to the same extent to immobilized His-TORC fusion 
protein indicates that the formation of a leucine zipper structure is required for the TORC-
DLK interaction. The coiled-coil structure formed by the N-terminal domains of 
tetramerized TORCs seems to be required for the interaction with the leucine zipper of 
DLK.  
In addition, DLK depending on its enzymatic activity reduced the nuclear translocation of 
TORC and TORC-dependent CRE-directed gene transcription as shown by 
immunocytochemistry and reporter gene assay, respectively. Moreover, the chromatin-
immunoprecipitation assay demonstrated that DLK prevented the recruitment of TORC to 
a CRE-containing promoter.  
Taken together, the present study shows that TORC is a target of the inhibitory action of 
DLK in beta-cells. The DLK-induced inhibition of TORC is a newly identified pathway, 
which may through regulation of CREB-dependent gene transcription govern the 
apoptosis and the proliferation of beta-cells, and thereby represent possibly a new target 
for the treatment of diabetes. 
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Zusammenfassung mit Schlußfolgerung 
Der ubiquitär exprimierte Transkriptionsfaktor CREB ist an zahlreichen zellulären 
Signaltransduktionswegen einschließlich der Regulation des Stoffwechsels, des Zellzyklus 
und –überlebens, des Zellwachstums und der Immunregulation beteiligt. Drei Isoformen 
des Transducer of Regulated CREB (TORC) wurden kürzlich als weitere Kofaktoren von 
CREB identifiziert. Die Phosphorylierung von TORC2 am Ser-171 bzw. von TORC1 am 
Ser-167 führt zu einer Interaktion mit 14-3-3 Proteinen, wodurch TORC im Zytosol 
verbleibt. Die Dephosphorylierung dieser Aminosäuren resultiert in der nukleären 
Lokalisation von TORC, wo es mit dem homodimesierten Leuzin-Zipper von CREB 
interagiert und so die CREB-abhängige Gentranskription vermittelt. Eine frühere 
Untersuchung zeigte, daß die Dual Leucine Zipper Kinase DLK die durch 
Membrandepolarisation stimulierte CREB-abhängige Gentranskription in Beta-Zellen 
hemmte. Da die Rekrutierung von TORC notwendig für die volle transkriptionelle Aktivität 
von CREB ist, könnte TORC ein Ziel von DLK sein. In der vorliegenden Untersuchung 
wurde die Regulation von TORC durch die DLK untersucht.   
Hierzu wurde die Wirkung von DLK auf die transkriptionelle Aktivität von TORC in Beta-
Zellen mittels Luciferasereportergenassays untersucht. Eine Interaktion zwischen DLK 
und TORC wurde durch in vitro Protein-Proteininteraktionsassays und 
Koimmunpräzipitation analysiert. Für die Untersuchungen zur Phosphorylierung von 
TORC durch DLK wurden Western Blot Analysen und in vitro Kinaseassays eingesetzt. 
Die Wirkung von DLK auf die nukleäre Translokation von TORC und die Rekrutierung an 
CRE enthaltende Promotoren wurde mittels immunzytochemischen Untersuchungen, 
Chromatinimmunpräzipitation und Luciferasereportergenassays untersucht.   
DLK hemmte die transkriptionelle Aktivität aller drei TORC Isoformen. Diese hemmende 
Wirkung war abhängig von der Fähigkeit DLK’s zu homodimerisieren und von ihrer 
Kinaseaktivität. Der in vitro Kinase Assay zeigte, daß weder TORC1 noch TORC2 direkte 
Substrate der Kinase waren. Jedoch zeigte sich im Immunoblot, daß die Überexpression 
von DLK zu einer verstärkte Phosphorylierung von TORC1 am Ser-167 und an anderen 
nicht identifizierten Aminosäuren führte. Zusätzliche Behandlung der HIT Zellen mit einem 
Hemmstoff von JNK, einer der DLK untergeordneten Kinase, reduzierte die 
Phosphorylierung von TORC1 am Ser-167 und hob die langsamere Migration weiterer 
phospho-TORC1 Banden auf. Diese Daten lassen vermuten, daß DLK wahrscheinlich 
durch Aktvierung von JNK die Phosphorylierung von TORC induziert.   
Neben einer Phosphorylierung konnte mittels in vitro Protein-Protein Interaktionsassays 
und Koimmunpräzipitationen gezeigt werden, daß DLK mit TORC interagiert. Diese 
Interaktion war abhängig von der Fähigkeit DLK’s zu homodimerisieren, da die DLK-PP 
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Mutante in einem deutlich geringeren Ausmaß als DLK Wildtyp an das immobilisierte His-
TORC Fusionsprotein band. Da  DLK Wildtyp und seine Kinase-tote Mutante in 
demselben Ausmaß mit immobilisierten His-TORC Fusionsprotein interagierten, kann 
geschlossen werden, daß die Ausbildung eines Leuzin-Zippers notwendig für die DLK 
TORC Interaktion ist. Ebenfalls scheint die coiled-coil Stuktur, die durch die N-terminalen 
Domänen des TORC Tetramers gebildet wird, für die Interaktion mit dem Leuzin-Zipper 
von DLK erforderlich zu sein.    
In Abhängigkeit von seiner enzymatischen Aktivität verminderte DLK die nukleäre 
Lokalisation von TORC und die TORC-abhängige, CRE-dirigierte Gentranskription. Die 
Chromatinimmunpräzipitation zeigte, daß DLK die Rekrutierung von TORC an einen CRE 
enthaltenden Promotor verminderte.   
Zusammengefaßt zeigt die vorliegende Untersuchung, daß TORC ein Ziel der 
hemmenden Wirkung von DLK in Beta-Zellen ist.  Die DLK induzierte Hemmung von 
TORC stellt einen neuen Signalweg dar, der durch Modifikation der CREB-abhängigen 
Gentranskription zur Regulation von Apoptose und Proliferation in Beta-Zellen beiträgt. 
Die Hemmung von DLK in Beta-Zellen  könnte somit ein Ziel für die Therapie des 
Diabetes mellitus darstellen.      
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Inhibition of the CREB co-activator TORC by the mitogen-activated kinase DLK in 
pancreatic beta cells 
P. Do Thanh and E. Oetjen  
Department of Pharmacology, University of Göttingen, 37099 Göttingen, Germany 
 
Objectives: The ubiquitously expressed transcription factor CREB was shown to play a 
pivotal role in the maintenance of beta cell function and mass. Recently, the three 
isoforms of Transducer of Regulated CREB (TORC) were identified as additional CREB 
co-activators. Upon dephosphorylation of S171 in TORC2, or S167 in TORC1, TORC 
translocates to the nucleus, interacts with the dimerized leucine zipper of CREB and 
confers transcriptional activity to CREB-dependent genes. Our previous studies showed 
that the dual leucine zipper bearing kinase DLK inhibits membrane depolarization-induced 
CREB transcriptional activity in beta cells. In the present study the effect of DLK on TORC 
was investigated.  
Methods: Luciferase reporter gene assays using the beta cell line HIT and an in vitro 
protein interaction assay were employed.  
Results: Using the GAL4-system, overexpression of DLK inhibited TORC1/2-directed 
transcription by 80 and 40%, respectively. This reduction was less pronounced using the 
DLK kinase dead mutant (DLK-K185A), whereas a DLK mutant unable to homodimerize 
(DLK-PP) showed no inhibitory effect on TORC activity. In addition, mutation of S167 or 
Ser171 in TORC1 and 2, respectively, prevented the inhibitory effect of DLK on TORC 
transcriptional activity. The in vitro protein interaction assays revealed that bacterially 
expressed His-tagged full length TORC1 and GST-tagged TORC1(1-44 amino acids) 
interacted with [35S]-labelled DLK and DLK-K185A to the same extent. Deletion of the first 
44 amino acids prevented the interaction. In addition, the interaction between DLK-PP and 
TORC1 was reduced by 40%.  
Conclusion: Our data suggest that DLK might inhibit the CREB coactivator TORC in beta 
cells by two mechanisms: 1. the DLK kinase activity might result in the phosphorylation of 
S167 in TORC1, thus preventing its nuclear translocation; 2. the DLK leucine zipper 
structure might interact with TORC, thereby retaining it in the cytosol.  
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The mitogen-activated protein kinase DLK inhibits the CREB co-activator TORC 
Phu Do Thanh and Elke Oetjen  
Abteilung Pharmakologie, Universität Göttingen, D-37075 Göttingen 
Recently, three isoforms of Transducer of Regulated CREB (TORC) were identified as 
additional CREB co-activators. Whereas the co-activator CBP interacts with on Ser-119 
phosphorylated CREB, TORC1 and TORC2 after dephosphorylation of Ser-167 and Ser-
171, respectively, translocate into the nucleus and interact with the dimerized leucine 
zipper of CREB.  TORC translocation is inhibited by the immunosuppressive drugs 
cyclosporin and tacrolimus. Our previous studies showed that both drugs activate the dual 
leucine zipper bearing kinase DLK. In the present study the effect of DLK on TORC was 
investigated.  
A luciferase reporter gene under control of 5 copies of the GAL4 binding-site was 
transiently cotransfected with expression vector for GAL4-TORC fusion proteins into the 
beta cell line HIT. Over expression of DLK inhibited TORC1 and TORC2 transcriptional 
activity by 80 and 40%, respectively. This reduction was less pronounced using the DLK 
kinase dead mutant (DLK-K185A), whereas a DLK mutant unable to homodimerize (DLK-
PP) showed no inhibitory effect on TORC activity. The mutation of Ser-167 or Ser-171 in 
TORC1 and 2, respectively, to Ala prevented the inhibitory effect of DLK on TORC 
transcriptional activity. The interaction between TORC and DLK was investigated by an in 
vitro pull down assay. Bacterially expressed His-tagged full length TORC1 or GST-tagged 
TORC1(1-44 amino acids) interacted with [35S]-labeled DLK and with DLK-K185A to the 
same extent. Deletion of the first 44 amino acids of TORC1 prevented this interaction. In 
addition, the interaction between DLK-PP and TORC1 was reduced by 40%. Our data 
show that DLK inhibits TORC activity, presumably by phosphorylation of Ser-167 or Ser-
171 in TORC1 and TORC2, respectively, thus preventing the nuclear translocation of 
TORC. In addition, DLK interacts with TORC1. This interaction depends on the N-terminal 
amino acids of TORC1 and the ability of DLK to dimerize. Thus, DLK might inhibit TORC 
through an interaction with and by the phosphorylation of TORC, thereby preventing the 
nuclear translocation of TORC and ultimately the stimulus-induced CREB transcriptional 
activity.    
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